A Study Of The Snd1/Prmt5 Axis In Liver Cancer By Genetic Mouse Models

Tanner Wright

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations

Part of the Genetics Commons, and the Molecular Genetics Commons

Recommended Citation
Wright, Tanner and Wright, Tanner, "A Study Of The Snd1/Prmt5 Axis In Liver Cancer By Genetic Mouse Models" (2023). Dissertations and Theses (Open Access). 1309.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1309

This Dissertation (PhD) is brought to you for free and open access by the MD Anderson UTHealth Houston Graduate School at DigitalCommons@TMC. It has been accepted for inclusion in Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact digcommons@library.tmc.edu.
A STUDY OF THE SND1/PRMT5 AXIS IN LIVER CANCER BY GENETIC MOUSE MODELS

by

Tanner Janson Wright, B.S.

APPROVED:

______________________________
Mark T. Bedford, PhD
Advisory Professor

______________________________
David G. Johnson, PhD

______________________________
Manu M. Sebastian, DVM, PhD

______________________________
Min Gyu Lee, PhD

______________________________
Laura Beretta, PhD

______________________________
Taiping Chen, PhD

APPROVED:

______________________________
Dean, The University of Texas
MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences
A STUDY OF THE SND1/PRMT5 AXIS IN LIVER CANCER BY GENETIC MOUSE MODELS

A

Dissertation

Presented to the Faculty of

The University of Texas
MD Anderson Cancer Center UTHealth Houston
Graduate School of Biomedical Sciences

in Partial Fulfillment
of the Requirements
for the Degree of
Doctor of Philosophy

by

Tanner Janson Wright, B.S.

December 2023
Dedication

“Wanting the desirable but unattainable is very different from failing to get the desirable and potentially attainable.”
Sydney Brenner 1996

This work is dedicated to each of the following:

To my mother who gave me the daily charge to “come back better”-

To my father who climbed “the” mountain to be with me-

To Bob who saw something that was worth encouraging to grow-

To my courageous and trusting wife who is the wind in my sails and the sunshine of my day-

And finally, to “Salmon shorts”, the young man who met mocking with courage, abuse with resolution, and persecution with poise- who inspired the change of course that has altered my trajectory forever.

“Es gibt nichts Gutes, ausser: Man tut es.”
“There is nothing good unless you do it.”
Erich Kästner
Acknowledgements

“Sometimes science is the excuse for exploration. I think it is rarely the reason.”
George Lee Malory

I express gratitude for my mentor, Dr. Mark Bedford for guiding my development as a scientist line upon line- for being patient as I learned- and for being understanding when duty called. In my experience, he is a mentor any trainee will be happy to learn from.

I also express gratitude for an exceptional and inspiring committee in no special order: Doctors Margarida Albuquerque Almeida Santos, Laura Beretta, Min Gyu Lee, Manu Sebastian, Taiping Chen, and David Johnson. Each member always encouraged growth and taking the next step.

To a second family, the Epigenetics and Molecular Carcinogenesis Department, I owe much and wish to thank all for their gracious help, expertise, and excellence. Everywhere I turned I found a group of welcoming and genuine friends. They weathered both literal and figurative storms as few organizations can. To the entire Smithville/Science Park community, thank you.

This work was greatly aided by Steven Vokes and Ernesto Guccione and the talented scientists in each of their labs.

Finally, I add my thanks to the past and present members of the Bedford Lab as I met them: Jason Friedemann, Cari Sagum, Jianji Chen, Goushen Gao, Fen Yang, Ishita Rehman, Swarnalatha Manickavinayaham, Leilei Shi, Sharad Awasthi, and Isaiah Mixon. Also, a special thanks goes to Yalong Wang and Sabrina Stratton- this work wouldn’t exist without you.

“The important thing about research is that it is new, and is about going where none have gone before, and you have no other recourse but to teach yourself…”
Sydney Brenner 1996
A STUDY OF THE SND1/PRMT5 AXIS IN LIVER CANCER BY GENETIC MOUSE MODELS

Tanner Janson Wright, B.S.
Advisory Professor: Mark T. Bedford, Ph.D.

Abstract:

Arginine methylation is an essential post-translational modification (PTM) in cells. Protein arginine methyltransferase 5 (PRMT5) is the primary enzyme that catalyzes symmetric dimethyl arginine (SDMA) and requires methylosome protein 50 (MEP50) for stability and enzymatic activity which are necessary for life and development. Effector proteins bind different types of PTM's to facilitate signaling. Staphylococcal nuclease Tudor domain containing 1 (SND1) is an effector that specifically binds SDMA via its single C-terminal Tudor domain. Both SND1 and PRMT5 have been implicated in hepatocellular carcinoma (HCC). SND1 has been confirmed as a driver of HCC using genetically engineered mouse models (GEMMs), though, it remains unknown if loss of SND1 or its methyl reading ability can protect against HCC formation. PRMT5 has been reported as upregulated in many cancers and may predispose hepatocytes to develop HCC. However, it remains to be determined if Prmt5 overexpression (OE) alone is sufficient to drive HCC. This work utilizes three new GEMMs, namely a Snd1 KO, Snd1 Tudor domain mutant (KI), and tissue specific Prmt5 OE mouse, to answer these key questions: 1) Does loss of SND1 or its methyl binding ability impact tumorigenesis? and 2) Does Prmt5 OE predispose mice to develop HCC? We characterize and validate each of these GEMMs and use a high penetrance HCC assay to determine the role of this effector/writer pair to begin answering these questions. First, the Snd1 KO and KI mice reveal a Tudor domain independent “small” phenotype and reveal distinct transcriptional control by SND1 and its Tudor domain. Snd1 KO and KI mice are further hepatoprotected against carcinogen-induced HCC. Next, Prmt5 OE mice reveal important insight into PRMT5 biology and suggest that elevated PRMT5 levels do not correlate with elevated SDMA levels. Carcinogenesis studies using two cancer-inducing models further strengthen our understanding of these processes. This work provides important information about the SND1/PRMT5 axis in liver cancer and how this axis may be a viable target for treating HCC.
# Table of Contents

0.1 Approval page ........................................................................................................... i  
0.2 Title page ................................................................................................................... ii  
0.3 Dedication .................................................................................................................... iii  
0.4 Acknowledgements ....................................................................................................... iv  
0.5 Abstract ....................................................................................................................... v  
0.6 List of Illustrations ....................................................................................................... ix  
0.7 List of Tables ................................................................................................................. x  
0.8 Key abbreviations ....................................................................................................... xi  

1 Chapter 1- Introduction ................................................................................................. 1  
1.1 Arginine methylation and Tudor domains ................................................................. 1  
1.1.1 Arginine methylation .......................................................................................... 1  
1.1.2 Arginine methyltransferases- “writers” .............................................................. 1  
1.1.3 Methyl binding effector proteins- “readers” ...................................................... 7  
1.2 Arginine methylation in cancer .................................................................................. 11  
1.2.1 PRMT5 in cancer ................................................................................................... 12  
1.2.2 SND1 in cancer ..................................................................................................... 14  
1.3 The SND1/PRMT5 axis in hepatocellular carcinoma ................................................. 15  
1.3.1 Introduction to HCC ............................................................................................ 15  
1.3.2 SND1 OE in clinical samples .............................................................................. 16  
1.3.3 Snd1 drives HCC in SB screen ............................................................................ 16  
1.3.4 SND1 drives HCC in OE GEMM ........................................................................ 17  
1.3.5 Evidence for Prmt5 in promoting HCC ............................................................... 17  
1.4 Summary and scope .................................................................................................... 20  

2 Chapter 2- Materials and methods .............................................................................. 22  
2.1 Mouse experiments .................................................................................................... 22  
2.2 Generation of mouse models .................................................................................... 22  
2.2.1 Snd1 KO and KI GEMMs .................................................................................. 22  
2.2.2 PRMT5 OE GEMM ............................................................................................ 23  
2.3 MEF isolation and immortalization .......................................................................... 24  
2.4 Genotyping ................................................................................................................. 24  
2.4.1 DNA extraction .................................................................................................... 24  
2.4.2 Genotyping Snd1 KO mice ................................................................................ 25  
2.4.3 Genotyping Snd1 KI mice ................................................................................ 25  
2.4.4 Genotyping PRMT5 transgenic mice .................................................................. 26  
2.5 Sequencing .................................................................................................................. 26  
2.6 Liver harvest for Western blot ................................................................................... 27  
2.7 Western blot analysis ............................................................................................... 28  
2.7.2 LI-COR detection by fluorescence- ................................................................. 28  
2.7.3 Western blot detection by chemiluminescence- ................................................. 29  
2.8 Antibodies .................................................................................................................. 29  
2.9 Peptide pulldown assay ............................................................................................ 30
2.10 RNA-extraction .................................................................................................................. 30
2.11 RT-qPCR primers .................................................................................................................. 30
2.12 RT-qPCR analysis .................................................................................................................. 31
2.13 RNA-sequencing of Prmt5OE samples ................................................................................. 31
2.14 DEN injection model .............................................................................................................. 32
2.15 Bloodwork ............................................................................................................................ 32
2.16 BrdU proliferation model ....................................................................................................... 33
2.17 In vitro methylation assay ................................................................................................... 33
2.18 Enhancer spray ...................................................................................................................... 34
2.19 Transient transfection .......................................................................................................... 34
2.20 Hydrodynamic Tail Vein Injection ....................................................................................... 34
2.21 Phosphatase inhibitor cocktail ............................................................................................. 35
2.22 Post-DEN treatment necropsy procedure .......................................................................... 35
2.23 Photoshop courtesy edits .................................................................................................... 36

3  Chapter 3- Characterizing loss or mutation of SND1 and the effect on HCC............. 37
  3.1 Introduction and scope ......................................................................................................... 37
  3.2 Generation and validation of Snd1 KO and KI mouse lines .............................................. 37
    3.2.1 Snd1 KO GEMM .......................................................................................................... 37
    3.2.2 Snd1 KI GEMM .......................................................................................................... 39
    3.2.3 Comparing the phenotype of Snd1 mutant mouse models ........................................... 41
  3.3 Transcriptional analysis of livers from Snd1 mutant mice .............................................. 41
  3.4 SND1 Carcinogenesis Models ............................................................................................ 43
    3.4.1 DEN carcinogenesis modeling ..................................................................................... 45
    3.4.2 BrdU proliferation assay .............................................................................................. 50
  3.5 Conclusions and Future Experiments ............................................................................... 50
    3.5.1 Snd1 KO and KI mice reveal Tudor independent functions for SND1 ....................... 50
    3.5.2 Transcriptional analysis .............................................................................................. 53
    3.5.3 Carcinogenesis modeling ............................................................................................ 54

4  Chapter 4- Characterizing a gain-of-function PRMT5 OE mouse and the effect on HCC .............................................................. 59
  4.1 Generation and validation of a Prmt5 OE GEMM ................................................................. 59
  4.2 Transcriptional analysis of PRMT5 OE GEMM ................................................................. 70
    4.2.1 Alternative splicing in Prmt5 OE livers .......................................................................... 70
  4.3 PRMT5 OE carcinogenesis models ..................................................................................... 72
    4.3.1 PRMT5 OE in unchallenged normal mice ..................................................................... 74
    4.3.2 Carcinogenesis modeling by DEN-induced HCC .......................................................... 74
    4.3.3 BrdU injection to measure Prmt5OE liver proliferation .................................................. 76
    4.3.4 Hydrodynamic tail vein injection .................................................................................... 78
  4.4 Discussion ............................................................................................................................ 80
    4.4.1 New insights into the control and activity of PRMT5 .................................................... 80
    4.4.2 PRMT5 OE in carcinogenesis ....................................................................................... 82
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Chapter 5- Summary of conclusions and future directions</td>
<td>84</td>
</tr>
<tr>
<td>5.1</td>
<td>Part I- The Reader</td>
<td>84</td>
</tr>
<tr>
<td>5.2</td>
<td>Part II- The Writer</td>
<td>87</td>
</tr>
<tr>
<td>6</td>
<td>Appendix A- Published review</td>
<td>90</td>
</tr>
<tr>
<td>7</td>
<td>Appendix B- Plasmid maps and sequences</td>
<td>145</td>
</tr>
<tr>
<td>8</td>
<td>Appendix C- Quantification of myc-Prmt5 OE.</td>
<td>158</td>
</tr>
<tr>
<td>9</td>
<td>Appendix D- Albumin-Cre documentation</td>
<td>162</td>
</tr>
<tr>
<td>10</td>
<td>Appendix E- BioRender license</td>
<td>163</td>
</tr>
<tr>
<td>11</td>
<td>Bibliography</td>
<td>164</td>
</tr>
<tr>
<td>12</td>
<td>Vita</td>
<td>195</td>
</tr>
</tbody>
</table>
List of Illustrations

Figure 1- Arginine methylation pathways in mammals 3
Figure 2- PRMT5 and MEP50 structure and enzymatic processing 4
Figure 3- SND1 graphical structure and protein-protein interaction mapping… 10
Figure 4- Snd1 KO GEMM validation 38
Figure 5- Snd1 KI GEMM validation 40
Figure 6- Litter and body size of Snd1 KO and KI mice 42
Figure 7- RT-qPCR of selected downregulated genes from KO and KI mice 44
Figure 8- Diethylnitrosamine induced HCC grossing and pathology 46
Figure 9- Tumor burden of DEN induced HCC in SND1 KO, KI, and WT mice 49
Figure 10- Proliferation assay in Snd1 variable mice 51
Figure 11- RT-qPCR of common drug metabolizing cytochromes Cyp3a44 and Cyp2c39 55
Figure 12- Prmt5<sup>OE</sup> GEMM design and sequence validation 61
Figure 13- Western blot and quantification for Prmt5<sup>WT</sup> and Prmt5<sup>OE</sup> from whole cell lysate 63
Figure 14- In vitro methylation of recombinant H4 by Prmt5<sup>WT</sup> and Prmt5<sup>OE</sup>… 64
Figure 15- Type II methylation of Prmt5<sup>OE</sup> liver tissues 66
Figure 16- Pan-tissue methylarginine comparison 67
Figure 17- Hypermethylation analysis in myc-PRMT5 overexpressing HepG2 cells 68
Figure 18- Hypermethylation analysis in myc-PRMT5 overexpressing HEK293T cells 69
Figure 19- Volcano plot of differentially expressed genes from Prmt5<sup>OE</sup> mice liver 71
Figure 20- Prmt5<sup>OE</sup> alternative splicing events 73
Figure 21- Prmt5<sup>OE</sup> vs Prmt5<sup>WT</sup> pathology and tumor burden for DEN injected mice 75
Figure 22- Proliferation of Prmt5<sup>OE</sup> livers by BrdU incorporation 77
Figure 23- Hydrodynamic tail vein injection of Prmt5<sup>OE</sup> and WT mice 79
List of Tables
Table 1- Published Prmt5 and Mep50 conditional knockout mice 5
Table 2- Sampling of Tudor domain proteins and their methyl species binding 8
Table 3- Published roles of PRMT5 in cancer 13
Table 4- Blood analyte comparison of Snd1 WT, KO, and KI DEN injected mice 47
Key abbreviations

ADMA- Asymmetric dimethyl arginine
BrdU- Bromodeoxyuridine
DEN- Diethylnitrosamine
GEMM- Genetically engineered mouse model
HCC- Hepatocellular carcinoma
HTVi- Hydrodynamic tail vein injection
KI- Tudor domain mutant, or knock in
KO- Knockout
MEF- Mouse embryonic fibroblast
MMA- Monomethyl arginine
MEP50- Methylosome protein 50
NAFLD- Non-alcoholic fatty liver disease
NASH- Non-alcoholic steatohepatitis
OE- Overexpression
PRMT5- Protein arginine methyltransferase 5
PTM- Post-translational modification
SDMA- Symmetric dimethyl arginine
SMI- Small molecule inhibitor
SN-domain- Staphylococcal nuclease like domain
SND1- Staphylococcal nuclease and Tudor domain containing 1
Chapter 1- Introduction

1.1 Arginine methylation and Tudor domains

1.1.1 Arginine methylation

Arginine is a bulky net positively charged amino acid. This electrophilic nature makes the side chain a reactive substrate for methylation, an abundant post-translational modification (PTM). Like its positively charged sibling lysine, arginine residues are methylated in many proteins which influences protein-protein interaction and signal transduction. This can impact a protein subcellular localization, modulate addition of other PTMs, or create docking sites for effector proteins to relay cellular signals. While lysine and arginine methylation have some similarities, they are not functionally redundant and serve essential and distinct functions in the cell. A well-recognized biological consequence of protein arginine methylation is the regulation of transcription by either activation or repression by H3R17me2a or H4R3me2s PTMs respectively. Beyond histones, there has been a metaphorical explosion of discovered methylarginine modified proteins and associated pathways with essential biological roles over the last twenty years (79). These targets and pathways of arginine methylation include regulating RNA polymerase II (80), splicing machinery (81), DNA damage repair (82), and potential roles in immunity.

1.1.2 Arginine methyltransferases- “writers”

The family of enzymes that deposit methylarginine marks are the protein arginine methyltransferases (Xu, et al., 2021). There is growing evidence that arginine methylation of histones is important primarily in development given their abundance in gametes compared to somatic cells (Tee, et al., 2010); (Wang, et al., 2014). Observations that PTMs on histones were reversible and could be selectively bound by distinct protein domains gave rise to the “Histone Code” hypothesis. This says that PTMs are added or “written” onto proteins which can then be bound or “read” by an effector protein creating an epigenetic code with similarities to the genetic code. Thus, the colloquial terms of “writer” and “reader” can quickly convey the function of many proteins.
methyltransferases (PRMTs) and are sequentially numbered 1-9 in mammals (84, 85). This family is further divided into three types, identified with roman numeral I-III, and are grouped based on the methyl-isomer they catalyze. The guanidyl chemical group at the end of an arginine side chain contains two ω-nitrogen (ω-NG) atoms, distinguished as ω-NG, and ω-N'G (said ‘omega-prime nitrogen’), and can be methylated in one of three configurations being either monomethylated (MMA), asymmetric dimethylated (ADMA), or symmetric dimethylated arginine (SDMA) (Figure 1). Type I PRMTs catalyze MMA and ADMA, Type II PRMTs catalyze MMA and SDMA, and Type III only catalyze MMA (16, 84).

Type I PRMTs are the largest subtype in the family consisting of PRMTs 1,2,3,4 (commonly called CARM1), 6, and 8. PRMT7 is the only Type III PRMT. PRMT5 and PRMT9 are Type II PRMTs, though PRMT5 is widely acknowledged as the major depositor of SDMA because verified PRMT9 substrates remain very limited (86). As the major Type II PRMT, PRMT5 plays an essential role in development and homeostasis.

Many in-depth reviews have been published about PRMT5 in normal and disease biology. The author has added one such review to this body of literature which is included as appendix A, and ref (16). In brief, PRMT5 is an essential housekeeping gene for development and cellular viability. Structurally, the protein is divided into a TIM domain, characteristic Rossmann fold, and a C-terminal β-barrel (Figure 2a) (16). In mice, full body knockout (KO) is early embryonic lethal at the preimplantation stage (77). Almost invariably, conditional KO of PRMT5 is deleterious. Many conditional KOs of PRMT5 have revealed the importance of PRMT5 for life (Table 1). This housekeeping nature holds true in cell culture as PRMT5 inhibition or knockdown is cytotoxic to cells. PRMT5 is normally found throughout the cell and methylates a variety of proteins. A small sampling of these includes the known SDMA marks on canonical histones, Sm proteins, and

---

4 See also (Bedford, et al.,2009) and (Blanc, et al.,2017)
5 Prolonged use of PRMT5 inhibitors at moderate concentrations will lead to drug resistance in cell lines. This is an important consideration as will be discussed later.
Figure 1- Arginine methylation pathway in mammals. Monomethylated arginine (MMA) guanidyl moiety highlighted in “pink”. Asymmetrically dimethylated arginine (ADMA) highlighted in “green” is dimethylation of $\omega$-N$^\ominus$. Symmetrically dimethylated arginine (SDMA) in “blue” is methylation at $\omega$-N$^\ominus$,N$^\ominus$. All PRMTs facilitate MMA formation.
The TIM- and β-barrel are needed for oligomerization to MEP50. PRMT5 dimerizes in a head to tail orientation. The canonical Rossman fold is responsible for binding S-adenosyl methionine (SAM), the universal methyl donor. The 60 residue dimerization domain, in “gray”, initiates heterodimerization of the complex (17). Full length protein is needed for enzymatic activity in vitro.

Figure 2- PRMT5 and MEP50 structure and enzymatic processing. a) PRMT5 graphical structure. The TIM- and β-barrel are needed for oligomerization to MEP50. PRMT5 dimerizes in a head to tail orientation. The canonical Rossman fold is responsible for binding S-adenosyl methionine (SAM), the universal methyl donor. The 60 residue dimerization domain, in “gray”, initiates heterodimerization of the complex (17). Full length protein is needed for enzymatic activity in vitro. b) MEP50 graphical structure. This protein contains seven tandem WD-domains. These orient into a 7 bladed “propeller” shape. MEP50 binds the TIM containing domain of PRMT5 (17, 19). c) Graphical representation of distributive methylation by PRMT5. Which effector binds SDMA modifications will determine what downstream pathways are impacted. Generated with BioRender.
Table 1- Published Prmt5 and Mep50 conditional knockout mice

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Conditional allele</th>
<th>Phenotype</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuron</td>
<td>Nestin&lt;sup&gt;cre&lt;/sup&gt;</td>
<td>- Postnatal lethality (14d)</td>
<td>(5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Neurological disorders; balance, tremors, akinesis (immobility)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Reduced brain size</td>
<td></td>
</tr>
<tr>
<td>Oligodendrocytes&lt;sup&gt;††&lt;/sup&gt;</td>
<td>Olig1&lt;sup&gt;cre&lt;/sup&gt;</td>
<td>- Postnatal lethality (14d)</td>
<td>(4, 9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Impaired myelination</td>
<td></td>
</tr>
<tr>
<td>Bone</td>
<td>Prx&lt;sup&gt;cre&lt;/sup&gt;</td>
<td>- Long Bone atrophy</td>
<td>(11, 12)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Oligodactyly</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>Alb&lt;sup&gt;cre&lt;/sup&gt;</td>
<td>- Liver cirrhosis</td>
<td>(15)</td>
</tr>
<tr>
<td>Blood</td>
<td>Inducible Mx1&lt;sup&gt;cre&lt;/sup&gt;</td>
<td>- Fatal bone marrow aplasia (moribund 16 days post-Cre induction)</td>
<td>(8, 18)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Loss of hematopoietic progenitor cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Splicing defects</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vav1&lt;sup&gt;cre&lt;/sup&gt;</td>
<td>- Embryonic lethal (post-day E14.5)</td>
<td>(19, 20)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Severe hematopoietic defects and DNA damage accumulation</td>
<td></td>
</tr>
<tr>
<td>T Cell</td>
<td>CD4&lt;sup&gt;cre&lt;/sup&gt;</td>
<td>- Impaired T cell maintenance</td>
<td>(21, 22)</td>
</tr>
<tr>
<td>Spermatogenesis</td>
<td>Tnap&lt;sup&gt;cre&lt;/sup&gt;, Stra8&lt;sup&gt;cre&lt;/sup&gt;</td>
<td>- Germ cell loss</td>
<td>(27, 28)</td>
</tr>
<tr>
<td>Lung</td>
<td>Shh&lt;sup&gt;cre&lt;/sup&gt;</td>
<td>- Lethality at birth; respiratory distress cyanosis (suffocation)</td>
<td>(33)</td>
</tr>
<tr>
<td>(Primary lung epithelial cells)&lt;sup&gt;†&lt;/sup&gt;</td>
<td>Constitutively active Cre</td>
<td>- Impaired cellular growth and proliferation</td>
<td>(38)</td>
</tr>
<tr>
<td>Muscle stem cell&lt;sup&gt;†††&lt;/sup&gt;</td>
<td>Pax7&lt;sup&gt;cre-ER&lt;/sup&gt;</td>
<td>- Depletion of muscle stem cells</td>
<td>(39)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Lack of muscular regeneration</td>
<td></td>
</tr>
<tr>
<td>Pancreatic beta cells</td>
<td>Pdx1&lt;sup&gt;cre-ER&lt;/sup&gt;</td>
<td>- Impaired glucose tolerance</td>
<td>(41)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Reduced insulin expression</td>
<td></td>
</tr>
<tr>
<td>Prostate*</td>
<td>PPR2Bi-Cre</td>
<td>- Impaired ductal structure</td>
<td>(47)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Altered secretory proteins and androgen receptor expression</td>
<td></td>
</tr>
</tbody>
</table>

*MEP50 knockout system- MEP50 conditional knockouts are expected to mimic PRMT5 KO systems.
† Ex vivo conditional knockout
†† This experiment provided an in vivo phenotype for the observation of myelin basic protein as a robust PRMT5 substrate (55).
††† This report suggests a distinct genetic regulation for developmental vs adult stem cell maintenance as embryonic myogenesis was unaffected in Prmt5 KO mice.
In considering known and purported PRMT5 substrates it is important to note that PRMT5 has some affinity for α-Flag antibodies. Thus, PRMT5 is co-immunoprecipitated in over 90% of Flag-based pull downs. A repository of spurious affinity artifacts is collected in the “CRAPome” (Mellacheruvu, et al.,2013).

Herein we note just a few established PRMT5 substrates. From this report, the authors note that full length PRMT5 expressed in insect cells formed dimers and was biochemically active, but formed aggregates and couldn’t be crystalized.

In considering known and purported PRMT5 substrates it is important to note that PRMT5 has some affinity for α-Flag antibodies. Thus, PRMT5 is co-immunoprecipitated in over 90% of Flag-based pull downs. A repository of spurious affinity artifacts is collected in the “CRAPome” (Mellacheruvu, et al.,2013). Herein we note just a few established PRMT5 substrates. From this report, the authors note that full length PRMT5 expressed in insect cells formed dimers and was biochemically active, but formed aggregates and couldn’t be crystalized.

6 Of note, systemic loss of MEP50 is also embryonic lethal in mice, albeit by day E8.5 rather than before preimplantation like Prmt5 KO mice.

7 GAR motifs typically have a ‘GRR’ or GRG amino acid sequence and are the preferred substrate motif for PRMT5. However, it can also methylate PGM motifs. Most PRMTs prefer either GAR or PGM motifs, like PRMT1 that prefers GAR, while CARM1 prefers PGM.

8 Of note, systemic loss of MEP50 is also embryonic lethal in mice, albeit by day E8.5 rather than before preimplantation like Prmt5 KO mice.

9 GAR motifs typically have a ‘GRR’ or GRG amino acid sequence and are the preferred substrate motif for PRMT5. However, it can also methylate PGM motifs. Most PRMTs prefer either GAR or PGM motifs, like PRMT1 that prefers GAR, while CARM1 prefers PGM.

10 PRMT5 can be post-translationally modified to regulate its activity. Phosphorylation by mutant Janus kinase decreases activity while other phospho-sites modulate interaction with substrates. Methylation by CARM1 at R505 increases activity. PRMT5 PTMs were recently reviewed here (Hartley, et al.,2020).
evidence of the importance of *Prmt5*, though it is not known if overexpression (OE) of *Prmt5* has a phenotype- or if *Prmt5 OE* will drive hypermethylation of substrates.

Loss of *Prmt5* using a conditional KO approach have conclusively shown *Prmt5* is essential for development and for maintaining homeostasis. On the other hand, PRMT5 has been implicated in nearly as many types of cancer which will be described further in section 1.2. PRMT5 and SDMA will be the topic of chapter 4. Chapter 3, however, will deal primarily with a specific effector that binds, or colloquially “reads”, SDMA.

1.1.3 Methyl binding effector proteins- “readers”

Methylation is recognized by many protein domains across dozens of effector proteins. Tudor domains, which are characterized by a 4-5 β-stranded aromatic cage that docks on methylated substrates, can recognize lysine-methylation and is the only domain to date which recognizes methyl-arginine residues (94, 95). The Tudor protein domain was first identified from a protein with the same name containing 11 Tudor repeats in *Drosophila melanogaster*. Tudor domains often occur in a tandem array but can occur singly. Individual Tudor domains exhibit amino acid specificity11, though some proteins with multiple Tudors can read both methyl-lysine and methyl-arginine marks by individual Tudors, as in the case with Spindlin112 (Table 2) (30, 31, 96, 97). In addition to amino acid specificity, Tudor domains have methyl-species (that is mono-, di-, di-asymmetric, di-symmetric, or tri-methylation) specific recognition. To date, relatively few methyl-arginine readers have been identified13.

---

11 Methyl-lysine vs. methyl-arginine specificity is thought to be facilitated by an additional α-helix and two additional β-strands called an “extended Tudor” (Liu, et al.,2010).

12 Spindlin1 is a histone reader with 3 tandem Tudor domains. The first and second Tudors exhibit crosstalk by reading a combination H3K9me3 with H3R8me2a mark. This combination reading is a recent discovery and illustrates the possible combinatorial power of “the histone code”.

13 There is, currently, a paradox in that Type II PRMTs, which have few writers, have several effectors that bind SDMA, while Type I PRMTs which are more numerous have fewer known effectors for ADMA (Wright, et al.,2021). Whether this discrepancy is biologically driven or is an artifact of technological limitations remains to be determined. As PRMT5 is the major depositor of SDMA in the cell, more SDMA binding effectors points to the importance of the associated methyltransferases.
Table 2- A sampling of Tudor domain proteins and their methyl-species binding.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Methyl Lysine</th>
<th>Ref</th>
<th>Protein</th>
<th>Methyl Arginine</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>53BP1</td>
<td>Kme2; H4K20me2</td>
<td>(1)</td>
<td>SMN</td>
<td>SDMA</td>
<td>(13)</td>
</tr>
<tr>
<td>JMJD2a</td>
<td>H3K4me3 H4K20me3</td>
<td>(1)</td>
<td>SND1†</td>
<td>SDMA</td>
<td>(1, 16)</td>
</tr>
<tr>
<td>Spindlin1-3rd Tudor</td>
<td>Unknown</td>
<td></td>
<td>TDRD 1,2,6,8 (Germ cell)</td>
<td>SDMA</td>
<td>(16)</td>
</tr>
<tr>
<td>Spindlin1-2nd Tudor</td>
<td>H3K4me3 H3K9me3</td>
<td>(30, 31)</td>
<td>SPF30</td>
<td>SDMA</td>
<td>(13)</td>
</tr>
<tr>
<td>PHF20</td>
<td>H3K4me2</td>
<td>(37)</td>
<td>TDRD3</td>
<td>ADMA</td>
<td>(53)</td>
</tr>
<tr>
<td>SGF29</td>
<td>H3K4me3</td>
<td>(59)</td>
<td>TDRD17 (mitochondria)</td>
<td>ADMA</td>
<td>(63)</td>
</tr>
<tr>
<td>UHRF1</td>
<td>H3K9me3, H3K4me0/1</td>
<td>(70)</td>
<td>Spindlin1-1st Tudor</td>
<td>ADMA</td>
<td>(31, 71)</td>
</tr>
<tr>
<td>SHH1</td>
<td>H3K9me3</td>
<td>(72)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHF1</td>
<td>H3K36me3</td>
<td>(76)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

†Also known as TSN, p100, and TDRD11
Staphylococcal nuclease Tudor domain containing 1 (SND1) is a unique protein that has both protein- and nucleic acid-binding properties\textsuperscript{14}. SND1 functions primarily as a RNA processing protein. Structurally, it contains four tandem SN-like domains (SN-domains) followed by a fifth SN-domain that is split by a Tudor domain (\textbf{Figure 3}). SND1 is expressed in most cell types but is enriched for in exosome and lipid secreting cells like liver, pancreas, and mammary tissues (16, 99). Within the cell, SND1 can shuttle freely between the nucleus and cytoplasm, but will form foci within stress granules in response to cellular stress (66, 67, 100-102). SN-domains have been identified as important for several biological processes including this stress granule formation, transcriptional coactivation (58, 75, 103), exosome processing (104), and binding RISC factors for RNA degradation (105-107) (\textbf{Figure 3}). The C-terminal Tudor domain, on the other hand, binds various splicing factors (68, 71, 73) and PIWI1/Miwi proteins to facilitate noncoding RNA biogenesis (1). Protein-protein interaction mapping reveals that SND1 generally interacts with either the Tudor or SN-domains. SND1 Tudor domain has preferential binding to SDMA\textsuperscript{15} (108). Indeed, we and others have identified that SND1 is able to bind SDMA modified E2F peptides (58, 109, 110). Recently mass spectrometry results from an SND1-BioID2 avidin purification returned many novel potential SND1-binding proteins (101). This suggests that there may yet be more unidentified proteins that SND1 can bind through its Tudor domain. Because SND1 preferentially recognizes SDMA, and because PRMT5 deposits nearly all SDMA in the cell, PRMT5 and SND1 form a writer/reader pair.

As mentioned above, SND1 is ubiquitously expressed (111), but is enriched for in exosome secreting cells such as the liver and pancreas (16, 112). Unlike KO of the writer PRMT5, SND1 loss does not exhibit embryonic lethality. This has been known for a time, but the SND1 KO

\textsuperscript{14} Also known as TSN, p100, and TDRD11.

\textsuperscript{15} Friberg et al were the first to identify that the SND1 Tudor domain preferentially binds SDMA over ADMA modified ligands. Additionally, they did not observe methyl-lysine binding for unmodified, mono-, di-, or trimethylated states.
Figure 3- SND1 graphical structure and protein-protein interaction mapping to Tudor and SN-domains. Adapted from Gutierrez-Beltran (2016). STAT6-CBP (14); PPARγ (29); STAT6-RHA (36); STAT6-PC1 (52); STAT5 (57); E2F1 (50, 58); EBNA2 (60); Metadherin (61); NF-κB (62); AEG-1 (64); Ago1, Ago2, TIAR, Pabp1, eIF4E (65); G3BP (66); ADAR1 (67); Prp8 (68); SmB, SmD1/D3 (17, 69) (71); SAM68 (73); PIWI (1); MHC-I (74).

† SND1 binds EBNA2 via TFIIE. Primary sequence of the interfacing acidic domain of EBNA2 and TFIIEα or -β reveal no obvious GAR motif to serve as a substrate for PRMT5 methylation and subsequent SND1 Tudor binding. Thus, transcriptional coactivation may be achieved via nuclease domain interaction. This has yet to be determined empirically either way, however.

†† This interaction has only been shown using peptides.

††† It is unknown what domains of SND1 interact with NFκB.

†††† C-Myb-Pim1 activity is strengthened by full length SND1 and is decreased in ΔC terminal mutants (75).

*Both the Tudor domain and the SN-domains can pull down STAT5. It is biologically unknown why this particular target interacts with both types of domains.
phenotype was only recently published\textsuperscript{16} (101, 113). However, the pathology and phenotype of an SND1 Tudor domain mutant mouse has not been described. We highlight the phenotype of a \textit{Snd1 KO} genetically engineered mouse model (GEMM) and present a SND1 Tudor domain dead (KI) mutant mouse in chapter 3.

\subsection*{1.2 Arginine methylation in cancer}

There is a growing appreciation of the role of arginine methylation in cancer at large. H4R3me2a and H3R8me2a, deposited by PRMT1 and PRMT2 respectively, are key marks of proliferation, migration, stemness, and differentiation— all of which are important cancer related processes\textsuperscript{17,18}. Also linked to transcriptional control, tumor suppressors and CDK inhibitors can be silenced transcriptionally by H4R3me2s which is deposited by PRMT5. Recently, it was shown that NF\textsubscript{IB} methylation by CARM1 is needed for small cell lung cancer development which mediates an opening of chromatin states (115). CARM1 also promotes error-prone non-homologous end joining DNA damage repair by repressing R-loop formation in ovarian cancers (116).

In the last decade, there has been a substantial increase in the number of publications and interest in targeting PRMTs (117). The availability and potency of small molecule inhibitors (SMI) have allowed many groups to study PRMTs in cancer. Many cancers are very sensitive to PRMT inhibitors, which have revealed the roles of PRMTs in splicing, DNA damage response, tumor immunity (118), and cellular signaling in cancer.

Both PRMT5 and SND1 have been implicated in a variety of cancers, especially liver cancer. Here, we briefly explore the role of each the writer and reader in cancer broadly speaking then look more closely at liver cancer in section 1.3.

\textsuperscript{16} SND1 KO mice have been available for several years (Fu, et al.,2018); (Su, et al.,2015); (Wang, et al.,2021).
\textsuperscript{17} H3R8me2a has primarily been shown at the enhancers and promoters of growth and survival related genes (Dong, et al.,2018).
\textsuperscript{18} See also (Blanc, et al.,2017).
1.2.1 PRMT5 in cancer

The role of PRMT5 in cancer is a substantial study by itself (Table 3). Yet, there are some common themes in PRMT5 research which hint at its overall role in neoplasms. As a sampling, PRMT5 has been shown to be overexpressed in glioblastoma, melanoma, breast, liver, prostate, pancreatic, bladder, ovarian, lymphoma, lung, and colorectal cancers (references in Table 3). Across the spectrum, PRMT5 improves the viability and proliferation of cell types, though through tissue specific molecular targets. Also interconnecting these findings is that targeting PRMT5 impairs cellular viability and has potential to serve as an anticancer therapy.

Cancer cells are very sensitive to loss of PRMT5\(^{19}\). To date, there are no known functional homologs of PRMT5\(^{20}\), and the PRMT5-MEP50 complex has several targetable folds\(^{21}\). Each of these facts has contributed to this protein being an active area of research in pharmacology. There are at least 14 unique compounds which selectively target PRMT5, many of which have made it to clinical trials and beyond (119). The targetable folds and the many SMI alludes to the several mechanisms of action (MOA) of these compounds including three combinations of SAM and substrate cooperative/competitive molecules, a PROTAC degrader, and covalent binding that blocks binding of SAM and peptide substrates (120) (121) (also see appendix A). The most recent MOA to be published is based on the sensitivity of PRMT5 to a natural feedback inhibitor, 5’-methylthioadenosine (MTA). MTA is a natural metabolite of the methionine cycle and byproduct of methylation that inhibits PRMT5 as a negative feedback modulator. Normally, methylthioadenosine phosphorylase (MTAP) processes MTA through its next step in the cycle, but in MTAP deleted cells, MTA accumulates as it cannot be processed by normal means thereby naturally inhibiting PRMT5. This new compound is a MTA-cooperative inhibitor that exhibits

---

\(^{19}\) Virtually every reference from Table 3 includes experiments which utilize siRNA to knockdown PRMT5 or SMI to decrease PRMT5 activity. Invariably, \(\alpha\)-PRMT5 treated cells show decreased proliferation and viability.

\(^{20}\) There have been no functional homologs of PRMT5 identified to date. This may partially explain why cells are so sensitive to \(\alpha\)-PRMT5 treatments. PRMT5 facilitates virtually all SDMA in the cell and so cells enter crisis upon loss of the primary Type II PRMT.

\(^{21}\) Truncated PRMT5 is inactive (Antonysamy, et al.,2012). Thus, pharmacologically targeting even a portion of the protein can be an effective means of disrupting normal PRMT5 function.
Table 3- Published roles of PRMT5 in cancer

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>PRMT5 related effect</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glioblastoma</td>
<td>Proliferation, migration, differentiation</td>
<td>(2-4)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Proliferation, increase in p27, alternative MDM4 splicing</td>
<td>(6-8)</td>
</tr>
<tr>
<td>Breast</td>
<td>Proliferation, inhibit apoptosis, FOXP1 recruitment for transcription</td>
<td>(10) (19)</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>Proliferation via ERK signaling, HNFα repression promoting EMT, de novo lipogenesis</td>
<td>(23-26)</td>
</tr>
<tr>
<td>Prostate</td>
<td>Transcriptional cofactor for Sp1 and Brg1 promoting cancer androgen receptor expression.</td>
<td>(32)</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>Proliferation, silencing of FBW7 to promote the Warburg effect</td>
<td>(34, 35)</td>
</tr>
<tr>
<td>Bladder</td>
<td>Increases proliferation and colony forming capacity, apoptosis suppression</td>
<td>(40)</td>
</tr>
<tr>
<td>Ovarian</td>
<td>Proliferation and correlation with tumor burden and worse prognosis</td>
<td>(42)</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>Proliferation, increase in cyclin D1, c-myc, and survivin protein†</td>
<td>(43-46)</td>
</tr>
<tr>
<td>Lung</td>
<td>Enhanced cell growth via decrease in GLIPR1, Leprel1 and BTG2 (tumor suppressors), and increase in FGFR and HER (growth factors) proteins.</td>
<td>(48, 49)</td>
</tr>
<tr>
<td>Colorectal</td>
<td>Invasion, differentiation</td>
<td>(50, 51)</td>
</tr>
<tr>
<td>Leukemia (MLL††)</td>
<td>Proliferation, self-renewal and differentiation block</td>
<td>(54)</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>Interaction promoting NFκB induced cellular growth</td>
<td>(56)</td>
</tr>
</tbody>
</table>

† This occurs via H3R8me2s repressive marks at promoters for regulators of WNT/β-catenin signaling.

†† Mixed lineage leukemia. Interestingly, leukemia’s have more sensitivity to PRMT5 inhibition than lymphatic cancers.
synthetic lethality in *Mtap* deleted cells (122). The potential of this drug is to specifically target MTAP delete cells while being ineffective in healthy cells22. The effectiveness of all of these compounds in cells and mice has encouraged research into their potential use as anti-cancer therapies.

While knockdown and inhibition of PRMT5 informs our understanding of PRMT5 in normal biology, it is also important to understand how the amount of PRMT5 makes a difference in normal and diseased states. PRMT5 is overexpressed in many cancer types and is thought to cause hypermethylation of methyl substrates, which will lead to transcriptional activation and promote cellular growth. As PRMT5 is involved in splicing, this regulation of oncolytic activity or oncosuppression by treatment with SMI could also occur at the splicing level. However, it has not been determined if PRMT5 OE alone is sufficient to induce tumorigenesis.

1.2.2 SND1 in cancer

*Snd1* has been implicated primarily in breast (124, 125), glioma (126), colon (127), lung, and liver cancer (112, 128-130) specifically with upregulation of the protein. To date, SND1 is thought to be oncogenic by increasing stabilizing factors, like Metadherin23, and by degrading tumor suppressor RNA directly or indirectly. SND1 pulls down principally with RNA binding proteins, suggesting it may also impact oncogenic RNAs. In recent review, a positive feedback loop was described for TGFβ-SND1 expression which may also serve in promoting cancer signaling (131). While involved in many tissues, SND1 is abundant in the liver making this role of SND1 in liver cancer of special interest.

---

22 *Mtap* deletion is present in 15% of solid tumors (Kalev, et al., 2021).
23 Metadherin is involved with RISC and plays an important role in miRNA processing. It is frequently upregulated in cancer (Blanco, et al., 2011).
1.3 The SND1/PRMT5 axis in hepatocellular carcinoma

Liver cancer is a major health concern worldwide. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and has a high mortality (132). Prmt5 has been implicated in HCC, but the data has been circumstantial. On the other hand, Snd1 has been robustly reported as overexpressed in clinical HCC samples implicating it as a potentially important axis of study. Additionally, Snd1 has been shown to drive HCC formation by multiple groups using GEMMs. These include two independent mutagenic Sleeping Beauty (SB) transposon screens and a tissue-specific conditionally active Snd1 OE mouse model. This section will first briefly introduce HCC, followed by describing the relevant SND1 information, and concluding with presenting evidence of PRMT5 in HCC.

1.3.1 Introduction to HCC

Liver cancer is the third leading cause of cancer mortality to a third of the world’s population, and is fourth overall (132). HCC is the most common form of primary liver cancer, reportedly contributing 75-90% of hepatic cancers (133, 134). Risk factors are well documented including alcohol abuse, chronic inflammation, obesity, aflatoxin or carcinogen exposure, type two diabetes, and the most prominent factor, hepatitis infection. These etiologies and tumor biology confound treatment options as most liver tumors are immunologically cold, chemoresistance is common, and many tumors are deemed inoperable due to patient health and late-stage diagnosis (136, 137). One of the challenges in treating HCC has been a limited understanding of the molecular drivers of the disease. Further study of genetic and epigenetic drivers of HCC to identify novel and potentially actionable pathways remains an important need at large.

---

24 A general review of these current standard therapies was recently published (Llovet, et al.,2021).
1.3.2 SND1 OE in clinical samples

There are at least two studies that show the OE of Snd1 in a clinical setting. The first uses tissue microarray wherein there is an upregulation of SND1 in 74% of tissues compared to normal tissues (64). Also, a pan-cancer analysis from TCGA data also indicated Snd1 upregulation in many cancer types (112). Further, Snd1 expression was correlated with a worse overall survival and disease-free survival in both glioblastomas and HCC. Various mutations of Snd1 improved patient outcomes of overall survival, disease-specific survival, disease-free survival, and progression-free survival (112). Together, these are hallmarks of oncogenic drivers and implicate SND1 as involved in HCC.

1.3.3 Snd1 drives HCC in SB screen

SB mutagenesis is a powerful tool that has been used to screen for potential oncogenes for nearly two decades (138). The SB transposon has undergone substantial genetic engineering to create increasingly potent and focused tool enzymes (139). Simply, SB mutagenesis uses a two-part insertion program to randomly incorporate a transposon vector into the host genome. The transposon vector contains promoter sequence and inverted stop codons. Splice donor and splice acceptor regions within the transposon allow the vector to insert a viral promoter or stop codon throughout the genome including into genes. A promoter incorporated vector will allow for amplification of oncogenes, while stop codons inserted into tumor suppressors will effectively silence their expression by the bi-directional stop-codon. Next-gen sequencing of tumor tissues then allows for identifying insertion sites and identification of potential driver genes25. The improved transposase iteration, SB11, was used for the studies that identified Snd1 as a potential driver in both SB screens using a chronic hepatitis and Pten null mouse respectively26. In both

25 These are an in-depth review of this system (Copeland, et al.; (Moriarity, et al., 2015).
26 B6.129 (Bard-Chapeau, et al.,2014) and B6.C (Kodama, et al.,2018) backgrounds.
models, insertion of the transposon upstream of Snd1, thereby amplifying the gene, was a potent driver of HCC (128, 130).

1.3.4 SND1 drives HCC in OE GEMM

Independently, a second group identified Snd1 as a bona fide driver of HCC. An exogenous copy of Myc-tagged human Snd1 was cloned behind the albumin promoter to create a liver-specific Snd1 OE mouse27. This mouse developed histologically verifiable HCC spontaneously. When these mice were exposed to carcinogen, they had an exacerbated tumorigenic response with more aggressive tumor growth28 (129).

Within this same study, authors used a general nuclease inhibitor, pdTp29, to target SND1 in tumor-initiating cells and HCC xenografts to show proof of concept that SND1 inhibition may impair tumorigenesis. These results support the need to better understand SND1 biology and if targeting SND1 may have therapeutic action against this axis. However, none of these approaches break down the functional domains of SND1 to determine if the Tudor domain is needed for these processes.

1.3.5 Evidence for Prmt5 in promoting HCC

PRMT5 has become an increasingly prominent topic in the HCC literature in recent years. However, the data remains circumstantial, and it is unknown if PRMT5 itself can drive liver cancer or if these correlations are byproducts of cancer cells evolving to meet biochemical demands. The reported literature thus far implicates PRMT5 in this disease by correlating protein level with disease, impacting an epithelial to mesenchymal transition (EMT), and promoting hepatocyte function. Each of these topics and examples are described in further detail in appendix A.

---

27 B6CBAF1 genetic background.
28 Expression of myc-SND1 quantitatively increased SND1 levels by approximately three-fold. Of interest, the mutagenic SB screen identified that insertion of an oncogenic transposon upstream of Snd1 increased its expression by approximately two-fold (Bard-Chapeau). Thus, each of these reports support that a comparative moderate increase of SND1 is oncogenic.
29 3',5'-deoxythymidine bisphosphate.
1.3.5.1 Correlation of PRMT5 levels and disease

PRMT5 has been shown to be overexpressed in HCC and correlates with a worse prognosis (23, 26, 142-144). High levels of PRMT5, shown with mRNA (142) or protein (26, 143), decreased survival and increased recurrence (26, 144). Interestingly, mRNA level does not always match protein level and Prmt5 mRNA is highly varied in different HCC cell lines and in resected liver tissue (142). One explanation for high protein level is the observation that PRMT5 interacts with the long intergenic non-coding RNA 1q21.2\(^{30}\). This interaction allows PRMT5 to escape proteasomal degradation. Accumulation of this non-coding RNA correlated with tumor size, alpha-fetoprotein (AFP)\(^{31}\), and hepatitis B surface antigen levels (145). The stabilization of PRMT5 protein could explain the phenomenon of increased protein levels while some mRNA databases don’t identify increased Prmt5 levels in HCC.

1.3.5.2 PRMT5 facilitates EMT related pathways

EMT is part of the classic hallmark of cancer, invasion and metastasis, from the year 2000. This descriptive characteristic can be influenced by many different pathways\(^{32}\). E-cadherin depletion is one such pathway that may be impacted by PRMT5. The PRMT5-MEP50 complex binds to AJUBA, a key scaffolding protein for SNAIL. Recruitment of these factors to the E-cadherin enhancer can repress its expression, with protein turnover depleting E-cadherin levels (146). Invasiveness, a next step of transition, is also impacted by PRMT5 controlling protein levels of matrix metalloproteinase 2 (23, 25)\(^{33}\). Expression of the liver-specific transcription factor hepatocyte nuclear factor 4\(\alpha\) (HNF4\(\alpha\)) is a cellular defense against dedifferentiation in

\(^{30}\) Also called LINC01138

\(^{31}\) AFP is a common blood contaminant in patients with HCC.

\(^{32}\) “Hallmarks” of cancer are primarily descriptive of cellular states rather than mechanistic explanation of cellular function. Thus, a hallmark like “evasion of apoptosis” or “invasion and metastasis” could impact hundreds of possible targets to achieve this behavior. Hence, EMT is less of a defined biochemical/molecular state, and is more a way to describe the overall cellular behavior.

\(^{33}\) This relationship of PRMT5 to matrix metalloproteinase 2 was shown in a PRMT5 knockdown and PRMT5 competent lines respectively. It was not shown if this was transcriptionally regulated, splicing impacted, or protein stability influenced.
hepatocarcinogenesis. H4R3me2s marks from PRMT5 at the Hnf4a promoter repress its transcription, thereby promoting cancer stemness and implicating PRMT5 as oncogenic (25).

1.3.5.3 Increased hepatocyte function by Prmt5 transcriptional control

Steatosis34 is preliminary to developing HCC. Thus, hepatocytes with overactive de novo lipid production is often concurrent with hepatic damage and increased risk of developing liver disease and cancer (147). Sterol regulatory element-binding protein 1 (SREBP1) is a central transcription factor that controls genes involved in synthesizing various lipids. PRMT5 methylates SREBP1 stabilizing the transcription factor and promoting gene expression. Overexpressing Prmt5 in HepG2 cells increases intercellular triglycerides, which is reversible with its knockdown35 (24). Taken together, PRMT5 promotes de novo lipogenesis, a key pathway that increases risk of developing HCC36.

It remains an important question to answer if PRMT5 activity is directly oncogenic in a hepatic setting. The findings to date have looked at PRMT5 in pre-diseased states. Thus, the findings that show PRMT5 promoting tumorigenesis could arise from other factors driving disease and transformation. Additionally, dependencies on PRMT5 could be the byproduct of overall cellular toxicity to inhibiting PRMT5 rather than specifically targeting oncogenic effects themselves. Thus, the direct role of PRMT5 in promoting HCC remains to be determined.

34 Fatty liver disease. The major risk factors of this fatty buildup in the liver is obesity and diabetes. This pathology is precursor to developing nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
35 Additionally, deletion of SREBP1 GAR motif (GAGRG- amino acids 365-369) impedes triglyceride accumulation in HepG2 cells.
36 There is evidence that PRMT5 methylates E2F1 to influence cellular fates and cellular signaling (Cho, et al.,2012); (Zheng, et al.,2013); (Roworth, et al.,2019); (Su, et al.,2015); (Barczak, et al.; (Pastore, et al.,2020). This may have substantial roles in HCC, especially given an expanding understanding of E2F1 in HCC (Farra, et al.,2017). Thus, PRMT5 could be important for driving HCC by altering cellular signaling.
1.4 Summary and scope

In cells, arginine methylation is an essential PTM for normal development and homeostasis. PRMT5 is the primary enzyme that catalyzes SDMA and requires MEP50 for protein stability and enzymatic activity. Conditional KO of Prmt5 is deleterious or even lethal in most tissues which has broadened our understanding of the role and function of PRMT5 in development and disease. However, it is not known if there is a phenotype for overexpressing PRMT5 in specific tissues. PRMT5 related proteins and pathways are important in the liver, giving us an interest in studying PRMT5 OE in the liver.

Effectors bind PTM’s to facilitate downstream signaling and activity. SND1 is a SDMA specific binder via its single C-terminal Tudor domain. Protein-protein interaction mapping identifies most proteins interact with either the SN- or Tudor domain of the protein. There may be additional targets of the Tudor domain which are yet to be identified. The phenotype for a Snd1 full body KO mouse was recently published. However, it is unknown what phenotypic changes are dependent on the Tudor domain of SND1.

Both PRMT5 and SND1 have been implicated in cancer at large and in HCC. SND1 is reported as increased in patient samples of HCC and has been confirmed as a driver of HCC using GEMMs. However, it remains unknown if SND1 loss can protect against HCC development. Further, it is unknown if the Tudor domain plays a part in this process. We hypothesize that the SND1 Tudor domain is critical for the oncogenic functions of SND1. Upstream of the SND1 Tudor domain, PRMT5, the writer of SDMA, has been reported to have a role in HCC by predisposing hepatocytes to develop HCC by impacting cancer transformation pathways. However, it remains to be determined if Prmt5 OE alone is sufficient to drive HCC formation. We hypothesize that liver-specific Prmt5 OE will be oncogenic.

This work utilizes three GEMMs to test these hypotheses, namely an Snd1 KO, Snd1 KI, and Prmt5 OE mouse, none of which have previously been published. For clarity and convenience in reading, the work is divided into two parts. First are the new findings of the reader
function of SND1. The second part contains the work done on the writer, PRMT5. Follows is a summary of conclusions written in the same order and giving an analysis of the results and the value of this work.
2 Chapter 2- Materials and methods

2.1 Mouse experiments

All mice used for experiments were age and sex matched as indicated. Every mouse experimental protocol was reviewed and approved by the Institutional Animal Care and Use Committee at MD Anderson Cancer Center (ACUF# 00001090-RN03).

2.2 Generation of mouse models

2.2.1 Snd1 KO and KI GEMMs

Both Snd1 KO and KI mice were generated using CRISPR/Cas9 gene-editing technology. sgRNA, donor DNA, and Cas9 protein were from Horizon Discovery. Snd1 KI mice were generated using sgRNA targeting tyrosine 766 of Snd1, donor DNA encoding the tyrosine to leucine substitution (Y-to-L mutation) were designed by Horizon Discovery. An AvrII restriction site was also introduced into the donor DNA for easy genotyping. To generate the Snd1 KO and KI mice, the sgRNA, Cas9 protein, and donor DNA (for Snd1 KI mice generation) were micro-injected into 1-cell FVB embryos. The injected embryos were transferred into pseudo-pregnant recipient female mice. Genomic DNA from the resultant pups was isolated and used for PCR genotyping. PCR products were purified and sequenced to identify heterozygous mice as founders. The founders were backcrossed with FVB strain background mice for four generations to separate any potential off-target event. The sequences of sgRNAs and donor DNA are as follows:

Snd1-KO sgRNA: tcctcgcaagaagctgattGGG; Snd1-KI sgRNA: catgtcttcatcgactaCGG
Snd1-KI donor DNA: CATTGCAGGTACCAGCCCGGGTAGAAAAGGTGGAGTCCCCTGCC
AAGTGCATGTCTTTCTACATCGACAAGTGAGTGCTGGGACCAGGGTGGAACA
GGCAAGGCAGGGACCATTGGGCACAG

2.2.2 PRMT5 OE GEMM

B6/C3HPRMTS mice were generated using homologous recombination of donor plasmid into the mouse genome by the Vokes Lab at The University of Texas, Austin. A V5-tagged full length murine Prmt5 adjacent to an IRES and full length murine MEP50 (with a C-terminal BGH polyadenylation signal) sequence was cloned into the pROSA26PA targeting plasmid. This pROSA26PAS-V5-Prmt5-Mep50 vector was then transfected into embryonic stem cells and subjected to antibiotic selection. Resistant cells were genotyped to identify those that had undergone homologous recombination. Genotyping primers amplified the entire V5-tag, beginning at the second loxP site and ending within the V5-Prmt5 transgene. Samples without the transgene have no amplicon from this primer set. These cells were microinjected into a blastocyst and transferred into female mice. The resulting chimeric pups were bred to create heterozygous founders. Genomic DNA from the resultant pups was isolated and used for PCR genotyping founders. Founders were backcrossed with B6/C3H mixed background mice for four generations to separate any potential off-target event. The V5-Prmt5-Mep50 sequence combined with the Rosa26 targeting sequence is included in appendix B.

Swiss-Webster Albumin-Cre mice were a gift from the David Johnson Lab, which were originally in an FVB background purchased from JAX laboratory (see appendix D). Swiss-Webster Albumin-Cre mice were backcrossed into B6/C3H background for 4 generations to generate a B6/C3HALb-Cre mouse. PRMT5 OE mice were generated by crossing B6/C3HPRMTS and B6/C3HALb-cre mice. Genomic DNA from pups was used to identify bi-transgenic, or bi-genic, mice.
2.3 MEF isolation and immortalization

We set up a timed pregnancy, and harvested embryos at 12.5-14.5 days post-crossing. Mothers were sacrificed for 5min using CO₂ and let sit for 3 min in cage to allow additional coagulation. Embryos were removed and placed in 1x PBS. We separated embryo’s and gently removed them from their sack. Embryos were decapitated and eviscerated, and the remaining tissue was minced and kept in trypsin (Sigma, cat# T2601) for >30min at 37°C. Trypsin was quenched, and samples homogenized by pipetting in a large volume of FBS containing culture media. The solution was then filtered using a 70um filter (Falcon, cat# 352350). Cells (in the flow through) were plated in 15cm plates and maintained in a designated and separate tissue culture setting. MEFs were genotyped by genomic tissue extraction from yoke sacks using Qiagen DNEasy blood and tissue kit (cat# 69506) according to the manufactures instructions and genotyped as described below.

2.4 Genotyping

2.4.1 DNA extraction

Routine genotyping DNA template was obtained by clipping ~2mm of each mouse tail from 4–7-day old pups and performing a NaOH based DNA extraction. Expanded, tail clips were boiled in 300uL 50mM NaOH for 30 min at 95°C followed by adding 25uL 10mM pH 6.8 TrisHCl and centrifuging at 15,000xg for 10 min. DNA was stored at 4°C following centrifugation. Genomic DNA for sanger sequencing of MEF genotyping was obtained from tissues collected during MEF generation using Qiagen DEasy blood and tissue kit according to the manufacture’s recommendation.
2.4.2 Genotyping Snd1 KO mice

*Snd1* KO mice were genotyped as previously described (151). In brief, genomic DNA extracted from pup tail clips and used as a template for amplification of the target gene region by PCR, to yield a 456bp PCR product. All genotyping PCR reactions utilized GoTaqGreen PCR Master mix (Promega, cat# M7123). The PCR product was split into two aliquots, and a *Snd1* wild-type (*WT*) control PCR product was added to one of the two aliquots. The PCR products were denatured and annealed before digestion with T7E1 endonuclease. The digested materials were then separated by electrophoresis through a 2% agarose gel. In the absence of an added *Snd1* WT control PCR product, only the heterozygous PCR samples were efficiently cleaved by T7E1, resulting in smaller cleaved products (228 bp/227 bp); in the presence of the added *Snd1* WT control PCR products, the *Snd1* KO samples are separated from the *Snd1* WT samples, as the added *Snd1* WT control PCR products resulted in the formation of heteroduplexes with the *Snd1* KO samples that are sensitive to cleavage by T7E1.

*Snd1*-KO genotyping forward primer: TTTAGGAGGCCCTGAGTGTG
*Snd1*-KO genotyping reverse primer: CAGGGCTGCTAGAGGTATGC

2.4.3 Genotyping Snd1 KI mice

*Snd1* KI mice were genotyped using genomic DNA extracted from either tail clips from pups or extracted tissues and subjected to amplification by PCR using the primers described below for 28 cycles. Amplicons were digested overnight with *AvrII* (New England Biolabs) using their recommended protocol and were visualized following electrophoresis through a 2% agarose gel. Digested PCR products from homozygous KI mice resulted in two bands (261bp/145bp), whereas products from heterozygous KI mice displayed 3 bands (406bp/261bp/145bp), representing *WT* and *KI* alleles.

*Snd1*-KI genotyping forward primer: TATTAATCTGCTGCCCGTGCT
*Snd1*-KI genotyping reverse primer: GAAGAGTGGCGGTGACCAATA
2.4.4 Genotyping PRMT5 transgenic mice

Genotype of the B6/CH3\textsuperscript{PRMT5} mice was determined using PCR amplification of genomic DNA for the V5-tag. Using the primers below, genomic DNA was PCR amplified for 34 cycles and visualized using electrophoresis through a 2% agarose gel with gel red (Millipore, SCT123). A 189bp amplicon indicated the presence of at least one copy of the V5-Prmt5 transgene.

\textit{V5-Prmt5} genotyping forward primer: CCCAGTGTGTCAGCTATTTC
\textit{V5-Prmt5} genotyping reverse primer: GAAGTTATTTTGTCGACGCT

We likewise genotyped for Albumin-Cre in the respective mice using a four-primer PCR approach with to amplify the Albumin-Cre transgene and an internal PCR control. B6/CH3\textsuperscript{Alb} positive samples resulted in a 500bp Albumin-Cre and 324bp control amplicons while samples lacking Albumin-Cre only showed a 324bp control amplicon.

\textit{Albumin-Cre} forward primers: CCAGGCTAAGTGCTTTCTACA
\textit{Albumin-Cre} reverse primers: AATGCTTCTGTCCGTTTGCCGGT
Internal PCR control forward primer: CTAGGCCACAGAATTGAAAGATCT
Internal PCR control reverse primer: GTAGGTGGAAATTCTAGCATCATCC

2.5 Sequencing

Genomic DNA was purified from MEF tissues using a DNeasy kit as described above. Purified DNA was PCR amplified using High-fidelity Taq-polymerase (New England Biolabs, 0491L) and run on a 2% agarose gel to confirm the appropriate size of amplicon and lack of off-target amplification in WT samples. Samples were then purified using a Qiagen QIAquick PCR purification kit (cat# 28104) according to the manufacture’s recommendations. Amplicons were then sequenced through the MD Anderson Sanger sequencing services.

\textit{Snd1 KO} and \textit{Snd1 Kl} genomic DNA samples were amplified using the genotyping primers shown above.
Prmt5^{OE} genomic DNA was amplified using six primer sets with overlapping 3’ to 5’ ends to amplify the complete V5-Prmt5 and Mep50 sequences. Due to the repetitive nature of IRES sequences, this portion of the transgene was excluded from PCR amplification and sequencing.

V5-Prmt5 set 1.1 forward: GAAGTTATTTTGTGACGCT
V5-Prmt5 set 1.1 reverse: GGAGGTCAGCTCACAATT
V5-Prmt5 set 2.1 forward: GTGGCATAACTTTCGGACTCT
V5-Prmt5 set 2.1 reverse: CCCAGAAGCTCACTGACAATAA
V5-Prmt5 set 2.2 forward: AGCTGACCTCCGTCGACTTA
V5-Prmt5 set 2.2 reverse: TGCTCAGCCATCATCTTT
V5-Prmt5 set 3.1 forward: CTCCGGAGAAAGCTGACATTAT
V5-Prmt5 set 3.1 reverse: CCTAGGAATGCTCGTCAAGAAG
Mep50^{trans} set 4.2 forward: GAGTCAATGGCTCTCCTCAA
Mep50^{trans} set 4.2 reverse CTACTGTCTCTCCTACATGAAAGAA
Mep50^{trans} set 5.1 forward AGCTGTCAGTGGTAGCAAAG
Mep50^{trans} set 5.1 reverse TAGGAAAGGACAGTGAGGT

2.6 Liver harvest for Western blot

Livers were extracted from 2-month-old male mice and washed in ice cold 1x PBS to remove surface blood. Liver chunks were taken in pie-shaped pieces from outside to center of the largest lobe and flash frozen in liquid nitrogen, storing at -80 for short term storage, and stored in liquid nitrogen for long term storage. During protein extraction, frozen liver chunks were weighed and added to 0.5mL/0.1g tissue lysis buffer. Liver lysis buffer for protein extraction was T-PER tissue protein extraction reagent (Thermo, 78510) with 1x Protease inhibitor cocktail set 1 and 1x phosphatase inhibitor cocktail. Tissue was homogenized in Dounce with tight pestle six times on ice. Slurry was then ultracentrifuged at 74k RPM for 60 min at 4°C. After ultracentrifugation, lipid layer was removed, and solution was flash frozen in liquid nitrogen as aliquots. Relative protein
concentration was obtained using Bio Rad protein assay dye reagent concentrate (Bio Rad, 5000006).

2.7 Western blot analysis

Cultured cells were lysed in 1x RIPA buffer containing 1x protease inhibitor cocktail set 1 (Millipore, cat# 535142), and 1x phosphatase inhibitor cocktail (shown below). Equivalent protein concentrations were boiled in 1xSDS laemmeli buffer for 10 min. Boiled samples were loaded and run in 10-15% in-house prepared polyacrylamide gels.

2.7.1.1 In-house prepared gradient polyacrylamide gels

Gels were made with: 30% Acrylamide bis (BioRad, Cat# 1610158), 1:1 diluted SDS solution 20% (BioRad, Cat# 1610418), N,N,N’,N’ tetramethyl ethylenediamine (Acros Organics, Cat#420580050), and ammonium persulfate (Sigma, Cat# A3678-100G). Polyacrylamide gel was then transferred to a methanol activated 0.45um PVDF membrane (Millipore, Cat# 88518) using semi-wet transfer.

2.7.2 LI-COR detection by fluorescence-

Wash buffer contained 1x PBS with 0.5% Tween20 (BioRad, Cat# 1610781) (PBS-T), and blocking buffer contained 3-5% nonfat powdered milk (LabScientific, Cat# M0841) dissolved in PBS-T (X% milk). After transfer, PVDF membranes were blocked for 1hr in 3% milk followed by incubating with primary antibody overnight. Rabbit and mouse primary antibodies were co-incubated overnight. Membranes were washed in cold water followed by two PBS-T washes for 12 min each. Respective secondary fluorescent antibody was next added in 3% milk for 1.5 hrs while rocking in the dark then washed twice in water for 12 min each.
2.7.3 Western blot detection by chemiluminescence-

PVDF membranes were blocked for 1hr in 5% milk followed by incubating overnight with 1° antibody. This was followed by three 10 min washes in PBS-T. 2° antibody was added for 1hr of rocking at RT followed by three PBS-T washes at 10 min each. Membranes were developed using Western Lighting (Perkin Elmer, 203-21341).

2.8 Antibodies

The following antibodies were used: name; company, catalog number.

β-Actin; Sigma, A1978

BrdU; BD BioScience, 8309543

MEP50; Cell signaling technology, 2018S

Myc-tag; CST, 2276S

ADMA- Developed by NEP and reported in (152)

MMA- Developed by NEP and reported in (152)

SDMA- Developed by NEP and reported in (152)

PRMT5; Cell signaling technology, 799985

SND1; Active Motif, 61473

SND1; Bethyl, Cat# A302-883A

V5-tag; Ab Cam, ab27671

α-Rabbit IgG Alexa fluor secondary; Invitrogen, YA354845

α-Mouse IgG Alexa fluor secondary; Invitrogen, VK307586

Streptavidin-HRP; Pierce, 21126

α-Rabbit IgG HRP secondary, Cell Signaling Technology, 7074
ECL α-mouse IgG HRP; GE Healthcare, NXA931

2.9 Peptide pulldown assay.

Streptavidin beads (Millipore, Cat# 16-126) were pre-washed with cell lysis buffer before incubation with biotinylated GAR-un/Rme2s peptides (10ug) in 500 µl cell lysis buffer for 1h at 4°C with rocking for conjugation. Lysis buffer was composed of the following Sigma compounds: 50mM sodium diphosphate (Cat# S0751-100G), 300mM sodium chloride (Cat# S9888-25G), 10mM imidazole (Cat# I5513-25G) all adjusted to pH 8.0. The conjugated peptide-beads complex was then incubated with cell lysates prepared from primary MEFs for 1h at 4°C with rocking. After incubation, the bound proteins were eluted by addition of SDS-Lammeli buffer for western blot analysis. GAR peptide sequences are as follows with SDMA marked by ***:

GAR-un peptide: GGRGRGGGFRGRGRGGGG-BIOTIN
GAR-Rme2s peptide: GG[R**]G[R**]GGGF[R**]G[R**]G[R**]GGGG-BIOTIN

2.10 RNA-extraction

Total RNA was harvested from 2-month-old mice using the manufacturer recommendations for total RNA harvesting using TRIzol reagent (Ambion, 368708) and Qiagen RNeasy Plus mini kit (cat#74136). Samples were run through a second round of isopropanol cleanup to increase purity of total RNA.

2.11 RT-qPCR primers

Primers were designed using the NIH Primer-BLAST software. Using accession numbers and requiring primer pair to be separated by at least one intron in genomic DNA. Primers were chosen based on having similar amplicon size, Tm, 3’ GC clamp, similar GC content, low similarity to off target sites, and covering junction sites.

Saa1 F: CATTTGTTTCACGAGGCTTTCC; Saa1 R: CTGAGTTTTTCCAGTTAGC
Saa2 F: CATTTATTGGGAGGCTTTCC; Saa2 R: CTCCATCTTTCCAGCCAGC
Lcn2 F: TGAAGGAACGTTCACCCGC; Lcn2 R: CCATTGGTCTCTGCGCATC
Orm2 F: CGCTGTGGGAAGTCAGC; Orm2 R: TAGGACAGCGCGACAAATGA
Moxd1 F: ATCACCGCAACATGCCCAGT; Moxd1 R: CCTCCGTGCGGGATTATCGT
Cyp3a44_set 1 F: CTGAGCTTTTCAGTGCTGTG; R: GATCCCCGAGAAACGGGTAAG
Cyp3a44_set 2 F: CTCACTTCGTCCTTCAG; R: GGTATGGGGATTGGGACTCT
Cyp2c39_set 1: AGGTCTGCATCATTCCTCGCT; R: ACCTGGACAGGATTCGAAGG
Cyp2c39_set 2: ACCTTTTGTGCAGGGGACA; R: GGGCTCGGTTGTCGATCAAT

2.12 RT-qPCR analysis

RNA was harvested from liver tissue as described above. A cDNA library was generated with an iScript cDNA Synthesis Kit (BioRad, Cat# 1708891) using the manufacturer’s recommended volumes and thermocycler conditions, before dilution in nuclease free water. From the diluted library, 20 ng cDNA was added to 500 nM primers in recommended volumes of 1x iTaq Universal SYBR Green Supermix (BioRad, Cat# 1725122) in 384 well plates. Thermocycler conditions were: step 1 - 95°C for 5 min; step 2 - 95°C for 15 sec, 60°C for 1 min; repeat step 2 39x; step 3 - 65°C for 5 sec, and 95°C 50 sec. Expression change was calculated using ΔΔCt methodology. Expressly, Ct values of Gapdh were obtained for each biological replicate. The ΔCt was next calculated as the difference of each raw Ct value from the respective biological housekeeping gene average. The average ΔCt was obtained for only the biological WT control for each gene of interest. The ΔΔCt was then calculated as the difference between each ΔCt, and the average ΔCt of the biological WT control. We then calculated and reported 2^ΔΔCt.

2.13 RNA-sequencing of Prmt5OE samples

Total RNA was purified as above and the RNA-seq library was prepared with an Illumina TruSeq stranded mRNA kit (Medgenome) and sequencing was performed using a NovaSeq
(PE150) machine. Paired-end sequencing was performed to a depth of 40 million reads (80M total). The RNA-seq raw reads were mapped to the mouse genome GRCm38(mm10) and the raw read count for genes was analyzed by the bioinformatics tool “featureCounts” (https://subread.sourceforge.net/featureCounts.html). The normalized read count was generated from built-in functions in DESeq2. The differential expression analysis was performed with a DESeq2 bioconductor R package using a cutoff of FDR $q \leq 0.05$. Differentiated genes were further analyzed by GSEA from Broad Institute (https://www.gsea-msigdb.org/gsea/index.jsp).

2.14 DEN injection model

DEN (Sigma, N0258-1G), also known as N-nitrosodiethylamine, was diluted to 2 mg/mL in sterile 0.9% saline and stored at 4°C. All DEN injections were performed on 14-day old male mice. Pups were interperitoneally injected with 20 mg/kg DEN using a 1mL TB/insulin style syringe and moved into a fresh Innovive cage for 14 days post-injection to allow drug wash out, switching the cage and weaning at 7 days post-injection. After wash-out, mature mice were then moved into normal caging and allowed to grow tumors for 272-274 days. We excluded females from DEN studies as they develop HCC in $<30\%$ of DEN injections with varied penetrance (153). This is compared with nearly 100% penetrance in males. Increased HCC incidence in males is also seen in humans. Thus, DEN induced HCC is a non-optimal approach for directly comparing tumorigenesis in females but is excellent for foundational HCC studies in males.

2.15 Bloodwork

>400uL whole blood was collected from sacrificed mice directly from the heart and immediately placed in a 1.5mL green capped lithium heparin tube (BD Microtainer, 365965). Analytes were then measured using an Integra 400 plus machine from Roche.
2.16 BrdU proliferation model

Pups were injected with DEN as described above. 24hrs post-DEN injection, mice received a 15mg/kg BrdU (Selleckchem, S7918) injection interperitoneally. After 1hr intercalation period, livers were harvested and stored in 10% formalin (Fisher Chemical, SF100-4) prior to paraffin emending and sectioning. Whole liver sections were taken from each mouse and stained with BrdU antibody. Liver section slides were analyzed by counting total cells and BrdU positive cells in an area of 600um x 700um, approximately 1300 hepatocytes. Each slide was counted twice, with each genotype contributing three individual mice. Slides were analyzed using ImageScope v 12.4.3.5008.

2.17 In vitro methylation assay

Livers were harvested from two-month-old mice from Prmt5 OE and Prmt5 WT littermates. Livers were washed in ice cold sterile PBS prior to cutting into 20-50mg wedge shaped slices and flash frozen in liquid nitrogen. 20mg frozen liver chunks were pulverized in liquid nitrogen using a mortar and pestle and the powder dissolved into 1mL PBS+0.5%Tween with 1x Protease inhibitor cocktail set 1 and 1x phosphatase inhibitor cocktail. Cellular slurry was then put into a glass Dounce and plunged 7 times with a loose pestle. The lysate was then spun at 15,000xg at 4°C. Following the spin, the following was added for the positive control samples: 16.5uL sterile PBS, 0.67ug PRMT5/MEP50 complex (Reaction Biology, HMT-22-148) enzyme, 1uL adenosyl-L-methionine, S-[methyl-3H] (3H-SAM) (Perkin Elmer, NET155V001MC) and 1.5ug Recombinant Histone H4 (New England BioLabs, M2504S). The following was added for their respective samples: 17.5mL liver lysate, 1.5ug recombinant Histone H4, 1uL 3H-SAM and 1uL MS023 (Sigma, cat# SML1555). Reactions were pipetted to mix and incubated at 30°C for 60 min or the respective number of minutes. The reaction was stopped by adding 5x SDS-buffer with bromophenol blue with β-mercaptoethanol and boiling for 10 min. Samples were then run on a 15% poly acrylamide gel at 150V for 70min. Sample was semi-wet transferred onto PVDF
membranes at 75V for 75 min. The membrane was then air dried then sprayed with homemade enhance solution (recipe below) twice, drying between, followed by exposing radiosensitive film for one week at -80 degrees C.

2.18 Enhancer spray

In-house enhance spray was generated from a recipe shared from Pål Falnes at the University of Oslo. We added the following to the respective final concentrations: 2-methylnaphthalene (Sigma Alderich, cat# M5700-500G), 57%; Pentyl acetate (Sigma, 109584-250Ml), 40%; and 2,5 Diphenyloxazole (D210404), 2.5%. Once mixed, the solution was stored in the chemical fume hood at room temperature in a spray bottle.

2.19 Transient transfection

Six-well plates were seeded to 30% confluency 24hrs prior to transfection. 18ug polyethylenimine (PEI) was incubated with 6ug myc-PRMT5 plasmid DNA in 100uL optimem (Gibco, 31985062) for 10min at room temperature. This full volume was then added to a single well and media changed after 5 hours. In non-transfected cells, Epz015666 (Sigma, cat# SML1421) was added to 10uM final concentration on the same day in an equal number of cells. 72 hours post-transfection, empty vector-transfected, myc-PRMT5 transfected, and Epz015666 treated non-transfected cells were harvested using a cell scraper and processed for western blot analysis as described above. The myc-PRMT5 plasmid was a gift from the Stephane Richards lab.

2.20 Hydrodynamic Tail Vein Injection

Hydrodynamic tail vein injection followed the protocol set forth previously (154-156). pT3-EF1a-c-myc (p-c-myc), px330-αTp53 (p-αTp53), and SB13 plasmids were a gift from the Ernesto Guccione Lab from Ichan School of Medicine at Mount Sinai. Five-week-old male mice were placed under a 125-watt heat lamp for 5 min to dilate tail veins. While tails were dilating, DNA for
p-c-myc, p-α Tp53, and SB13 was diluted to 10mg/kg for the first two and 2.5mg/kg for the latter into 10% of the mice mass in 0.9% sterile saline. Single mice were restrained using a TV-150 Braintree Scientific Inc with a standard barrel (sku # TV-150 STD) and tail cleaned with 70% ethanol. Using a 27.5-gauge needle in a 3mL sterile syringe, 10% of the mouse mass by volume was injected into the tail vein over the course of ~5 seconds. Mice were immediately removed from the restraint and placed into a fresh cage and observed for wellbeing until they returned to normal activity.

Mice were followed for thirty days with daily observation. On the thirtieth day, surviving mice were sacked and livers excised. Terminal mouse mass and liver mass was obtained for each mouse surviving to day thirty. Necropsies were performed and mice were checked for distal lesions. Following hepatectomy, if tumor lesions were distinguishable, they were excised and arrayed onto white paper and photographed. Livers were saved in 10% formalin for downstream H&E staining.

2.21 Phosphatase inhibitor cocktail

1000X concentration phosphatase inhibitor cocktail was prepared from the following: 1M sodium orthovanadate, 1M sodium molybdate, 4M sodium tartrate, 1M sodium fluoride, 2mM Imidazole, 2mM β-glycerophosphate, and 1mM sodium pyrophosphate. All compounds were solubilized in water.

2.22 Post-DEN treatment necropsy procedure

DEN-induced tumorigenesis mice were allowed to age for an additional 272-274 days post-DEN injection. Upon sacrifice, terminal mouse mass was obtained. ≥400uL blood was taken from the heart followed by a full necropsy. Livers were excised and terminal liver mass obtained. Photographs were obtained of each mouse and liver. Mice were examined for additional neoplasms throughout the organism. 3 ~100mg pie shaped section was taken from the large
lobe of each of the mice and flash frozen in liquid nitrogen or OCT. Remaining liver and any other lesion containing tissues were fixed in 10% formalin for downstream H&E staining.

2.23 Photoshop courtesy edits

Photos of tumor grossing have been courtesy edited to remove residual blood and normalize colors to fix differences between cameras. Under the “image” tools and “adjust” ribbon, the “shadow and highlights” dialog box was used to increase the “amount”, “tone”, and “radius” options under the shadows option. Values were adjusted till color saturations were similar between photographs taken with different cameras. Next, peripheral blood was removed using the “stamp” tool to mimic adjacent clean areas of the image.
Chapter 3- Characterizing loss or mutation of SND1 and the effect on HCC

3.1 Introduction and scope

SND1 is involved in several biological processes. It is not known what the phenotype of an SND1 Tudor domain mutant is or if there are transcriptionally regulated genes under the control of the Tudor domain. Loss of the Tudor domain alone may contribute to the KO phenotype. SND1 has been identified as a driver of liver cancer when overexpressed. However, it is unknown if SND1 loss can protect against tumor development. Further, it is unknown if the Tudor domain is needed for driving tumorigenesis. We hypothesize that the SND1 Tudor domain is important for developing HCC. Two GEMMs were recently developed in our lab for SND1 studies, namely a Snd1 whole body KO mouse (Snd1 KO) and a Snd1 Tudor domain mutant (Snd1 KI) mouse. These mice are functionally validated, and their transcriptome analyzed. We then chemically induced liver cancer in these mice to study the impact of Snd1 loss or mutation on tumor formation.

3.2 Generation and validation of Snd1 KO and KI mouse lines

3.2.1 Snd1 KO GEMM

First, a Snd1 KO mouse line that expressed no SND1 (Snd1 KO) was generated. These were generated in our lab by using a CRISPR/Cas9 guide RNA to target the third exon of SND1, corresponding to the SN-1 domain (Figure 4a). The sgRNA and purified Cas9 protein were micro-injected into 1-cell embryos and transferred into pseudo-pregnant female mice to complete gestation. Random mistakes in DNA damage repair will result in a subset of these pups having an out-of-frame genetic deletion in the targeted sequence. This mutation becomes the target of

37 Developed by Y. Wang.
Figure 4- Snd1 KO GEMM validation: a) Graphical structure of WT SND1 with KO design schematic. Expanded below is WT codons in black with amino acid translation above and amino acid number beneath. Frame shift highlighted in red. Below is WT and KO amino acid sequence, with red indicating frameshift translation. b) Screen shot of sanger sequencing for annotated WT and KO samples with gRNA and PAM sequence highlighted. c) Western blot of MEFs from heterozygous Snd1 KO crosses.
genotyping. We obtained genomic DNA from one Snd1 KO pup and Sanger sequenced the target region which revealed a single nucleotide deletion that resulted in a frame shift at amino acid 90, and introducing a premature stop codon corresponding to I99 (Figure 4a,b). This founder was backcrossed into FVB background mice for four generations to reduce chances of off-target effects of non-specific CRISPR/Cas9 cleavage. Heterozygous Snd1 KO mice were intercrossed, and mouse embryonic fibroblasts (MEFs) were generated from 12 days post-coitus (dpc) mouse embryos. Western analysis of these MEFs isolated from a single litter indicated that Snd1 KO samples did not express detectable protein (Figure 4c, lane 1 and 3). The epitope that is recognized by this antibody (Active Motif) is within the 4th SN-domain. To confirm successful knockout, we used a second antibody raised to the N-terminus of SND1 (Bethyl) which binds the 100-150 amino acid in the SN-1 domain. No protein was detected with this antibody indicating successful Snd1 KO.

3.2.2 Snd1 KI GEMM

The structure of the SND1 Tudor domain has been resolved with at least two different SDMA modified peptides. This reveals a four-residue aromatic cage involving F740, Y746, Y763 and Y766 whereupon mutation of any of these residues results in a dramatically reduced binding (1). Having validated the Y766 residue as necessary for SDMA binding, we proceeded with generation of a mouse expressing a full length SND1 protein with a single mutation in the Tudor domain (Snd1 KI). This was done by micro-injecting purified Cas9 protein, sgRNA, and donor DNA to permit homologous recombination at the Y766 site. The mutation was also designed to introduce a novel AvrII restriction enzyme site for genotyping (Figure 5a). We validated the founder by Sanger sequencing and backcrossed into a FVB background against off-target effects for four generations as before (see section 3.2.1). As designed, Snd1 KI mice

---

38 Data not shown.
39 This finding was validated by Y. Wang using recombinant GST-Tudor fusion protein with a Y766L mutation in a peptide pull down. Mutant SND1 was unable to pull down SDMA modified GAR peptide.
40 Developed by Y. Wang.
Figure 5- Snd1 KI GEMM validation: a) Graphical structure of Snd1 KI mouse. Expanded portion is WT and KI design sequence. Y766L mutation highlighted in red. WT translation above, amino acid residue number below. b) Annotated screenshot of WT and KI mouse sanger sequence with gRNA and PAM sequence. c) Peptide pulldown from WT and KI MEFs. Pull down used a GST-tagged SDMA modified GAR peptide (GAR-Rme2s).
harbored the Y766L mutation and AvrlI restriction site (Figure 5b). As before, heterozygous Snd1 KI mice were intercrossed, and MEFs were generated from 12dpc mouse embryos. Protein extracts from Snd1 WT and homozygous Snd1 KI MEFs were used in pulldown assays with SDMA methylated and unmethylated GAR peptides. The SDMA-GAR peptide pulled down SND1 from WT, but not KI samples (Figure 5c). This validated that Snd1 KI mice produce a full length SND1 that cannot read SDMA.

3.2.3 Comparing the phenotype of Snd1 mutant mouse models

While breeding the Snd1 mouse lines, we noticed a slight decrease in fertility in the Snd1 KO mice. Snd1 KO mating cages were monitored for infanticide or postnatal mortality. From our observations, birthed pups consistently reached maturity. Snd1 KO litters from homozygous crosses had significantly fewer pups, while Snd1 KI litters from homozygous crosses did not have a significant change in litter size compared to age matched WT mice (Figure 6a). This keeps with observations in both Drosophila and Mus, as Snd1 has been implicated in spermatogenesis (94, 157). We also noticed that Snd1 KO males were not successful breeders after 4 months of age. Following heterozygous crosses, we observed a decreased mass in both 4-week-old male and female Snd1 KO mice (Figure 6b), consistent with previous reports (101). One copy of Snd1 was sufficient to rescue the mass difference between KO and WT mice. This difference in size was not present in the Snd1 KI mice indicating Snd1 has a role in development and growth that is unaffected by our Tudor domain mutation.

3.3 Transcriptional analysis of livers from Snd1 mutant mice

In mice, Snd1 OE promotes HCC (128-130). Therefore, we sought to determine how loss of SND1 or mutation of the SND1 Tudor domain might influence gene expression that could ultimately impact oncogenic pathways in the liver. A Snd1 KO gene expression profile was

---

41 Heterozygous KO crosses were not tested for fertility.
Figure 6- Litter and body size of Snd1 KO and KI mice. a) Litter size of Snd1 KO and Snd1 KI homozygous crossed mice. Points represent the number of pups per litter. Pups were counted on the day of birth. Litters n = 21, 30 and 25 for WT, KO, and KI, respectively. b) The relative body mass of 4-week-old Snd1 KO and Snd1 KI mice resulting from heterozygous crosses. n = WT (3m, 5f), KO (3m, 5f) and KI (5m, 5f). Statistical t-test, two-tailed unpaired, P-value *<0.05; **<0.01; ***<0.001.
recently published by the Silvennoinen group (101). We noted that several of the top downregulated genes included acute inflammatory response genes involved in innate immunity.

As chronic inflammation is a known driver of HCC, we tested the RNA level of the top dysregulated inflammatory response genes by qPCR. Saa1, Saa2, Orm2, and Lcn2 were all significantly downregulated in Snd1 KO and KI liver samples compared to WT (Figure 7a). These genes, which play a major role in innate immunity, are known to be regulated by IL6/STAT3 signaling in the liver. However, lipopolysaccharide (LPS) activation of IL6 is not negatively impacted in Snd1 KO bone marrow derived macrophages (101). Thus, currently it is unclear how SND1 regulates the expression of acute phase proteins.

The top dysregulated gene in the published Snd1 KO transcriptional analysis was Moxd1, a monooxygenase that localizes to the endoplasmic reticulum (158). Beyond structural similarity to other DBH42 like proteins (159) and localization, little is known about the normal function of this protein43. Interestingly, we saw downregulation of Moxd1 by qPCR in Snd1 KO, but a significant upregulation in Snd1 KI mice (Figure 7b). This altered difference between Snd1 KO and Snd1 KI livers could be indicative of distinct transcriptional profiles for both genotypes.

Taken together, the downregulation of acute phase response proteins (APPs) indicate loss of SND1 or its methyl reading capacity may impact gene expression related to liver function44. Further, the SND1 Tudor domain may have distinct transcriptional control over select targets.

### 3.4 SND1 Carcinogenesis Models

Moderate increase in SND1 is sufficient to promote HCC. With carcinogenic challenge, three-fold SND1 OE resulted in increased tumor burden and a doubling of liver weight (129). Two-fold OE was sufficient to drive tumorigenesis in Pten−/− mice (128) (see also footnote 28).

---

42 Dopamine-beta-hydroxylase.

43 A PubMed search identifies fewer than 30 publications in the last 25 years concerning Moxd1, nearly all having been published in the last 5 years. The primary topics described in these are for Moxd1 in cancer and ER stress induced apoptosis.

44 See section 3.5.3.2 for description of APPs.
Figure 7- RT-qPCR of selected downregulated genes from KO and KI mice, performed in triplicate for 3 WT, 2 KO, and 3 KI independent biological replicates for each genotype. Statistical t-test, two-tailed unpaired, P-value ***<0.001; ****<0.0001. a) Acute phase response proteins are downregulated in published Snd1 KO transcriptome analysis. b) Top dysregulated gene in published Snd1 KO dataset.
From a clinical standpoint, a two-fold increase in SND1 protein levels were observed in 70% of human HCC samples contained on a tissue microarray (112). To determine if loss of SND1 or mutation of the SND1 Tudor domain might have the opposite effect and be protective against HCC development, we treated mice with the carcinogen diethylnitrosamine (DEN).

3.4.1 DEN carcinogenesis modeling

DEN has been known to be carcinogenic for over 60 years and is well established as a chemical tool for studying carcinogenic liver injury in mice45 (153, 160, 161). In cells, DEN is activated by cytochrome P450 enzymes that generate alkylating metabolites which modify DNA bases46. Alkylated bases activate the DNA damage response which can result in cell death, proliferative response, and random oncogenic mutations. Tailored feeding and injection protocols can allow study of different classifications of liver cancer47. Single injection in two-week-old pups is sufficient to drive liver carcinogenesis in virtually 100% of male mice after nine months which recapitulates a toxic exposure to a carcinogen (153). This tumorigenic penetrance makes this chemical useful for comparing liver tumorigenesis in different genotypes. We injected two-week-old male pups with DEN in Snd1 KO, KI, and WT control mice and assessed tumor development at nine months post-injection (Figure 8a). Gross examination of whole liver from 9-month-old mice showed both larger and more abundant surface nodules in WT mice than in either Snd1 KO or KI mice (Figure 8b).

A common way of confirming tumorigenesis in DEN and other HCC modeling is to identify an increase in liver contaminates in the blood that can indicate liver damage. To some degree, this can be used to determine how advanced liver disease has become. We collected whole blood from all injected mice and measured the level of 16 analytes. Only total protein and albumin

---

45On the morphology of diethylnitrosamine induce liver changes and tumors in rats” (PMID: 13776439) was published in 1961 (original in German). The “nitrosamine” family of chemicals, however, have been known to be carcinogenic for even longer.
46 This occurs by hydroxylation by various Cyp superfamily genes, which creates a reactive -OH group that can covalently link to nucleic acids (Liu, et al., 2005).
47 For example, these can include co-injection with CCl₄ for liver fibrosis and hepatitis associated HCC or include high-fat diet to look at non-alcoholic fatty liver disease associated HCC.
Figure 8- Ditethylnitrosamine (DEN) induced HCC grossing and pathology: a) Top, schematic of DEN injection schedule. Only male mice were used for DEN injection studies. n = WT (28); KO (10) and KI (10). All mice survived to nine-month termination. (Bottom) Representative images of whole liver with gallbladder (scale bar = 1 cm). Ventral and dorsal respective to mouse orientation. b) Ratio of observed pathologies from liver lobe sections representing all 240 lobes from 48 mice (n = 50 lobes from each of KO and KI and 140 from WT). Hepatocellular carcinoma and adenocarcinoma were binned together as carcinoma.
Table 4: Blood analyte comparison of *Snd1 WT, KO, and KI* DEN injected mice. Statistical t-test, two-tailed unpaired, P-value, significance <0.05. Significant values in bold.

<table>
<thead>
<tr>
<th>Analyte</th>
<th>DEN Injected</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WT avg</td>
<td>KO avg</td>
<td>KI avg</td>
<td></td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td>3.99</td>
<td><strong>3.5</strong></td>
<td><strong>3.59</strong></td>
<td></td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>251</td>
<td>183.5</td>
<td>95.8</td>
<td></td>
</tr>
<tr>
<td>Calcium mg/dL</td>
<td>10.9</td>
<td>10.9</td>
<td><strong>10.23</strong></td>
<td></td>
</tr>
<tr>
<td>Phosphorus mg/dL</td>
<td>9.29</td>
<td><strong>10.27</strong></td>
<td>8.81</td>
<td></td>
</tr>
<tr>
<td>Glucose mg/dL</td>
<td>242.2</td>
<td>245.9</td>
<td>265.4</td>
<td></td>
</tr>
<tr>
<td>Total Protein g/dL</td>
<td>6.14</td>
<td><strong>5.53</strong></td>
<td><strong>5.39</strong></td>
<td></td>
</tr>
<tr>
<td>ALP (U/L)</td>
<td>102.7</td>
<td>89</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>193.8</td>
<td>169.9</td>
<td>309</td>
<td></td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>24.99</td>
<td>25.39</td>
<td><strong>21.7</strong></td>
<td></td>
</tr>
<tr>
<td>Chloride (mg/dL)</td>
<td>109.3</td>
<td>110.6</td>
<td>109.65</td>
<td></td>
</tr>
<tr>
<td>Globulin (g/dL)</td>
<td>2.148</td>
<td>2.005</td>
<td><strong>1.794</strong></td>
<td></td>
</tr>
<tr>
<td>Potassium (mEq/L)</td>
<td>10.04</td>
<td>10.40</td>
<td>9.974</td>
<td></td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>1039</td>
<td>660</td>
<td>1095</td>
<td></td>
</tr>
<tr>
<td>Sodium (mEq/L)</td>
<td>151.5</td>
<td>152.2</td>
<td>150.6</td>
<td></td>
</tr>
</tbody>
</table>
levels were significantly lower in both Snd1 KO and KI mice compared to WT (Table 4). As the remaining 14 analytes were not uniformly altered, and as we did not measure blood analyte levels of non-injected mice, we determined that we could not use blood analytes as a measure of liver disease.

To compare overall tumor burden and to create a quantitative comparison of neoplastic growth rather than gross observation, we established a pipeline to assess tumor type, average tumor-foci, and average tumor area. In brief, we sectioned all five liver lobes from each mouse and performed H&E staining on each section. These sections were digitally scanned with an Aperio AT2 slide scanner and analyzed with ImageScope software to determine the number of tumor foci and the ratio of tumor to tissue area for each section. These images were then read and scored by a pathologist for tumor type; either hepatocellular carcinoma and adenocarcinoma (binned as carcinoma), adenoma, and hepatocellular hypertrophy (indicating an absence of either tumor type) (Figure 8b). Compared to Snd1 WT mice, KO and KI mice had a greater proportion of liver sections with hypertrophy (8% vs 28% and 26%, respectively) and adenomas (6% vs. 26% and 24%, respectively). This corresponded to fewer carcinomas (88% vs 46% and 50% respectively). This shift in pathology is relevant as HCC progresses through worsening disease states in humans. Carcinomas are typically more aggressive than adenomas and define later stage HCC. The mean ratio of tumor to section area was significantly decreased in Snd1 KO and KI mice compared to WT controls (Figure 9a). A deeper analysis of individual liver lobes revealed the mean number of tumor foci was significantly lower in all five KO lobes and in four of five lobes from KI sections compared with WT (Figure 9b).

Liver index is the ratio of liver mass to mouse mass and is a common metric of tumor burden. In principle, the greater the index, the greater the tumor burden. The body mass of one-month-old male and female Snd1 KO mice was reduced by approximately 20% (Figure 6b). This was independently noted that Snd1 KO mice have smaller body size and livers at 2 months (101). In the case of DEN-treated mice, this mass difference was lost at 9-months, while liver mass was
Figure 9- Tumor burden of DEN-induced HCC in Snd1 KO, KI, and WT mice. 

**A** Percent tumor area per section area of all tumor types from the livers in Figure 8b. Area obtained using ImageScope software and plotted as the ratio of tumor to liver area. Percent tumor area used for statistical test, two-tailed unpaired, P-value ****<0.0001.

**B** Number of tumor foci per lobe section from the livers analyzed in a. Sections with hypertrophy had no foci. Right medial (RM), right lateral (RL), left medial (LM), left lateral (LL), and caudate (Caud). Statistical t-test, two-tailed unpaired. P-value *<0.05.

**C** Ratio of liver plus gallbladder mass to full mouse from the livers analyzed in a. Mouse liver mass obtained post-0sacrifice, prior to further manipulation. Statistical t-test, two-tailed unpaired. P-value *<0.05.
significantly decreased in both Snd1 mutant lines compared to WT. This resulted in the mean liver index being significantly lower in the mutant compared to WT lines (Figure 9c).

Several metrics were obtained to determine the extent of tumor burden between chemically induced HCC between Snd1 WT, KO, and KI mice. Comparison of pathologies, the ratio of tumor to tissue, number of foci, and liver index all indicate that either loss of SND1 or incapacitation of the Tudor domain confers hepatoprotection against DEN-induced HCC.

### 3.4.2 BrdU proliferation assay

To understand the mechanism of how SND1 mutant mice developed less tumors in a DEN induced cancer setting, we tried to determine if proliferation was altered. Liver KO of a master cell cycle regulator, retinoblastoma protein (RB), show increased proliferation in response to DEN treatment (163). Similarly, we injected two-week-old pups with DEN followed by BrdU as previously described. BrdU staining revealed that Snd1 KO mice were unable to induce a proliferative response to DEN treatment, while Snd1 KI mice did (Figure 10).

### 3.5 Conclusions and Future Experiments

Structure/function studies of SND1 in vivo provide valuable insight into the potential importance of its scaffolding, nuclease, and methyl-reader properties. This work provides evidence for distinct roles of the SN- and Tudor domains in development, in transcription, and development of HCC.

#### 3.5.1 Snd1 KO and KI mice reveal Tudor independent functions for SND1

Homozygous KO of Snd1 results in a small body size and reduced fertility. This observation is Tudor domain independent as the Snd1 KI mice have no discernable change in
Figure 10- Proliferation assay in Snd1 variable mice: a) Mice were treated with either DEN (Treated), on non-treated (NT) as a control. For each experimental condition, mice n=3, each sample was counted twice. Sampling area was 600umx700um, ~1300 cells per count, reporting the percent (%) BrdU positive cells. Statistical t-test, two-tailed unpaired, P value *<0.05.
size or fertility. It is not known if the small body size and reduced fertility are linked, however. Here we hypothesize that these phenotypes may be independent from each other.

3.5.1.1 Proposed explanations for a small body size of Snd1 KO mice

Currently, we do not know mechanistically why Snd1 KO mice have a small body size. An early hypothesis was that this phenotype might be linked to lipid metabolism as SND1 is known to be involved in lipid synthesis\(^{48}\). However, there is no data to support that deletion of lipid-synthesis-associated interacting proteins would result in a small body size. SND1 is involved in many other processes which may impact body size. Published RNA-seq dataset identifies that under normal conditions, full-length SND1 controls transcription of a few genes, which expands in response to a stress stimulus\(^{49}\) (101). However, there is no indication that these targets influence total body size. SND1 is involved in RISC activity, stress granule formation, splicing, and protein processing at the ER which implicates many potential cellular pathways that could impact body size. Identifying other genetic knockouts in these pathways that phenocopy the Snd1 KO GEMM will be important in identifying the cause of small body size from loss of SND1.

3.5.1.2 Reduced fertility in Snd1 KO mice

One copy of Snd1 is sufficient to rescue a reduced fertility phenotype. This rescue is independent of the Tudor domain. However, it is not clear if this is because of SN-domain scaffolding or SN-domain nuclease activity. As examples of these functions, CA- and UA-rich miRNAs can be directly degraded by SND1 during G1/S phase (167, 168). Also, SND1 is recruited to RISC as a scaffolding protein for the complex and binds many different RNA-binding proteins for transcriptional regulation (Figure 3). Accordingly, decreased fertility could be

\(^{48}\) As early as 2000, SND1 was shown to be involved with lipid droplets in mammary tissues in mice and cows (Keenan, et al., 2000). Importantly, SND1 does not appear to be exported in exosomes, but rather functions in lipogenesis itself. Sucrose gradient reveals SND1 pulls down with endoplasmic reticulum and golgi proteins (Garcia-Arcos, et al., 2010). Finally, overexpressing SND1 in rat HCC cells deregulates cholesterol synthesis (Navarro-Imaz, et al., 2016).

\(^{49}\) SND1 has a dynamic control in response to stimuli. This includes recruitment to stress granules in repose to heat shock (Gao, et al., 2010).
impacted in any number of pathways through these enzymatic or structural roles. Of note, loss of SND1 in *Drosophila* exhibit decreased spermatogenesis and a faster reduction in fertility with age (169). As we noticed males had difficulty mating after 4 months, this could indicate that *Snd1 KO* mice have impaired spermatogenesis resulting in reduced fertility. This can be tested by TUNEL\textsuperscript{50} staining and tracking the fertility over time of *Snd1 KO* male mice (170). Another possible reason for observing decreased fertility is that *Snd1 KO* embryos could be developmentally impaired and absorbed by the mother. A series of timed pregnancies and inspecting the number of embryos will determine if *Snd1* loss compromises some embryos.

3.5.2 Transcriptional analysis

We were able to validate a group of the top dysregulated genes from a published dataset within a separate mouse. This similarity of differentially expressed genes indicates that our *Snd1 KO* mouse is similar to the published datasets even though the knockouts were generated in different mouse backgrounds (FVB and C57BL/6N, respectively).

We identified that several APPs are downregulated in both *Snd1 KO* and *Snd1 KI* mice, implicating the Tudor domain as involved in their expression. As we see with *Moxd1*, this is the first indication that a Tudor domain mutant SND1 may have a distinct transcriptional profile from a full body *Snd1 KO* (Figure 7). The next steps in understanding the transcriptional control of the SND1 Tudor domain will be a robust analysis of the transcriptome of both *Snd1 KO* and *KI* samples by ChIP-seq and CUT&RUN. SND1 is known to bind SDMA modified SmB/B’ and SmD1/D3 which are core proteins of the spliceosome (71). It remains to be determined if *Snd1 KO* can alter global splicing, and further, if Tudor domain mutation will phenocopy a splicing defect of loss of SND1.

\textsuperscript{50} TUNEL- Terminal deoxynucleotidyl transferase dUTP nick end labeling.
3.5.3 Carcinogenesis modeling

We found that the loss of either SND1 or its Tudor domain reader function has a protective role in DEN-induced tumorigenesis (Figure 8 gross tumor observations and pathologies and Figure 9 tumor burden). The mechanism for protection remains to be determined. We propose two means of protection by changes in transcriptional regulation from the loss of SND1. Though preliminary results implicate transcriptional regulation, we note that these processes may be transcriptionally independent. Following these considerations will be a description of how to leverage the vulnerability of SND1 loss with our current understanding of SND1 in hepatocarcinogenesis.

3.5.3.1 Transcriptional control of DEN metabolizing enzymes

Cytochromes are involved in drug processing in the liver. In hepatocytes, DEN is hydroxylated by cytochrome P450 proteins, upon which hydroxy-DEN will alkylate DNA and initiate a DNA damage response$^{51}$ (162, 171-173). The cytochrome P450 3a (Cyp3a) family is reported to be involved in metabolizing 30-60% of current pharmaceuticals and may be involved in DEN processing$^{52}$ (174). Cytochrome expression can be suppressed by repressing cytokine signaling via the JAK/STAT signaling (172). SND1 is a transcriptional co-activator by binding STAT6 and RNA Polymerase II (175). Thus, loss of SND1 could result in loss of STAT-mediated transcription of cytochrome proteins. It has been noted that different cytochrome family members were dysregulated in Snd1 KO mice (101). As a pilot test, qPCR of a few Cyp2 and Cyp3a family members, known to be involved in drug and DEN processing show decreased mRNA in Snd1 KO and KI mice (Figure 11). This decrease in cytochrome P450 proteins could result in decreased metabolism of DEN, lowering the exposure to the carcinogen. A more in-

$^{51}$ Cyp2a6, Cyp2E1, and Cyp2C11 have been shown to be directly involved in DEN metabolism. There may be additional cytochromes which can hydroxylate DEN.

$^{52}$ Mechanistic drug activation by cytochromes is an ongoing field of research.
Figure 11- RT-qPCR of common drug metabolizing cytochromes Cyp3a44 and Cyp2c39. n= 3 WT, 2 KO, and 3 KI independent biological replicates run in triplicate. Statistical t-test, two-tailed unpaired, P-value *=0.05; **=0.001; ***=0.0001. Two different primer pairs were used for each gene.
depth analysis of DEN activating cytochromes and systemic transcriptional analysis will provide additional insight into this possible mechanism.

3.5.3.2 Transcriptional control of APPs

Transcriptome analysis of SND1 loss in the liver reveals that some of the top differentially expressed (DE) genes encode APPs, which we validated by RT-qPCR (Figure 7) (101). The acute-phase response is part of a general, systemic response to infections and tissue damage. By definition, proteins whose plasma concentrations change by at least 25% in response to pro-inflammatory stimuli are termed APPs (176). APPs are produced primarily in the liver and their production is triggered by inflammatory interleukin-6 (IL-6). It is unclear whether the induced APPs are bystanders or participants in carcinogenesis (177). However, chronic inflammation is a hallmark of HCC formation. If APPs are indeed participants in the development of HCC, then their reduced expression in Snd1 KO and KI livers might be responsible for the hepato-protective effect we observe after DEN-treatment.

3.5.3.3 Transcription-independent function of SND1

SND1 pulls down primarily with RNA-binding proteins. Indeed, most of the known SND1 protein-protein interactions are mediated through SN-domains (see Figure 3). RISC, stress granule formation, signal transduction, and splicing are each SND1 related, transcriptional-independent processes which could impact tumorigenesis. Additionally, there may be unknown mechanisms of SND1 recruitment or scaffolding which may be important for cancer.

As an example, subcellular localization of SND1 can impact its scaffolding and RNA processing functions. SND1 is phosphorylated at T103 which allows localization to stress granules. Kinase inhibition decreases SND1\textsuperscript{T103} phosphorylation and impairs recruitment to stress granules. Further, phospho-site mutant T103A lost interaction with G3BP, a key protein in stress granule formation (102). It is thought that this recruitment will impact protein-RNA aggregation (65) and processing of specific cytoplasmic RNAs (178). SND1 is recruited to stress
granules via poly-ADP ribose PTMs (179), thus serving as a scaffold to recruit RISC components, like Ago1/2 (180). Thus, known and potentially unknown scaffolding functions of SND1 may impact tumorigenesis independent of transcription.

3.5.3.4 Leveraging the vulnerability in HCC to loss of SND1

There are many mouse models for studying HCC in mice. These include GEMMs, exposure to carcinogenic agents, induction of liver disease\textsuperscript{53}, xenograft, and cancer cell injection modeling\textsuperscript{54}. A number of GEMMs can induce spontaneous tumor development by manipulating a single gene under an albumin promoter including $\text{Pten}^{-/-}$ (182), $\text{p53}^{-/-}$ (183), $\text{Snd1 OE}$ (129), and $\text{Tak1}^{-/-}$\textsuperscript{55} (184). Deletion of a second gene decreases tumor latency, as is seen with co-deletion of $\text{Akt1/2}$ (185) or $\text{Pten/Grp94}$ (186). Also, carcinogen exposure in these experimental models can decrease latency and recapitulate specific liver disease/damage states that are clinically relevant, including heterogenous genomic mutational burden.

The most frequent genetic alterations in HCC are $\text{Tert}$ promoter amplification, $\text{Tp53}$ mutation or deletion, and $\text{Ctnnb1}$ or $\text{Arid2}$ mutation. Remaining recurrent genetic aberrations make up less than 10\% of clinical cases each (187). It is generally thought that ethnicity, etiology, and environmental exposure all contribute to this perplexing heterogeneity in HCC. Adding to this complexity, the liver exhibits inter- and intra-lobular heterogeneity in gene expression profiles further confounding genetic considerations alone (188). Given the heterogeneity of liver cancer (135, 187, 189), we deemed that DEN injections provides valuable proof of principle of the potential vulnerability of HCC by specifically targeting $\text{SND1}$\textsuperscript{56}. This work indicates that inhibition of the SND1 Tudor domain may provide a druggable target to treat HCC.

The methylarginine reader function of SND1 can be therapeutically targeted in two ways; either by 1) limiting the available SDMA marks recognized by the SND1 Tudor domain by

---
\textsuperscript{53} This can be through high fat diet, alcohol-induced liver disease, or cholestasis.
\textsuperscript{54} An extensive review on each of these approaches was recently published (Brown, et al.,2018).
\textsuperscript{55} Also known as MAPK3K7.
\textsuperscript{56} DEN induces extensive, random DNA damage in cells.
inhibiting the methyltransferase that deposits SDMA (i.e., using PRMT5 inhibitors), or 2) developing small molecule inhibitors that dock into the aromatic cage of the SND1 Tudor domain to block interaction of this domain with SDMA. Many PRMT5 inhibitors have been developed (190), but PRMT5 has many substrates and is often essential for cell viability. Importantly, analysis of copy number alteration has identified a recurrent homozygous deletion of CDKN2A and MTAP in HCC primary tumors (191), which would make this HCC-subset selectively sensitive to MTA-cooperative PRMT5 inhibitors. Of note, many cell types will develop resistance to prolonged treatment with PRMT5 inhibitors, though this may sensitize cells to other therapeutic strategies. PRMT5 inhibitor-resistant Kras mutant/Tp53-null lung adenocarcinoma cells exhibited an acquired paclitaxel sensitivity that was specific to resistant cells (192). As PRMT5 impacts many different processes, there may be other acquirable vulnerabilities that have not yet been discovered.

Alternatively, inhibitors could be developed that block the ability of the SND1 Tudor domain to read SDMA marks. Because the SND1 Tudor selectively binds SDMA, this would impact fewer cellular targets and could be less toxic to cells. Notably, SMN is another reader of PRMT5-catalyzed SDMA marks and inhibitors that block the SMN Tudor/SDMA interaction have recently been described (193). Also, localization and protein-protein interaction of SPF30, a single Tudor domain-containing protein, could be disrupted with a SMI57 (194). Discovery of these Tudor domain SMIs set a precedent for successfully adopting this approach.

57 SPF30 is also known as SMNDC1.
4 Chapter 4- Characterizing a gain-of-function PRMT5 OE mouse and the effect on HCC

PRMT5 is the major type II arginine methyltransferase responsible for virtually all SDMA in the cell. MEP50 is an essential cofactor for the methylosome complex. Much of our understanding of the protein has come from knockout studies and cancer related studies. Both approaches reveal PRMT5 is essential for life and has important roles in disease. While PRMT5 loss is detrimental, Prmt5 OE is associated with oncogenic pathways and tendencies58. However, the impact of PRMT5 to promote de novo disease has yet to be determined. PRMT5 related proteins and pathways are important in the liver, sparking our interest in the potential role of Prmt5 in hepatocarcinogenesis. Prmt5 OE is thought to be disease promoting. We hypothesize that liver-specific Prmt5 OE will result in hypermethylation of substrates that lead to changes in transcription and splicing. Related to disease, we hypothesize that liver-specific Prmt5 OE will sensititize hepatocytes to develop HCC. Follows is the generation and functional validation of a liver-specific Prmt5 OE GEMM and induced HCC modeling to study the impact of Prmt5 OE on tumor formation. The results of these experiments provide valuable insight into PRMT5 biology for normal and diseased states.

4.1 Generation and validation of a Prmt5 OE GEMM

There is a plethora of tissue-specific PRMT5 knockout mouse models (see Table 1). However, Prmt5 OE studies have, to date, been restricted to tissue culture methods and bacterially derived vectors. There has yet to be published a genetically engineered PRMT5 overexpressing mouse model. One of the challenges of creating an active Prmt5 OE system is that PRMT5 requires the cofactor MEP50 for protein stability and enzymatic activity (17, 89). To meet this need, the Vokes Lab from the University of Texas, Austin, developed a tissue-specific

58 These include increased proliferation and survival, repression of tumor suppressors.
inducible Prmt5 OE mouse model. This was done by generating a PRMT5-MEP50 conditionally activatable vector (see appendix B for plasmid map and sequence). The construct contains a Lox-Stop-Lox sequence preceding a V5-tagged murine Prmt5 (V5-PRMT5), followed by an internal ribosomal entry site (IRES) and murine Mep50 (MEP50\textsuperscript{trans}) sequence (Figure 12a). Thus, Prmt5 OE can be selectively induced through constitutively active tissue-specific or drug induced-Cre expression. This construct was cloned and ligated into a Rosa26 targeting vector to allow homologous recombination of the transgene into the genome. This KI vector was transfected into embryonic stem cells and subjected to antibiotic selection. Resistant cells were genotyped to identify those that had undergone homologous recombination. These cells were microinjected into a blastocyst and transferred into female mice\textsuperscript{59}. The resulting chimeric pups were bred to create heterozygous founders. Transgenic mice were PCR genotyped using primers against the entire V5-tag, beginning at the second \textit{loxP} site and ending within the V5-Prmt5 transgene. We received mice from the Vokes lab and confirmed genotyping by their standard. To confirm insertion of the entire transgene and to check for mutations, the length of the transgene was divided into five sections and new primers designed with overlapping ends of 50-100bp\textsuperscript{60} (Figure 12b). PCR amplicons of each section of transgene were Sanger sequenced and revealed complete inclusion of the construct and was free from mutation.

In chapter 3, we describe how loss of SND1 Tudor domain was hepatoprotective against carcinogen-induced HCC. It has been shown that Snd1 OE can induce HCC and drive tumor formation (129). As the SND1 Tudor domain is important in the liver and is well established as an SDMA binder, and as PRMT5 is the primary enzyme responsible for adding SDMA in the cell, we sought to determine if Prmt5 OE could phenocopy Snd1 OE in the liver. We crossed and backcrossed albumin-cre (Alb-cre) mice from a Swiss-Webster background into B6/C3H mice\textsuperscript{61}.

\textsuperscript{59} Of note, these B6/C3H mice were heavily mixed. Extensive inbreeding periodically gave rise to traditional B6 colors, but most mice maintained B6/C3H pattern, especially when crossed with Cre-containing mice.

\textsuperscript{60} IRES contain highly repetitive sequences that are difficult to sequence and can be problematic in PCR amplification. Accordingly, this section of the transgene was excluded from PCR amplification and subsequent sequencing.

\textsuperscript{61} These Alb-cre mice were a gift from the David Johnson lab.
Figure 12- Prmt5\textsuperscript{OE} GEMM design and sequence validation. a) Prmt5\textsuperscript{OE} transgene schematic. b) Prmt5 transgene amplicon design. Predicted amplicon coverage in green and base pair (bp) coverage. Primer set 2.2 was included to cover a short section of DNA with limited coverage by sets 2.1 and 3.1. c) Genotyping pups from a B6/C3H\textsuperscript{PRMT5/WT} heterozygous mice crossed with B6/C3H\textsuperscript{Alb-Cre/WT} heterozygous mice showing all four possible genotypes. 500bp band represents Alb-cre transgene. Lower 324bp band is an internal PCR control to confirm presence of DNA. B6/C3H\textsuperscript{PRMT5/Alb-cre} (PRMT5\textsuperscript{OE}) in samples 1 and 2. B6/C3H\textsuperscript{PRMT5} in 7 and 8. B6/C3H\textsuperscript{Alb-cre} in 4 and 5. B6/C3H\textsuperscript{WT} (negative for both transgenes) in 3 and 6.
Following these backcrosses, the F4 generation of Alb-cre mice were crossed with the PRMT5 transgenic mice to investigate the PRMT5 axis in the liver. Resulting pups had three possible genotypes with normal PRMT5 expression: B6/C3H without either transgene, B6/C3H with only the V5-Prmt5 transgene (B6/C3H^{PRMT5}), and B6/C3H with only Alb-cre transgene (B6/C3H^{Alb-cre}) (these three are collectively referred to hereafter as PRMT5^{WT}, or WT). Only pups containing both the V5-Prmt5 and Alb-Cre transgene could express the V5-PRMT5 transgene (B6/C3H^{PRMT5/AlbCre}, hereafter called PRMT5^{OE}, or OE) (Figure 12c).

We sought to confirm and quantify tissue specific OE of PRMT5 in the liver. By western blot, Prmt5^{OE} liver tissues revealed a 75 kDa doublet corresponding to endogenous and V5-tagged PRMT5. Neither the doublet nor V5-tagged protein were observed in Prmt5^{WT} samples (Figure 13a first, second and third row; b, quantification). Total MEP50 was increased only in Prmt5^{OE} samples (Figure 13a fifth row; c, quantification). Comparing total PRMT5, endogenous protein (lower band, first and third row) was significantly increased in Prmt5^{OE} over WT samples (Figure 13a,b). This observation can be explained by the increase of total MEP50 enabling the stabilization of the endogenous protein. Knockdown of PRMT5 or MEP50 will concomitantly decrease expression of the other, so this finding fits with reciprocal observations (88).

We sought to confirm that the V5-PRMT5 protein was enzymatically active. However, as PRMT5 dimerizes with itself, we were unable to separate ectopically expressed PRMT5 from endogenous enzyme. Rather, we used a variation of a traditional in vitro methylation assay to assess total PRMT5 activity using whole-cell lysate to look at ectopic plus endogenous PRMT5 activity\(^\text{62}\). We used recombinant histone H4 as substrate combined with adenosyl-L-methionine, S-[methyl-\text{\textsuperscript{3}}H] (\text{\textsuperscript{3}}H-SAM) in the presence of Prmt5^{WT} or Prmt5^{OE} whole-cell lysate from livers as the PRMT5 enzyme source. We also included a Type-I arginine methyltransferase inhibitor, MS023, to exclude potential methylation signal from enzymes other than PRMT5. Recombinant

\(^{62}\) For reference, a traditional in vitro methylation assay includes recombinant substrate, along with adenosyl-L-methionine, S-[methyl-\text{\textsuperscript{3}}H] as a radioactive label, and purified enzyme from either bacterial or mammalian cells. The resultant methylation from this biochemical assay can be visualized using PAGE and fluorography.
Figure 13- Western blot and quantification for Prmt5\textsuperscript{WT} and Prmt5\textsuperscript{OE} from whole-cell lysate tissues. a) Western blot of whole-cell lysate from livers from respective genotypes. b) Fold change of endogenous and V5-PRMT5 normalized to actin. Quantified using LI-COR quantification tool. c) Fold change quantification of total MEP50 over Prmt5\textsuperscript{WT} samples normalized to actin. Quantified using LI-COR quantification.
Figure 14- *In vitro* methylation of recombinant H4 by *Prmt5WT* and *Prmt5OE* liver whole-cell lysate. 

**a)** Positive control (+cntrl) recombinant PRMT5/MEP50 with recombinant H4 (H4) substrate and ³H-SAM. Top, whole-cell-lysate with added H4 in *Prmt5OE* or *Prmt5WT* whole-cell lysate with or without Type I PRMT inhibitor (MS023). H4 blot is the fluorograph of the radioactive signal, and actin loading a western blot of the same membrane. Bottom, time course stopping the reaction at 15 min, 30 min, or 60 min respectively all in the presence of MS023. 

**b)** Complete fluorograph (and loading western below) of whole cell lysate without H4 substrate with and without MS023 (left) and time course with MS023 (right).
H4 methylation was increased in \( Prmt5^{OE} \) sample (Figure 14a, top). A time course experiment in the presence of MS023 also showed time-dependent increase of methylation (Figure 14a,bottom). Further, we observed an increase in global methylation in \( Prmt5^{OE} \) lysates compared with \( Prmt5^{WT} \) samples (Figure 14b). These data, along with our sequencing validation, confirm that the \( Prmt5^{OE} \) mouse is a functional OE GEMM.

In PRMT5 knockdown or inhibition studies, global decrease of SDMA is used to show effective impairment. Conversely, we anticipated that such a dramatic quantitative increase of endogenous and exogenous PRMT5 would result in a marked increase of SDMA. However, MMA and SDMA were only subtly increased in a few targets (Figure 15a,b respectively). This raised an important functional question about the role of excess PRMT5 in the cell. While PRMT5 is indispensable for most cell types, it is unknown if increased PRMT5 protein level corresponds to increased SDMA levels.

As a baseline, we tested global methylation of several different cell types of different tissue origins (Figure 16). While PRMT5 levels were consistent between cell types, SDMA levels differed substantially. This supports that PRMT5 methylates targets in a tissue specific manner. Transient transfection of myc-tagged PRMT5 (myc-PRMT5) in HEPG2 and HEK293T (293T) cells resulted in abundant accumulation of myc-PRMT5 in these cell types\(^{63}\) (Figure 17, Figure 18 respectively). Yet, even with discernibly increased PRMT5 by western blot, a concomitant global hypermethylation was not observed\(^{64}\). Changes in MMA and ADMA were not detected.

Taken together, the \( Prmt5^{OE} \) mouse is a functional PRMT5 overexpressing GEMM. These mice exhibit an eighteen-fold increase in total PRMT5. PRMT5 OE in these mice as in HepG2 and 293T cell lines results in minor hyperproliferation of a few targets. These might suggest that SDMA levels are heavily methylated with normal PRMT5 levels and increasing PRMT5 does not increase SDMA levels.

\(^{63}\) This myc-PRMT5 vector is very high expressing and is the standard vector used to purify PRMT5 from mammalian cells for in vitro methylation assays.

\(^{64}\) PRMT5 OE was quantified as >10 and >200 fold increase in HepG2 and HEK293T lines respectively. Quantification included in appendix C.
Figure 15- Type II methylation of Prmt5 OE liver tissues. a) Western blot of whole-cell lysate from Prmt5WT and OE mouse livers from Figure 13a probing for monomethyl arginine (MMA) using a custom α-pan-MMA antibody. αMMA rabbit primary antibody and α-β-actin mouse primary antibody allow co-immunoblotting of target and loading control. b) Whole-cell lysate western blot from Figure 13a tissues against symmetric dimethylarginine (SDMA) using a custom α-pan-SDMA antibody.
Figure 16 - Pan-tissue methylarginine comparison. Western blot of equal cell counts of A549, H1922, HeLa, and U2OS cell lines compared for SDMA, MMA, ADMA, or PRMT5 respectively.
Figure 17- Hypermethylation analysis in myc-PRMT5 overexpressing HepG2 cells. Three 35mm wells were transfected with empty vector (EV), myc-tagged PRMT5 (myc-PRMT5), or EV plus 10uM Epz015666 (inhib.) PRMT5 inhibitor in triplicate. Cells were harvested after 72 hours and probed with respective antibodies.
Figure 18- Hypermethylation analysis in myc-PRMT5 overexpressing HEK293T (293T) cells. Three 35mm wells were transfected with empty vector (EV), myc-tagged PRMT5 (myc-PRMT5), or EV plus 10uM Epz015666 (inhib.) PRMT5 inhibitor in triplicate. Cells were harvested after 72 hours and probed with respective antibodies.
4.2 Transcriptional analysis of PRMT5 OE GEMM

PRMT5 is known to regulate transcription by methylating histones and transcription factors. Further, splicing proteins are known to be symmetrically dimethylated by PRMT5. Loss of PRMT5 results in altered transcriptional profiles and splicing (5). To determine if Prmt5 OE could inversely alter either of these processes, we performed RNA-sequencing (RNA-seq) of total RNA collected from the livers of three two-month-old Prmt5WT and Prmt5OE male mice and compared the expression profiles to each other.

We visualized the DE genes by volcano plot and observed limited changes in transcriptional regulation (Figure 19). Principle component analysis of Prmt5OE to Prmt5WT samples did not cluster into distinct genotypes (not shown). Thus, transcriptional differences between genotypes were limited.

4.2.1 Alternative splicing in Prmt5 OE livers

To determine if splicing was impacted by Prmt5 overexpression, alternative splicing events were identified using replicate multivariate analysis of transcript splicing (rMATS) for Prmt5OE and Prmt5WT mice. This approach allows for both calling of splicing events and visualization of global changes to splicing.

To explain the visualization, alternative splicing events are determined by aligning sequencing reads and categorizing variations between WT and experimental (in our case OE) RNA samples. These events are divided into five categories being alternative 3'/5' splicing sights (A3SS or A5SS respectively), mutually exclusive exons (MXE), retained introns (RI), or skipped exons (SE). The read counts are then normalized for each gene individually. The difference of the normalized counts is reported as the 'inclusion level'. An 'inclusion level' that is less than zero is enriched in experimental samples while a level of greater than zero is enriched in normal samples. A false discovery rate (FDR) is also calculated for each counted gene to determine
Figure 19 - Volcano plot of differentially expressed (DE) genes from Prmt5\textsuperscript{OE} mice liver. Top DE genes identified in red. DE upregulated genes, 42. DE downregulated genes, 52.
statistical significance\(^{65}\). Using a FDR of <0.1, the ‘inclusion level’ of significant splicing events can be visualized for global changes in splicing. A skewing of the average inclusion level, or in the distribution of significant events, will indicate a substantial shift in alternative splicing. As a second measure, graphing the significant FDR can show a change in distribution of significant events as a measure of confidence in called events. A skew towards zero indicates greater confidence in accurate calling of splicing events.

Comparing the splicing events from WT to OE mice, we graphed the ‘inclusion level’ of significant events with a false discovery rate (FDR) of <0.1. Distribution of ‘inclusion level’ were not skewed to either genotype across the five alternative slicing event types (Figure 20a). Further, the FDR distribution of all significant splicing events skew towards 0, indicating that false positives are unlikely for identified splicing events (Figure 20b). We identified the top DE genes in OE mice relative to WT and compared these to the genes with significant alternative splicing (FDR <0.1). None of the top dysregulated genes from OE mice had alternative splicing with a FDR <0.1. Taken together, Prmt5 OE in the liver had limited effect on splicing and transcription which may reflect the fact that we do not observe a major impact on SDMA level, upon PRMT5 OE.

4.3 PRMT5 OE carcinogenesis models

PRMT5 is involved in many different cancer types (Table 3). In most of these settings, PRMT5 level is correlated with a worse prognosis, and knockdown or inhibition is cytotoxic to cells. There is preliminary evidence that PRMT5 plays a role in HCC by impacting some of the pathways that drive HCC. However, the previous work implicating PRMT5 in cancer has been in established cancer settings. It has yet to be identified if PRMT5 is able to function as a \textit{de novo}

\(^{65}\) Working with large data sets, multiple testing limits the effectiveness of standard statistical p-values, especially with gene sets which have thousands of tests. One method for resolving multiple testing is to use FDR cut offs in place of p-values. Typically, a FDR of <0.1 is used as a significance cut off.
Figure 20- *Prmt5OE* alternative splicing events. Events are noted as alternative 3' start site (A3SS), alternative 5' start site (A5SS), mutually exclusive exons (MXE), retained introns (RI), and skipped exons (SE).

(a) Inclusion level is the difference between reads from WT to OE samples. An inclusion level that is less than 0 is enriched in OE samples while a level >0 is enriched in WT samples. Splicing events, n= A3SS (230); A5SS (166); MXE (88); RI (219); SE (785).

(b) False discovery rate (FDR) for splicing events in a.
oncogenic driver in the liver. We sought to determine if Prmt5 OE itself could drive tumorigenesis in non-cancer transformed cells.

4.3.1 PRMT5 OE in unchallenged normal mice

Previous work has correlated PRMT5 level with disease progression in established liver cancer settings. However, whether Prmt5 OE can drive tumor formation in non-cancerous tissues has yet to be determined. Snd1 OE mice developed spontaneous HCC lesions in 50% of male mice at 12-months-old. Additionally, for other GEMMs with spontaneous HCC formation, macroscopic tumors develop in a range of 4-20 months. Prmt5OE mice had no gross or histologically evident tumors up to 18 months, and livers appeared healthy like Prmt5WT littermates (data not shown). This indicated that alone, Prmt5 OE in the liver was insufficient to drive neoplastic growth.

Clinical HCC forms in the background of other hepatic diseases like cirrhosis, hepatitis, and fibrosis. Genetic mouse models of HCC can be improved by altering multiple genes. As an example, c-Myc expression in the liver alone is insufficient to drive tumorigenesis, while concomitant knockdown of Tp53 can drive HCC in a matter of weeks (155). Likewise, addition of carcinogen can stimulate carcinogenesis and reduce tumor latency (181). While Prmt5OE mice did not develop spontaneous tumors, this did not preclude that Prmt5 OE may predispose hepatocytes to develop tumors upon exposure to carcinogen exposure or hepatic insult.

4.3.2 Carcinogenesis modeling by DEN-induced HCC

As described in chapter 3, we performed DEN injections in both Prmt5WT (including both B6/C3HPRMT5 and B6/C3H Alb-cre genotype) and Prmt5OE mice.66 Prmt5WT and Prmt5OE livers were grossly indistinguishable, developing many surface nodules in both lines (Figure 21a). To compare tumor burden and the extent of neoplastic growth between Prmt5WT and Prmt5OE mice

---

66 For reference, two-week-old pups receive a single intraperitoneal injection of DEN and age for 9 months.
Figure 21- *Prmt5<sup>OE</sup> vs Prmt5<sup>WT</sup>* pathology and tumor burden for DEN injected mice: a) Only males were used for injection studies. n=WT (33); OE (22). Representative images of liver and gallbladder (scalebar 1cm). Images courtesy edited. b) Ratio of observed pathologies from liver lobe sections representing all 265 lobes from 53 mice (lobes/mice n= WT (155/31); OE (110/22)). c) Percent tumor area per section area of all tumor types from the livers in b obtained using ImageScope and plotted as the ratio of tumor to liver area. Software calculated areas were used for statistical test; Statistical t-test, two-tailed, unpaired. d) Number of tumor foci per lobe section from liver sections in b. Sections with hepatocellular hypertrophy had no foci. Statistical t-test, two-tailed, unpaired. e) Ratio of liver plus gallbladder mass to total mouse mass representing the livers in b. Mouse liver mass obtained post-sacrifice, prior to further manipulation. Statistical t-test, two-tailed unpaired.
we followed the pipeline established for the Snd1 mutant mice (described in 3.4.1)\(^{67}\). Binned pathologies revealed a small tendency towards disease in Prmt5\(^{OE}\) mice over WT samples with carcinomas (70% vs. 68.13%, respectively) and adenomas (21.82% vs. 16.5%, respectively) being slightly elevated. (Figure 21b). Hypertrophy was slightly decreased (8% vs. 15.63%, respectively). However, the mean ratio of tumor to section area was not significantly different (Figure 21c). Also, we compared the number of foci by individual lobes, and saw no lobe had a significant change in number of tumors between genotypes (Figure 21d). As a last comparison of tumor burden, liver index was also unchanged (Figure 21e).

Taken together, Prmt5 OE was insufficient to drive an exacerbated tumorigenic response in DEN-induced HCC. This implies that PRMT5 may not have a driving role in promoting liver disease.

### 4.3.3 BrdU injection to measure Prmt5\(^{OE}\) liver proliferation

Unchecked cellular proliferation is a common metric to show improved cancer forming capacity. High PRMT5 levels are generally thought to increase proliferation, while targeting PRMT5 by SMI or siRNA decreases proliferation\(^{68}\). We sought to determine if Prmt5 OE might impact cellular proliferation in hepatocytes, and further, if hepatocytes might respond with a proliferative response to carcinogen treatment\(^{69}\). Two-week-old pups were injected with BrdU, or DEN+BrdU. Prmt5\(^{OE}\) livers did not exhibit increased proliferation with or without DEN treatment as measured by BrdU incorporation (Figure 22). It remains to be determined why PRMT5 OE in hepatocytes suppressed proliferation in response to DEN treatment.

---

\(^{67}\) For reference, the pipeline is described as follows: “we sectioned all five liver lobes from each mouse and performed H&E staining on each section. These sections were digitally scanned with an Aperio AT2 slide scanner and analyzed with ImageScope software to determine the number of tumor foci and the ratio of tumor to tissue area for each section. These images were then read and scored by a pathologist for tumor type.” See pg 43

\(^{68}\) Proliferation sensitive cancer types include: lung (Liu, et al.,2021), breast (Han, et al., 2020), glioblastoma (Yan, et al.,2014), hepatic and colorectal cancers (Ji, et al., 2017).

\(^{69}\) Two-week-old pups are still developing their digestive organs and thus have residual cellular growth in the liver. It was unknown if Prmt5 OE might increase or decrease this residual growth.
Figure 22: Proliferation of Prmt5OE livers by BrdU incorporation. For each experimental condition, n=3, each sample counted twice. Counting area of 600umx700um, ~1300 cells per count. Statistical t-test, two-tailed unpaired, P value *<0.05.
4.3.4 Hydrodynamic tail vein injection

*Prmt5 OE* was insufficient to drive an exacerbated tumorigenic response in DEN-induced HCC. However, we could not exclude the possibility that a clinically relevant genetic predisposition to cancer may provide a permissible setting for PRMT5 driven HCC. We identified hydrodynamic tail vein injection (HTVi) as a means of inducing HCC with a targeted genetic perturbation. HTVi is a recently developed method for introducing self-incorporating oncogenic plasmids which recapitulate genetic drivers of liver cancer and can be applied to any genetic background to study tumorigenesis\(^\text{70}\). In brief, oncogenic *MYC (c-myc), \(\alpha\)Tp53* siRNA, and SB encoded vectors are diluted in a large volume of saline and tail vein injected into adult mice in a few seconds\(^\text{71}\) (155)\(^\text{72}\). This over-pressurizes the capillaries leading to cardiac congestion, and capillaries dilate for the liver to uptake the excess fluids, including the oncogenic plasmid\(^\text{73}\) (156, 198). SB transposes *c-myc* and *\(\alpha\)-Tp53* sequences into the genome of hepatocytes, and results in developing tumors in 21-30 days (155). As Tp53 alterations and c-myc contribute to approximately 40% of HCC combined, HTVi is a suitable alternative for looking at the effect of *Prmt5 OE* in a system genetically predisposed to develop HCC.

We injected four-week-old *Prmt5\(^{\text{WT}}\) and Prmt5\(^{\text{OE}}\) with 10ug c-Myc, 10ug \(\alpha\)Tp53, and 2.5ug SB vectors into a pilot study number of male mice (see appendix B for plasmid maps) (**Figure 23a**). Thirty days post-injection, mice were severely diseased with aggressive hepatic malignancies. However, we were unable to identify substantial differences between tumorigenesis in *Prmt5\(^{\text{OE}}\) and Prmt5\(^{\text{WT}}\) samples (**Figure 23b**).

\(^\text{70}\) This approach was described in 1999 to deliver luciferase reporter plasmid to the liver (Liu, et al.,1999). This was followed by proposing this as a means of gene therapy but has most recently been suggested as a means of studying carcinogenesis (Molina-Sánchez, et al., 2020).

\(^\text{71}\) For reference, mice are injected with 10% of their body mass in volume. Thus, a 20g mouse would receive a 2mL injection of plasmid diluted in 0.9% saline.

\(^\text{72}\) This group recently tested combinations of 23 oncogenes and tumor suppressors and found 9 combinations that resulted in liver tumor formation. Among these combinations, c-myc and \(\alpha\)-Tp53 were among the most potent combinations at generating liver tumors.

\(^\text{73}\) The large volume is also thought to dilute cytoplasmic nucleases which degrade cytoplasmic DNA. Experiments with smaller injection volumes have lower transfection efficiency, even when increasing the concentration of injected DNA (Lecocq, et al.,2003).
**Figure 23** - Hydrodynamic tail vein injection (HTVi) of Prmt5\textsuperscript{OE} and WT mice: a) Visual schematic of injection schedule. b) Representative images of Prmt5\textsuperscript{WT} (n=5) and Prmt5\textsuperscript{OE} (n=5) mice with most and least aggressive tumorigenesis. Pathology confirmed as HCC. Pathological gross examination describes high tumor burden as “containing multiple expansive vascular masses present in all lobes with extensive fibrotic scarring. Also, displacement of liver tissue with palpable and visible replacement of parenchyma.” Images are courtesy edited. Scale-bar, 1cm.
4.4 Discussion

Homeostasis and health are maintained by constantly adjusting the balance of biological macromolecules. PRMT5 is an essential housekeeping gene that provides virtually all the SDMA requirements of the cell. This impacts protein-protein interaction, splicing, transcriptional regulation, and more. Conditional KO is deleterious in every tissue tested (Table 1) clearly marking this enzyme as essential for development and life. There remains much to be discovered about how PRMT5 concert with cellular control for methylation of targets. This work provides new insights into PRMT5 biology.

4.4.1 New insights into the control and activity of PRMT5

We generated a liver-specific Prmt5 OE GEMM. Exogenous V5-tagged PRMT5 and total MEP50 were substantially increased which significantly stabilized endogenous PRMT5. It is generally thought that increase in total PRMT5 may induce hyperproliferation in cells. However, Prmt5 OE in mouse livers resulted in only a modest increase in SDMA. Using a high protein expressing plasmid encoding myc-PRMT5, we showed that transient PRMT5 OE in HepG2 and Hek293T cells exhibit limited hyperproliferation. This may be due to tight regulation of the enzyme, substrates of PRMT5 being heavily methylated under normal conditions, or adapter protein availability mediating enzymatic activity.

4.4.1.1 Regulation of PRMT5 to mediate methylation

PRMT5 is under considerable control in cells. Phosphorylation and adapter proteins regulate the recruitment of PRMT5 to various substrates (92, 93, 199). Figure 16 shows extant tissue specific arginine methylation. Further, our whole-cell lysate in vitro methylation assay shows an increase in signal after cells were lysed (Figure 14b). This is likely from substrates that don’t encounter each other within the cell, but which do when the cell is lysed. PRMT5 was found to be localized to the cytoplasm in prostate cancer, and forced re-localization to the nucleus
inhibited growth (200). Indeed, subcellular localization of PRMT5 has a role in disease and development. Determining more about substrate recruitment and PRMT5 localization in specific tissues may ultimately help in developing even more selective PRMT5 inhibitors to target a specific group of substrates or protein-protein interactions. The spatiotemporal control of substrate methylation is an area of ongoing research and is aided by knowing that protein abundance may have less impact on disease than substrate recruitment and activation of the enzyme.

4.4.1.2 Substrates are heavily methylated with normal levels of PRMT5

Another potential reason for seeing a minimal increase in global SDMA could be that substrates of PRMT5 are heavily methylated with normal levels of PRMT5. Whole-cell lysate from Prmt5OE livers (Figure 15) or myc-PRMT5 transfected cells (Figure 17 and Figure 18) show hypermethylation of a select few targets. Remaining SDMA-modified substrates show no difference in SDMA. Thus, increasing PRMT5 may have little effect on driving hypermethylation because low levels of PRMT5 are sufficient for heavily methylating most PRMT5 substrates. Indeed, this is supported as Prmt5± (heterozygous) mice are viable and normal, indicating that even half the normal level of PRMT5 is sufficient for cellular SDMA needs (8, 77).

4.4.1.3 Adaptor proteins availability mediating PRMT5 enzymatic activity

Adaptor proteins are important for bringing the PRMT5/MEP50 complex and target substrates into proximity for methylation. This allows for spatiotemporal and modular control over symmetric methylation. Several adaptors have been identified including RIOK1 (202), COPR5

---

74 PRMT5 localization plays an important role in development and specific cell types and is discussed at length here (Stopa, et al., 2015).

75 Authors note: As with all experiments, these experiments are only as good as the reagents. Pan-methyl antibodies are inherently biased towards the epitope used to generate them. The antibodies used for these experiments may only recognize heavily methylated substrates, or the methylated substrates which are most abundant. However, even if these antibodies are unable to recognize methyl-substrates that are being hypermethylated in PRMT5OE mice, there are yet no discernable liver related diseases with hepatic-specific Prmt5 OE, bringing into question if hypermethylation is important.
Mulvaney et al. recently identified a conserved amino acid motif that they term a “PRMT5 binding motif” between RIOK1, COPR5, and pICln that docks into groove in PRMT5 to facilitate methylation (92). Different adaptors facilitate increased methylation of various targets. For instance, COPR5 recruits the PRMT5/MEP50 complex to nucleosomes which is necessary for myogenic differentiation (208) while pICln promotes PRMT5/MEP50 and Sm binding to facilitate splicing (209). However, it is not known if an increase in adaptor proteins can promote an increase in methylation by the PRMT5/MEP50 complex.

### 4.4.2 PRMT5 OE in carcinogenesis

Liver specific Prmt5 OE mice did not develop spontaneous liver tumors, nor did they have an exacerbated tumorigenic response to DEN-induced HCC (Figure 21) or HTVi (Figure 23). However, PRMT5 inhibition has clearly been shown as a potential anticancer therapy. The new class of MTAP-dependent PRMT5-MTA cooperative inhibitors are even more selective by having increased toxicity against Mtap−/− cells, which is very often co-deleted with Cdkn2a in cancer (122, 123, 211) (see also section 1.2.1). Further, eight phase I/II PRMT5 inhibitor clinical trials were underway as of mid-year, 2022 (119). Indeed, PRMT5 inhibition has potent anti-proliferative effects in many cancer types (see Table 3).

Our data suggests that PRMT5 may not function as a driver in neoplasms but is essential for cellular viability. We propose that cancer correlated amplification of Prmt5 may be an adaptation of cancer cells to meet the extensive protein synthesis requirements of rapidly dividing cells. Normal mitotic cells must completely duplicate their genome and generate enough protein for both daughter cells to be self-sufficient. Normally, cell-cycle signaling can allow adequate time and material for faithful genomic reproduction and ample protein production. However, in cancer cells, which escape cell cycle regulation, the cell must rapidly produce protein without the

---

76 Mtap is deleted in over 90% of Cdkn2a−/− cancers (Zhang, et al.,1996).
protection of cell-cycle signaling to mediate division upon suitable conditions. Importantly, both full body and conditional Prmt5 KO GEMMs reveal that PRMT5 is essential for many processes. Thus, cancer cells may adapt by increasing PRMT5 protein levels to accommodate the splicing, signal transduction, PTM, and transcriptional regulation demands of uncontrolled cell growth. Thus, inhibition of PRMT5 may decrease cell viability by starving cells of essential arginine methylation in cancer cells.
5 Chapter 5- Summary of conclusions and future directions

This work provides important insight into the basic functions of both SND1 and PRMT5 and their role in disease. This is accomplished by generating three novel mouse models, namely a Snd1 KO, a Snd1 KI, and Prmt5 OE GEMM. We functionally characterize each of these mice and identify important characteristics of how each mouse responds to induced carcinogenesis. This work reveals the SND1/PRMT5 axis may be a targetable axis to treat HCC using available or novel small molecule inhibitors. There is much that can yet be learned from these GEMMs about this axis in normal and disease settings.

5.1 Part I- The Reader

We identify that Snd1 KO mice have a small phenotype and reduced fertility that is independent of the Tudor domain (Figure 6). From our observations in mice and known observations from Drosophila (169), reduced fertility may arise from an impaired spermatogenesis. However, it remains to be determined if there are maternally linked meiotic differences in Snd1 KO mice that impact reproduction. Fertility tracking of both male and female mice will help elucidate if loss of SND1 also impairs oogenesis. Regardless of male/female reproductive differences with loss of SND1, since a reduction in litter (mouse) and brood (fly) sizes increases in severity with time, this suggests that SND1 may have an important role in cellular maintenance of undifferentiated cells. To this point, oncogenes often impact cellular stemness, and Snd1 OE primary liver cells were able to expand cancer stem cells\(^\text{77}\) (129). Thus, SND1 may have important roles in cell stemness that can impact fertility.

Recent mass spectrometry analysis of the SND1 complex from 293T cells identified many novel SND1 binding proteins (101). However, it remains to be determined what protein-protein interactions are specifically facilitated by the Tudor-domain. A BioID2-HA tagged SND1 and

\(^{77}\) In this experiment, WT primary hepatocytes formed abortive spheres. However, Snd1 OE hepatocytes could form spheres that could gradually grow and expand.
Tudor domain mutated SND1 mass spectrometry pulldown may provide important insight into key protein-protein interactions that are important in a variety of tissues. This may also help distinguish potential interactions that are important for the small phenotype. Further, this could be done in hepatocytes to determine potential interactions that may be involved in normal liver function and tumorigenesis.

*Snd1 KO* and *Snd1 KI* mice have a reduced expression of key APPs (Figure 7). This reduction could have an impact on the overall ability of mice to respond to hepatic stress and inflammation. However, it is not clear how SND1 regulates APPs. Further work is needed to identify if the hepatic-inflammatory response differs with *Snd1* loss or mutation. An important next step will be to identify how APP expression changes in response to DEN treatment or to other hepatic strains like alcohol consumption. Further, it is not known how chronic inflammation is impacted by reduced APP expression. Crossing the *Snd1 KO* and *Snd1 KI* mice to a hepatitis prone mouse model may determine if there are changes in chronic hepatic inflammatory responses, and thereby if inhibiting SND1 activity may have an anti-inflammatory effect. To this point, NF-κB activation is upregulated in *Snd1 OE* cells (62), which transcriptionally upregulates inflammatory response genes. Use of a general nuclease inhibitor, pdTp, decreased nuclear phospho-p65, indicating SND1 inhibition may decrease inflammatory response transcription (129).

It remains to be determined if there is crosstalk between the SN- and Tudor domains. **Figure 7b** and unpublished data suggests there may be additional transcriptional SN/Tudor domain crosstalk that impacts transcription in Tudor-mutant SND1 mice. These results should be followed up to determine the extent of Tudor domain mediated transcription. CUT&RUN or similar ChIP-seq approaches may identify specific targets of SND1 Tudor dependent transcription.

---

78 LPS triggered induction of IL-6 similar to *Snd1 WT* and *KO* macrophages.
79 This occurs by phosphorylation of p65, thereby re-localizing this protein to the nucleus and transcriptional upregulation of inflammatory genes.
The Snd1 KO and KI mice are hepatoprotected and develop less tumors than WT mice in DEN-induced carcinogenesis (Figure 8 and Figure 9). However, there remain several questions about how loss of SND1 or its methyl-reading ability decreases tumor burden in these mice. Moving forward, work is needed to determine 1) if the SN-domains of SND1 are involved in promoting tumors, and 2) if loss of SND1 can protect against other types of induced HCC.

5.1.1.1 Are SN-domains involved in promoting tumors?

First, it remains to be determined if hepatoprotection is a SN-domain independent process. The SND1 Tudor domain may be necessary for its recruitment for SN-domains to impact RNA processing. A mis-localization of RNA processing proteins may dysregulate RNA processing and could thereby impact tumor formation. Thus, an important next step will be to determine if mutation of the SN-domains can impact tumorigenesis. Progressively shorter nuclease domain truncations reveal that all four-SN domains are needed for nuclease activity. This was explained by molecular modeling that showed adjacent SN-domains sandwich double stranded nucleic acids in a single orientation for digestion (212). Thus, a truncated SND1 will be unable to create a concave tertiary fold to bind nucleic acids. From this, either point mutation of enzymatic residues or n-terminally truncating SND1 may be enough to disrupt SND1 for these experiments.

5.1.1.2 Are Snd1 KO and KI mice hepatoprotected with other types of inducible-HCC?

Second, there are many types of inducible HCC, each of which allow researchers to study a particular subtype of HCC. For instance, high fat diet in transgenic MUP-uPA mice can be used for studying steatosis and NASH associated HCC to study inflammation associated HCC\(^8\) (213). Alternatively, expression of hepatitis B surface antigen allows for study of Hepatitis induced

\(^8\) Major urinary protein-urokinase-type plasminogen activator (MUP-uPA) transgenic mice express high amounts of this fusion protein in the liver. These mice undergo transient ER stress, and ultimately develop NASH and HCC.
tumorigenesis. Crossing both a Snd1 KO and Snd1 KI mice into a model that is genetically predisposed to develop HCC will help determine if targeting SND1 may reduce carcinogenesis from other etiologies.

It should be noted that not all liver diseases ultimately progress to become HCC. We observed that Snd1 KO and KI mice can still develop HCC, but with more mice harboring early stages of the disease (Figure 8). Thus, loss of SND1 may impact early processes of tumorigenesis, and thus may impact risk factors that ultimately lead to HCC. Thus, these SND1 altered mice may also provide insight into novel treatment for basic liver disease such as diabetes and fibrosis. However, it first needs to be determined if loss of SND1 impacts specific process associated with these diseases.

5.2 Part II- The Writer

We developed the first liver specific Prmt5 OE mouse. This mouse is viable and expresses a V5-tagged PRMT5 and MEP50 that can increase total PRMT5 activity (Figure 13 and Figure 14). Herein we determine an important piece of PRMT5 biology, namely that PRMT5 OE alone does not induce hypermethylation. We propose that PRMT5 methylation is highly controlled, with most targets being heavily methylated with normal levels of PRMT5. Prmt5OE mice have very mild SDMA hypermethylation (Figure 15). Comparing MMA, ADMA, and SDMA in multiple cell types, arginine methylation exhibits tissue specificity (Figure 16). Finally, transiently expressed myc-PRMT5 did not show a dramatic increase in SDMA (Figure 17 and Figure 18). This is important for understanding how PRMT5 activity is controlled in the cell and may help develop substrate targetable PRMT5 inhibitors.

PRMT5 conditional knockouts have greatly expanded our understanding of PRMT5. In this same way, the Prmt5OE mice will be valuable for determining the effects of Prmt5 OE in other tissue types. PRMT5 methylation of histones is important in development and is correlated with

---

81 These models can be paired with aflatoxin or DEN exposure to exacerbate tumorigenic response and look at specific subtypes of liver disease.
proliferation. However, it is not known if Prmt5 OE can alter the proliferation or development of germ cells or other continuously dividing cells. Hepatocytes can regenerate, but this is usually in the context of cellular damage. Thus, it will be important to determine if Prmt5 OE impacts cells which are continually dividing and have more pluripotency.

We propose targeting the SND1/PRMT5 axis in HCC by use of PRMT5 inhibitor to impair SND1 methyl reading function. This is not the first work to propose the use of PRMT5 inhibition to treat liver cancer. However, there are disparate conclusions about the pharmacological efficacy of using PRMT5 inhibitors in the liver that both support and refute their use.

L. Huang et al (2018) showed high fat diet was able to induce PRMT5 expression, decrease AKT signaling, and transcriptionally decrease mitochondrial biogenesis pathways\(^{82}\). Mitochondrial dysfunction plays a role in liver disease, including diabetes and NAFLD. In liver cells, PRMT5 knockdown or inhibition decreased peroxisome proliferator-activated receptor \(\gamma\)-coactivator 1\(\alpha\) (PGC-1\(\alpha\)), a master transcription factor for genes involved in energy metabolism. Thus, use of PRMT5 inhibitors may prevent liver disease by increasing mitochondrial biogenesis (215).

However, J. Wang et al generated a PRMT5 liver specific conditional knockout mouse that shows a liver cancer promoting phenotype resulting from hepatic loss of PRMT5. These mice develop liver fibrosis and cirrhosis at 6 and 12 months respectively, with 50% mortality at 16 months. These results suggest prolonged use of PRMT5 inhibitors may have the opposite desired effect in livers by inducing fibrosis and polyploidization of nuclei (42).

Taken together, it remains to be determined how PRMT5 inhibition impacts liver tumor formation\(^{83}\). The recently developed MTAP-dependent inhibitors may have greater therapeutic

---

\(^{82}\) Induction of PRMT5 expression by diet is independent of obesity. Mice with dominant mutations in the agouti locus will develop several metabolic diseases including obesity with age. PRMT5 levels were unchanged in obese-normal chow agouti mice, but upregulated in high fat chow fed non-mutant mice.

\(^{83}\) Adipogenesis and atherosclerosis risk were recently assessed in mice with PRMT5 inhibitor treatment (Zhang, et al., 2023). Though their results were linked to fatty liver disease, they were not further linked to HCC development.
potential by specifically targeting $Mtap^{-}$ cells, thereby circumventing the potential long-term liabilities of inhibiting PRMT5 in the liver. However, these disparate results also support the development of a SND1-Tudor domain small molecule inhibitor. This would target only a subset of PRMT5 methyl-substrates and be more targeted than PRMT5 inhibitors.
6 Appendix A- Published review


Authors Note: This is a review published in 2021 with Multidisciplinary Digital Publishing Institute (MDPI) on the role of the PRMT5/SND1 axis in HCC, and is referenced as a source within as (16). For all articles published in MDPI journals, copyright is retained by the authors. See https://www.mdpi.com/authors/rights for details.
The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma

Tanner Wright 1,2, Yalong Wang 1 and Mark T. Bedford 1,*

Received: 13 December 2020
Accepted: 3 January 2021
Published: 5 January 2021
https://doi.org/10.3390/epigenomes5010001

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

1Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA; TWright3@mdanderson.org (T.W.);
YWang68@mdanderson.org (Y.W.)

2Graduate Program in Genetics & Epigenetics, UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA

*Correspondence: mtbedford@mdanderson.org
Abstract: Arginine methylation is an essential post-translational modification (PTM) deposited by protein arginine methyltransferases (PRMTs) and recognized by Tudor domain-containing proteins. Of the nine mammalian PRMTs, PRMT5 is the primary enzyme responsible for the deposition of symmetric arginine methylation marks in cells. The staphylococcal nuclease and Tudor domain-containing 1 (SND1) effector protein is a key reader of the marks deposited by PRMT5. Both PRMT5 and SND1 are broadly expressed and their deregulation is reported to be associated with a range of disease phenotypes, including cancer. Hepatocellular carcinoma (HCC) is an example of a cancer type that often displays elevated PRMT5 and SND1 levels, and there is evidence that hyperactivation of this axis is oncogenic. Importantly, this pathway can be tempered with small-molecule inhibitors that target PRMT5, offering a therapeutic node for cancer, such as HCC, that display high PRMT5–SND1 axis activity. Here we summarize the known activities of this writer–reader pair, with a focus on their biological roles in HCC. This will help establish a foundation for treating HCC with PRMT5 inhibitors and also identify potential biomarkers that could predict sensitivity to this type of therapy.

Keywords: arginine methylation; PRMT5; SND1; Tudor-SN; p100; HCC
1. Introduction

Signal transduction is the process by which information is relayed through a cell. Extracellular signals, such as growth factors or contact points with other cells, stimulate receptors on the cell surface to initiate this process by converting one stimulus (ligand binding) into another (phosphorylation). This signal initiation event is then propelled through the cytoplasm and into the nucleus using a series of sequential PTM events that rely on “reader” proteins, or effector molecules, to dock onto a specific PTM and then promote the deposition of a new PTM downstream, which in turn is read and relayed by another effector. There is a vast array of different PTMs including, but not limited to, phosphorylation, acetylation, ubiquitination and methylation, which can all be read by specialized protein domains in effector molecules [1]. These globular do-main types include SH2s (phosphor-tyrosine readers), FHAs/14-3-3s/BRCTs (phosphor-serine/threonine readers), Bromo/YEATS domains (acetyl-lysine readers), UBA/UIM/GAT/CUE domains (ubiquitinated-lysine readers), Chromo/PHD/Tudor/BAH domains (methylated-lysine readers), and Tudors (methylated-arginine readers). In this review, we will focus on just one single thread in this hairball of signaling networks: the PRMT5–SND1 axis.

Arginine residues are frequently methylated post-translationally, and these modifications come in one of three flavors: monomethylarginine (MMA), asymmetric dimethylarginine (ADMA), or symmetric dimethylarginine (SDMA) (Figure 1). These methyl-mark additions occur at the peripheral omega nitrogen of arginine guanidine moieties commonly seen at glycine- and arginine-rich (GAR) motifs. Protein argi-nine methyltransferases (PRMTs) are the family of nine closely-related enzymes which deposit all three of these marks [2]. There is a tenth arginine methyltransferase called NDUFAF7, which is not a member of PRMT family, and seems to be a dedicated mitochondrial enzyme [3]. PRMT1 is the primary Type I PRMT, which deposits the majority of ADMA marks. Other Type I PRMTs include PRMT2, PRMT3, PRMT4/CARM1, PRMT6 and PRMT8. PRMT7 is capable of depositing only MMA marks, and it is referred to as a Type III enzyme. That leaves the Type II enzymes, which deposit SDMA marks. PRMT9 has
Figure 1. The PRMTs, the marks they deposit, and the effectors of those marks. PRMT5 and PRMT9 deposit the SDMA mark, in “green”. PRMT1-4, 6 and 8 all deposit the ADMA, in “blue”. Methyl groups are highlighted in “red”. The effectors, or readers, of the methyl marks are Tudor domain-containing proteins.
just one known substrate (SAP145) [4], and NDUFAF7 is also dedicated to just one mitochondrial substrate (NDUFS2) [3]. All the remaining proteins marked with SDMA are thought to be PRMT5 substrates. Arginine methylation is a relatively abundant PTM and over the years, a number of studies have reported similar ratios of the different types of arginine methylation in both tissue and cell lines [5–7], which generally breaks down to 1000:5:0.5:0.1 for Arginine:ADMA:SDMA:MMA. So, approximately 0.6% of all arginine residues found in proteins are arginine methylated.

Tudor domains are the only globular folds known to bind methylated arginine motifs [8]. This domain type was first identified in the Drosophila melanogaster Tudor protein which contains repeating domains that are present in a number of other proteins in many different species [9]. A detailed understanding of how Tudor domains interact with SDMA motifs was first gleaned from biochemistry and structure studies involving the human survival motor neuron (SMN) protein [10,11], which is mutated in spinal muscular atrophy syndrome. All in all, eight Tudor domain-containing proteins have been reported to be methyl-arginine readers. The vast majority of methyl-arginine readers recognize SDMA motifs, including SMN, SPF30, and SND1, which are ubiquitously expressed, and TDRD1, TDRD2, TDRD6, and TDRD9, which are all germ cell-specific proteins. TDRD3 is currently the only known ADMA motif effector protein that is also ubiquitously expressed (Figure 1).

PRMT5 has emerged as an important player in HCC [12], the fourth leading cause of cancer mortality in the world [13]. This link to HCC is strengthened by the fact that a downstream reader of the PRMT5-deposited SDMA marks—SND1—has been identified as a driver of HCC formation [14], though the precise molecular mechanism of action remains poorly understood. This review focuses on summarizing key biological functions of the PRMT5–SND1 reader–writer pair (Figure 2), then surveys what is known about these proteins as they relate to HCC, and concludes with speculation on unexplored avenues of therapeutic modulation of methylarginine levels in HCC as a potential form of treatment.
Figure 2. PRMT5 and SND1 structural domains. PRMT5 contains three distinct regions. A triosephosphate isomerase (TIM) barrel, which contains eight consecutive alpha helices, followed by a Rossmann fold, which contains the amino acid residues that bind S-adenosylmethionine. The C-terminus of PRMT5 contains a beta barrel in which the dimerization domain has been mapped. In hetero-octamerization complexing with MEP50, PRMT5 dimerizes head to toe with other PRMT5 proteins. SND1 contains four intact SN-like domains capable of binding nucleic acids and have nuclease activity. A fifth truncated SN-like domain is split by the Tudor.
2. Biological Roles of PRMT5—The Primary Depositor of SDMA Marks

PRMT5 is the predominant Type II arginine methyltransferase, indicating that it confers both MMA and SDMA marks on target substrates in a distributive manner [15] (Figure 1). The primary targets of PRMT5 methylation are RNA-binding proteins, epi-genetic modulators and core histones, which has implicated this enzyme in transcriptional regulation and the control of faithful alternative splicing [16]. PRMT5 is not enzymatically active on its own, and is found in a protein complex called the methylosome.

2.1. PRMT5 Forms a Stable Complex with MEP50

Regardless of the methylation target, PRMT5 requires the co-factor methylsome protein 50 (MEP50) for stability and enzymatic activity [17]. MEP50 is also referred to as WDR77. Loss of MEP50 results in the destabilization of the PRMT5 protein and vice versa [18]. Enzymatic activity is further dependent on hetero-octamerization of these two proteins to form a complex of four PRMT5 molecules and four MEP50 molecules [19–21]. MEP50 has also been identified as a potential coactivator of the androgen receptor [22], but it is unclear whether PRMT5 is recruited with MEP50 in this context, or whether it functions independently. Importantly, HeLa cell fractionation studies from a sucrose gradient indicate that PRMT5 and MEP50 only occur together and are not found in a complex without the other, nor do they exist in the free un-complexed form [17]. Similar fractionation experiments using Xenopus egg extracts and gel filtration also reveal the existence of a single PRMT5–MEP50 complex and no free monomeric form of either protein [23]. Thus, these two proteins are tightly complexed and likely do not function independently.

2.2. The Methylosome is Targeted to Distinct Substrates by Adaptor Proteins

The PRMT5–MEP50 protein complex requires additional adaptor proteins to aid in identifying substrates that will be targeted for symmetric methylation. There are five known adaptors that link the methylosome to its substrates, and these are pICln, RI-OK1, COPR5, Sharpin and OXR1A. pICln is a spliceosome assembly chaperone, which recruits PRMT5 to facilitate the efficient methylation of SmB/B’ and SmD1/2 [24,25], as well as a number of
A second adaptor is RIOK1, which is critical for the methylation of nucleolin by PRMT5–MEP50 [27], and is important for pre-rRNA transcription and processing. RIOK1 and pICln compete for binding, suggesting that there may be a common pocket for adaptor protein binding, either on PRMT5 or MEP50 [27]. COPR5 is the third adaptor to be identified, and it recruits PRMT5 activity to nucleosomes to support the deposition of H3R8me2s and H4R3me2s marks, in its role as an epigenetic regulator [28]. The fourth adaptor is Sharpin, and this interaction targets PRMT5 to methylate the transcription factor SKI [29]. Finally, OXR1A also regulates PRMT5’s ability to methylate histones, and it is the H3R2me2s methylation that is stimulated by this adaptor [30]. OXR1A and PRMT5 interact in the pituitary gland and regulate growth hormone expression, which in turn impacts liver metabolism. Both RIOK1 and pICln were identified in independent shRNA screens that also identified PRMT5 as a vulnerability in MTAP-null tumors [31–33], further supporting the key role that these adaptors play in helping the PRMT5–MEP50 methylosome find its targets for methylation.

2.3. The Identification of PRMT5 Substrates Implicate It in the Regulation of Transcription, Splicing, Signal Transduction and the Repair of DNA Damage

The initial characterization of PRMT5 as an arginine methyltransferase revealed that it methylates H2A and H4, using an in vitro methylation assay [34]. Importantly, the first five residues of H2A and H4 are identical (SGRGK…), and it is the arginine in position 3 that is methylated by PRMT5. Knockout studies showed that the H2AR3me2s modification is particularly sensitive to PRMT5 loss in vivo [35]. Sm proteins were also shown to be methylated by PRMT5 early on in the study of this PRMT [24]. Since then, over the last twenty years, a large number of PRMT5 substrates have been identified [16]. These studies have been spurred on by the development of efficient pan-substrate antibodies that recognize Rme2s marks on different substrates, and can be used to enrich for methylated peptides from tissue and cell extracts, which can then be identified by mass spectrometry. The first such substrate screens were performed by the Richard lab [36], and subsequent screening studies have dramatically expanded on the number of known symmetrically methylated proteins into the 100s [37]. Gene ontology (GO)
analysis of the identified PRMT5 substrates reveals strong enrichment of RNA splicing and processing, as well as PTM regulated gene expression pathways and, to a lesser extent, translation.

2.4. PRMT5 Functional Misdirection Due to Cross-Reactivity with the FLAG Antibody

The PRMT5 field has been confounded by the occurrence of a major artifact of tandem affinity protein (TAP) complex purifications that use the FLAG-tag. Over the years, it is well established that when purifying a FLAG tagged protein using FLAG-M2 beads, a major contaminant is the PRMT5–MEP50 protein complex, because the M2 antibody binds directly to PRMT5 and purifies both it and its associated proteins. This was first reported by Danny Reinberg's lab over 18 years ago [38]. Subsequent studies by the Siekhattar lab reported the same thing [39]. PRMT5 is also listed as a common contaminant of FLAG immunoprecipitation experiments [40]. Most recently, the CRAPome was published, which highlights the major problems with affinity purification-mass spectrometry data sets [41]. Indeed, they showed that 94% of all FLAG purifications data sets detect PRMT5 peptides. Thus, the misassignment of PRMT5 in many FLAG-tagged protein complex purifications has led many researchers astray, and these artifacts have found their way deep into the published literature.

2.5. Mouse Models Reveal a Number of Biological Roles for the Methylosome

It is very likely that loss of PRMT5 and MEP50 in mice will phenocopy each other, as they are codependent on each other for protein stability. Indeed, the interdependence and essentiality of MEP50 and PRMT5 complexing is supported by the fact that the mouse knockouts of both PRMT5 and MEP50 result in early lethal developmental defects. MEP50 knockout mice display an early embryonic lethal phenotype with no null embryos detected at E8.5 [42]. The PRMT5 knockout mice also display a very early embryonic lethal phenotype [35].

The early lethality of these total knockouts has made it necessary to generate conditional alleles for both PRMT5 and MEP50, to help elucidate the biological roles of this protein complex in vivo. Importantly, conditional knockouts of PRMT5 have provided additional insights into its roles in T and B cell development, limb development and neural development [43–47]. A
conditional allele for the study of MEP50 loss in adult mice is also available, but has only been used in two studies related to prostate development [48] and lung development [49], although the conditional knockout was performed ex vivo in the latter study.

The first conditional PRMT5 knockout mice were generated by crossing PRMT5fl/fl and Nestincre mice, which resulted in postnatal lethality in all homozygous null mice, and implicated PRMT5 in neuronal development [43]. Further exploration determined that this mortality was linked to splicing variations of Mdm4, which induces a p53 response, leading to severe cranial abnormalities. Subsequently, PRMT5 was conditionally knocked out in oligodendrocytes, using Olig1cre, and identified as a key factor for myelination [50]. Myelin basic protein has long been known to be a robust substrate for PRMT5 in vitro studies, and the myelination defect in the conditional knockout mice provides in vivo evidence for the functional importance of this PTM [51].

A number of additional conditional knockouts of PRMT5 have been performed in adult mice. PRMT5 is also essential for the initiation and maintenance of hematopoiesis [44,52]. Methyl-transferase localization appears to impact the modification of splicing machinery, whereas loss of PRMT5 results in alternative splicing defects via intron retention and exon skipping, which is critical for hematopoietic stem cell quiescence and viability [44,53]. Both conditional knockout and small-molecule inhibitor studies reveal that loss of PRMT5 has anti-tumor activity against MLL-rearranged acute myeloid leukemia (AML) likely due to hypomethylation of essential splicing factor like SRSF1 [54,55], and further vulnerability of cancer to PRMT5 loss is bestowed on the tumors that harbor driver mutation in splicing factors [56]. Using a CD4cre, it was recently shown that PRMT5 is dispensable for late T cell development, and is required for peripheral T cell expansion and survival [46]. The removal of PRMT5 activity from pancreatic beta cells, using the Paxcre, reveals its role on regulation of insulin expression in vivo [57]. PRMT5 has also been shown to play a role in muscle stem cell expansion in adult mice (using Pax7cre), but does not seem important for the proliferation and differentiation of myogenic progenitor cells during embryonic development [58].
In a mouse embryo developmental biology setting, PRMT5 has been identified as a key for certain differentiated chondrocytes, and in this case Prxcre was used to remove PRMT5 from developing limb buds [59]. Conditional deletion of PRMT5 in hind limbs of mice led to severe phenotypes of atrophied long bone and knee. While essential for some chondrocyte lineages, PRMT5 is dispensable for general chondrocyte maintenance in adult mice. Inactivation of PRMT5 in germ cells (using Tnapcre) results in defects in spermatogenesis [60], and loss of PRMT5 in the developing lung epithelial cells (using Shhcre) causes defects in branching morphogenesis [61].

Although PRMT5 biology has been studied extensively through conditional knockouts in both adult mice and embryos, far fewer mouse genetic studies have been performed with the other key component of the methylosome—namely MEP50. Importantly, a conditional allele for mouse MEP50 has been generated [48]. However, it has only been used in one study, and that was to investigate the role of MEP50 in the prostate (which we mentioned earlier). Using the Probasincre mouse, MEP50 was conditionally removed from all lobes of the developing mouse prostate. This inactivation of PRMT5 had a severe inhibitory effect on prostate development during embryogenesis, which is likely mediated by the deregulation of androgen receptor (AR) target genes due to the ability of MEP50 (and likely PRMT5) to function as an AR cofactor.

While PRMT5 and MEP50 knockouts have been shown to be essential for many key developmental pathways, PRMT5 also harbors many oncogenic characteristics through its ability to repress the expression of the tumor suppressors ST7 and NM23 [62]. Likewise, loss of E-cadherin, a characteristic of epithelial to mesenchymal transition (EMT) which is key for metastasis, is actively repressed through the binding of PRMT5 and AJUBA to SNAIL [63]. Overexpression of PRMT5 further induces hyperproliferation of cell lines in culture [64,65]. In addition, PRMT5 has been shown to be overexpressed in many different cancers including gastric [66], colorectal [67], lung [68,69], lymphoma [64], ovarian [70], melanoma [71], and glioblastoma [72,73]. The focus of this review is on the overexpression of PRMT5 in HCC and there are numerous reports of elevated PRMT5 levels in liver cancer [12,74–78]. Most of these
published studies demonstrate that PRMT5 is overexpressed in many different cancer types, and PRMT5 overexpression correlates with aggressive tumors and poor prognosis. However, it is not clear whether PRMT5 is an oncogenic driver, or whether the elevated PRMT5 levels are an aftereffect of a transformed state. In other words, it is still unknown whether high PRMT5 expression is a cause or a consequence of cellular transformation.

3. Biological Roles of SND1—A Major Reader of SDMA Marks

SND1 (also known as TSN, p100, or TDRD11) is a ubiquitously expressed Tudor domain-containing protein [79]. Unique characteristics of SND1 include four tandem SN domains which convey nucleic acid binding and nuclease activity [79,80] (Figure 2). The SN domains are followed by a single Tudor domain that exclusively recognizes SDMA marks, which is fused to a fifth split SN domain [79,81]. This dual ability to simultaneously interface with nucleic and amino acids allows SND1 to impinge on a wide range of different signaling pathways. Some have claimed that this multifacility endows SND1 with the ability to “positively impact all hallmarks of cancer” [82]. Despite its preferential SDMA reading specificity, SND1 has been called a promiscuous binder given its affinity for RNA and DNA, and it regulates multiple pathways that control various aspects of gene expression [83,84].

3.1. The Tudor Domain of SND1 Interacts Selectively with SDMA Marks

Methylated lysine motifs are bound by at least eight different domain types—Chromo, PHD, MBT, Tudor, PWWP, Ank, BAH and WD40 domains. In the case of methylated arginine motifs, only members of the Tudor family are known effectors, with a handful of Tudor domain-containing proteins either binding SDMA or ADMA marks [8]. Importantly, there are a few individual PHD and WD40 domains whose binding affinity is also impacted by arginine methylation. Tudor domains were identified simultaneously by two research groups, which both realized that the Drosophila melanogaster Tudor protein contains previously unrecognized repeating domains, which were found in a number of other proteins in many different species [9,85]. Interestingly, SND1 was one of the first proteins to be identified as a Tudor domain-containing protein [85]. Initial structural studies involving the Tudor domain of SND1 identified an
aromatic cage that suggested it might recognize methylated peptide ligands [86]. Subsequent crystal and NMR structural studies found that the extended Tudor domain of fly SND1 bound a short GAR motif from SmB, only when this motif was symmetrically dimethylated [87]. Finally, work involving the human SND1 protein revealed that it bound PIWIL1 in an arginine methylation-dependent manner, with a strong preference for SDMA motifs over ADMA motifs [88]. Thus, SND1 reads marks that PRMT5 deposits.

3.2. SND1 as a Transcriptional Coactivator

SND1 was originally identified as a transcriptional coactivator of EBNA2 (Epstein–Barr nuclear antigen-2) [89], which interacts with many general transcription factors and coactivators, and positions SND1 as a central player in transcriptional regulation. Indeed, SND1 has been found to directly engage with a number of transcription factors. Signal transducer and activator of transcription 6 (STAT6) is a key player in transcriptional activation upon IL-4 stimulation. SND1 acts as a transcriptional coactivator by binding the C-terminus of STAT6 along with RNA Polymerase II. In this way, SND1 acts as a bridge between STAT6 nuclear localization and transcriptional activation [90]. A second STAT protein, STAT5, induces transcriptional activation in response to lactogenic hormones, which is facilitated in a similar fashion by SND1 binding the C-terminal transcriptional activation domain [91]. SND1 also functions as a coactivator for the c-Myb transcription factor [92], and in this context it is regulated by phosphorylation. Using a protein domain microarray approach, we identified the Tudor domain of SND1 as a reader of a PRMT5 deposited SDMA motif within the E2F1 transcription factor [81]. E2F proteins are widely known for their central role in transcriptional activity and their close association to proliferation and cancer. Follow-up mechanistic studies by the La Thangue group revealed that the recruitment of SND1 to arginine methylated E2F1, results in cross-talk between transcriptional regulation and altered splicing regulation of a subset of E2F1 transcriptional target genes [93]. Independent luciferase-based assays have validated the ability of SND1 to coactivate E2F1 transcriptional activity [94]. SND1 is also an interactor and coactivator of the transcription factor peroxisome proliferator-activated receptor γ (PPARγ), and regulates adipogenesis [95]. Thus, SND1 interacts
directly with a number of transcription factors (STAT5/6, c-Myb, E2F1 and PPARγ) and promotes their transcriptional activity.

3.3. SND1 Is a Splicing Factor

The splicing of precursor mRNA is a highly ordered process that is orchestrated by the spliceosome. The spliceosome is composed of five small nuclear ribonucleoprotein particles, which by definition harbor a mix of small nuclear RNAs (snRNAs U1, 2, 4/6 and 5) and proteins (Sm proteins plus additional splicing factors). SND1 interacts with both the RNA and protein components of the spliceosome. Indeed, due to its unique structure, with a Tudor domain for protein binding and SN domains for RNA binding, it plays a role in spliceosome complex formation. The Tudor domain of SND1 interacts directly with the arginine methylated forms of SmB/B’ and SmD1/D3 [96], and also the splicing factor Sam68 [97]. The interaction of SND1 with the U RNAs is likely mediated through the Sm core proteins, which bind directly to U1, U2, U4, U5, and U6 snRNAs, as the Tudor domain of SND1 can pulldown U RNAs, but the SN domains cannot [98].

As mentioned above, SND1 directly associates with a number of transcription factors. It has been proposed that the recruitment of SND1 by transcription factors to enhancer/promoter elements can directly impact the alternative splicing of the transcripts that are being activated by that particular transcription factor, at least in the case of E2F1 [93]. In summary, PRMT5 is a key regulator of RNA splicing [55], and as an effector molecule for SDMA marks deposited by PRMT5, it is not surprising that SND1 is also integral to the maintenance of normal splicing programs that can go awry in a cancer setting.

3.4. SND1 Regulates RNA Stability

Apart from splicing, SND1 is involved in many other aspects of RNA biogenesis. SND1 is not only a component of the spliceosome, but also the RNA-induced silencing complex (RISC), which are both ribonucleoprotein particles. The RISC is a “carrier” of miRNA and siRNA, which when loaded with Argonaute can target mRNA for cleavage to regulate gene expression. A biochemical purification of RISC in Drosophila identified SND1 along with Argonaute 2 and VIG-
1 [99], and SND1 is enriched in size fractioned extracts that also contain the 250 kDa miRNA complex. SND1 was also confirmed to be a component of the mammalian RISC enzyme. SND1 was shown to have ribonuclease activity that is specific for inosine-containing dsRNAs [100], and it was subsequently found that SND1 selectively degrades a highly edited pri-miR-142 that is not processed by Drosha [101]. SND1 has four intact SN domains (the 5th SSN domain is split by the Tudor domain), and structural studies have revealed that a minimum of two tandem SN domains are necessary and sufficient for RNA binding [102]. Recent studies have found that SND1 is involved in regulating the turnover of a sub-set of mature miRNAs with a common CA/UA dinucleotide sequence signature [103]. This process is known as Tudor-staphylococcal/micrococcal-like nuclease (TSN)-mediated miRNA decay (TumiD), and it is promoted by the UPF1 helicase [104]. Thus, as a component of RISC, SND1 is actively involved in processing miRNAs.

3.5. SND1 as a Component of Exosome Cargo

Extracellular vesicles (EVs), including exosomes and microvesicles, carry high levels of SND1 as part of their secreted cargo. Exosomes are critical carriers of molecular and signaling information in the extracellular environment of organ systems, where they transfer molecules from one cell to another via membrane vesicle trafficking. Exosomes are approximately 100 nm in size, and are produced in the endosomal compartment (the Golgi network) of most eukaryotic cells. With the development of cancer, exosomes become important messenger packages that “speak to” the tumor microenvironment. The first hint that SND1 was sorted into vesicles came from a study showing the presence of SND1 protein in lipid droplets that are generated by milk secreting cells [105]. Subsequent work has revealed that EVs are enriched for miRNAs, mRNAs and Ago2, which a key protein component of RISC [106–108]. SND1 is also an integral component of RISC [99], and it is thus not surprising that it is also part of these miR-NA/Ago-enriched EVs. An analysis of the changes in the protein composition of exosomes, after ionizing radiation, reveals an increase in SND1 [109]. In addition, patient urinary EVs, which are secreted by bladder cancer cells also contain high levels of SND1 [110]. Exosome-mediated intracellular
communication within the tumor microenvironment seems to play an important role in the development and progression of HCC [111].

3.6. SND1 Expression Patterns at the RNA and Protein Levels

Detailed profiling of SND1 expression has found it to be ubiquitously expressed, with the highest expression in proliferating cells and active secretory organs such as exocrine pancreas, lactating mammary glands and the liver [112]. Western analysis of SND1 reveals that it is most highly expressed in the pancreas and the liver [88] (see Figure S1 in Liu et. al., 2010). We have reproduced this data and also see a very similar expression pattern (Figure 3). RNA-seq analysis, curated by the NCBI, was performed on 27 different human tissues from 95 individuals, and also reveals fairly ubiquitous RNA expression of SND1, with approximately a two-fold variable between tissues (Figure 3A). We performed Western analysis on protein extracted from a panel of cell lines, and we observed ubiquitous expression of SND1, albeit at varying levels (Figure 3B). When comparing the protein and RNA expression of SND1, there seems to be a disconnect between the high protein levels of SND1 in pancreas and the liver, and the equal and ubiquitous RNA expression of SND1 in different human tissues. This observation could be explained by the post-transcriptional regulation of SND1 possibly by the proteasome. Indeed, mass spectrometric analysis of SND1 reveals at least 10 different lysine residues that can be ubiquitinated (see the CTS—PhosphoSite database). However, no studies have yet been performed to evaluate the protein stability of SND1 in different tissue settings. Alternatively, certain organs such as the liver and pancreas harbor levels of exosome activity, and SND1 may by sorted and secreted in the tissues from these organs, resulting in extracellular accumulation and retention.

3.7. Mouse Models of SND1 Overexpression Support Its Potential Oncogenic Functions
The SND1 knockout mouse has yet to be described. However, it does seem that this mouse has...
been generated [95], but the knockout phenotype was never presented, and these mice were only ever used to generate SND1 knockout mouse embryonic fibroblasts (MEFs) for further analysis [94,113]. Phenotyping performed by the mouse genome informatics (MIP) project at the Jackson Labs and the international mouse phenotyping consortium (IMPC), which both perform high-throughput phenotyping of spontaneous and trapping mutant mice, suggests that the SND1 knockout is partially viable, with knockout mice appearing at lower than expected Mendelian rations (approximately 50% of the expected ration). This data suggests that adult SND1 knockout mice will be available for detailed analysis (albeit at low numbers). However, very little information has yet been gleaned from the systemic knockout of SND1. It would be very informative to compare an SND1 knockout phenotype to a SND1 Tudor-dead knockin phenotype, as this would reveal the importance of the methylarginine reader abilities of SND1, and reveal what signaling pathways are dependent of SND1’s ability to read PRMT5 deposited marks, and what SND1 functions are independent of PRMT5 activity.

An overexpression model has revealed that SND1 is a driver for HCC when the induction of expression is focused on the liver, using an Albumin promoter (see section 4.2) [14]. Similar overexpression models for PRMT5 would be extremely valuable to investigate whether this mouse would phenocopy the SND1 as a driver of HCC. Although we have generated other PRMT overexpression transgenic mouse models (including PRMT1, CARM1 and PRMT6) [114], the PRMT5 overexpression transgenic mouse has not yet been developed.

3.8. Mouse Syngeneic Tumor Models Reveal a Role for SND1 (and PRMT5) in Antitumor Immunity

The melanoma B16F10 cell line has been used to investigate the role of SND1 in facilitating immune evasion of tumor cells [115]. B16F10-SND1-KO cells were transferred into the flank of syngeneic mice and monitored over a number of days. The resulting tumor size and weight were smaller for growths seeded with SND1-KO cells than in the control parental cell. Furthermore, it was found that SND1-null tumors elicited a robust immune response, when compared to the parental cells. This suggests that the loss of SND1 may sensitize tumors to
immune checkpoint inhibitors. Importantly, very similar experiments involving siRNA-mediated PRMT5 knockdown or PRMT5 inhibition by small-molecule treatment in B16F10 cells also showed that the presence of PRMT5 activity attenuates immune checkpoint therapy [116]. Thus, the loss of either PRMT5 or SND1 will convert an immunologically “cold” microenvironment into a “hot” one, further supporting a mechanistic link between this writer–reader pair. HCC may be sensitized to respond to immune checkpoint inhibitors (which block PD1, PD-L1 and CTLA-4 activity) by prior treatment with PRMT5 inhibitors.

3.9. SND1 Is Likely an Oncogene

Like PRMT5 [16], SND1 is upregulated in many different cancer types [117,118]. There is a particular interest in HCC, stemming from the observation made ten years ago, that SND1 protein levels are elevated in HCC and that its expression increases with the stage of the disease [119]. Interestingly, the analysis of RNA expression data-bases (TCGA and GEO) does not support a role for SND1 expression in the clinical progression of liver cancer [117], but the analysis of protein expression by immunohistochemistry does [119]. This suggests that SND1 may be post-transcriptionally regulated in certain tissues, as we have eluded to above (Figure 3). We will next summarize the reported roles of PRMT5 and SND1 in HCC, which can serve as a pre-clinical (mouse) and clinical (human) model system for understanding the link between this enzyme and its effector.

4. Hallmarks of HCC

Liver cancer comes in a variety of types and frequencies, from the common HCC and cholangiocarcinoma to the rare liver angiosarcoma and pediatric hepatoblastoma. HCC is cited as constituting approximately 75% of all liver cancers according to the Cancer Treatment Centers of America. Among all cancers, HCC is the fourth leading cause of cancer mortality worldwide [13]. Traditionally, HCC has affected more males than females, though recent studies have begun to suggest occurrence may have less gender disparities than previously thought [120,121]. Induction of HCC is often preceded by other hepatic ailments which ultimately develop into HCC. Non-alcoholic fatty liver disease (NAFLD) is one such malady that ultimately leads to
HCC and is associated with obesity and metabolic syndrome [122,123]. Progression towards HCC from NAFLD often occurs in successive stages from NAFLD which develops into non-alcoholic steatohepatitis (NASH), increasing to fibrosis and cirrhosis, concluding with HCC and metastasis [124].

Atypical lipid accumulation is characteristic of hepatic damage and malignancies and HCC is no exception [125,126]. Hallmark metabolic dysregulation in hepatic tissues include increased de novo synthesis of lipids over extracellular lipid uptake to fulfill the lipid requirements needed for excessive cell division in the transformed state [126–128]. Upswing in lipogenesis arises in part from the liver being the center of lipid synthesis allowing a microenvironment permissible for de novo lipid synthesis. Sterol regulatory element-binding protein (SREBP) is a transcription factor directly upregulated in hepatocytes with active de novo lipogenesis. Accordingly, in HCC and premalignant hepatocytes, lipid accumulation is a tell-tale indicator of increased HCC risk. Lipid accumulation can be grossly visualized as lipid droplets within cells. Additional markers of HCC used in the clinic include measurement of alpha-fetoprotein (AFP), Alanine transaminase (ALT), and Aspartate transaminase (AST). Each of these enzymes, when elevated in the blood stream, can suggest malignancy and dysregulation of hepatocytes as they are typically seen in low abundance extra-hepatically. HCC is highly vascularized allowing excessive signaling and growth factor secretion for rapid expansion of cancer cells and is subsequently supported by sustained nutrient availability [129]. Hepatitis B/C (HBV and HCV, respectively) is the most common risk factor for developing HCC. Many reviews have explored HBV and HBC as they relate to HCC. Interestingly, PRMT5 can methylate the HBV core protein [130], and regulates its nuclear accumulation. Thus, there may be cross-talk between PRMT5–SND1 axis and hepatitis, but this issue will not be further addressed here.

4.1. PRMT5 and HCC

PRMT5 has, in recent years, become an increasingly prominent character in HCC research. Multiple studies have reported a worse prognosis of HCC patients with in-creased
PRMT5 expression [12,74–76,131]. PRMT5 combined with the lysine methyl-transferase SET8 have been identified as predictors of overall survival and recurrence in HCC patients [131].

EMT and invasion are key hallmarks of metastasis and PRMT5 has been identified as important in both. In vitro knockdown of PRMT5 in HCC and colon cancer cells de-creases matrix metalloproteinase-2 expression [75]. This impaired expression decreases invasiveness of these lines along with decreasing proliferation which is supported by another study confirming increased HCC proliferation in PRMT5 competent lines [78]. A current model of E-cadherin depletion, characteristic of EMT, proposes the zinc finger domains of SNAIL directly bind the E-cadherin enhancer. AJUBA links PRMT5–MEP50 complex to SNAIL thereby permitting PRMT5 to mediate the SNAIL-dependent gene repression of E-cadherin [63].

A cellular defense against EMT in hepatocytes is the transcription of hepatocyte nuclear factor 4α (HNF4α). HNF4α has been shown to re-differentiate HCC cells to-wards hepatocytes and repress EMT, thereby blocking hepatocarcinogenesis [121,132,133]. While HNF4α works to drive differentiation towards hepatic cellularity, PRMT5 antagonizes HNF4α expression assisting in liver cancer stem cell maintenance. In HCC cells, PRMT5 binds H4R3 generating H4R3me2s at the HNF4α promoter. This methylation of H4R3 represses HNF4α transcription, while inhibition of PRMT5 activity restores HNF4α transcription and differentiation activity [78].

Another tumor suppressor, BTG2, is known to suppress proliferation, and is typically inhibited in cancers. While tumor suppressors are commonly inactivated by genetic mutations, deleterious mutations in BTG2 have not to date been identified, suggesting its downregulation may be a result of epigenetic reprogramming. PRMT5 has recently been linked to repressing BTG2 expression (again, in the context of HCC) through ERK signaling, though the mechanism of repression remains unknown [74].

As previously mentioned, lipid accumulation is concurrent with hepatic damage [125]. Lipid accumulation is driven by de novo lipogenesis over extracellular uptake, implying that drivers of lipid synthesis harbor oncogenic potential in hepatocytes. Sterol regulatory element-
binding protein 1 (SREBP1) is a transcription factor that regulates the expression of genes involved in the synthesis of fatty acids, triglycerides and phospholipids, and has recently been shown to directly interact with PRMT5 [134]. Furthermore, PRMT5 methylates SREBP1, which stabilizes this transcription factor and helps promote the expression of its target genes and consequently also de novo lipogenesis. The overexpression of PRMT5 in HepG2 cells increases the levels of intracellular triglyceride levels, and conversely, the knockdown of PRMT5 results in a decrease in Oil red-O staining (a marker for intracellular lipid droplet accumulation). Furthermore, the overexpression of SREBP1 causes an increase in Oil red-O staining, which is not observed when the mutant form of SREBP1 (that cannot be methylated by PRMT5) is overexpressed. Thus, PRMT5 promotes de novo lipogenesis by methylating a single site on SREBP1 [134].

Long non-coding RNAs (lncRNAs) have emerged as key regulators of normal physiology as well as pathogenesis. Long intergenic non-coding RNA 1q21.2 (LINC01138) has been shown to correlate with PRMT5 expression as well as HCC tumor size, AFP levels, and hepatitis B surface antigen levels. PRMT5 and LINC01138 were shown to interact in HCC, which allowed PRMT5 to evade proteasomal degradation [77]. Increased PRMT5 stability may explain why we see increased protein expression of PRMT5, but not an increase in PRMT5 mRNA levels in some patient samples.

Recent findings reveal that PRMT5, in combination with SND1, promotes the dynamic regulation of E2F1 target genes. PRMT5 has been shown to promote cell growth, which contrasts to PRMT1 asymmetric dimethylation of E2F1 which promotes apoptosis [67,81]. PRMT5 methylation of E2F1, and the subsequent recognition of this methylated site by SND1, expands traditional E2F1 transcriptional control of genes to an extended set of targets that are traditionally poorly regulated by E2F. Extended targeting is accomplished by E2F1-dependent alternative splicing of targets. This alternative splicing activity is dependent on both PRMT5 activity as well as SND1 recognition of SDMA marks on E2F1 [93]. While PRMT5 driven proliferation via E2F1 methylation has been identified, it remains unclear whether this signaling pathway is active or
important for the development of HCC. However, given the emerging role of E2F1 in HCC [135], the activation of this regulatory node could be a critical consequence of elevated PRMT5 and/or SND1 protein levels.

4.2. SND1 and HCC

While the role that PRMT5 plays in the development of HCC is largely circumstantial—elevated PRMT5 levels clearly correlate with the promotion of HCC and poor prognosis of these cancer patients—its effector molecule, SND1, is more solidly implicated as a driver of HCC. Indeed, a landmark study of SND1 in HCC emerged from a mouse model with SND1 overexpression [14]. Transgenic mice carrying SND1 under the control of an albumin promoter/enhancer element, selectively overexpress SND1 in the liver, and this is sufficient to drive spontaneous HCC formation with partial penetrance. While half of the overexpressing mice develop HCC spontaneously, all overexpressing mice showed more aggressive tumors in HCC that is chemically induced by diethylnitrosamine (DEN). Hepatocytes from SND1 overexpressing mice have higher levels of spheroid-generating tumor-initiating cells. Furthermore, SND1 overexpression resulted in a steady proinflammatory state [14], similar to what is seen in chronic inflammation, a central hallmark of HCC progression.

SND1 contributes to alterations in the signaling cascades within HCC that control both transcriptional and post-transcriptional regulation. Angiotensin 2 receptor 1 (AT1R) mRNA stability is augmented through overexpression of SND1 [136]. Importantly, upregulation of AT1R is associated with both the progression of HCC, as well as unfavorable outcomes with respect to overall survival of cancer patients [137]. This increased stability of AT1R mRNA, and subsequent elevation of its protein levels, activates the ERK and SMAD signaling pathways, leading to a downstream increase in TGFβ signaling in HCC cells [138]. TGFβ signaling is known to drive proliferation and EMT progression [139]. Furthermore, TGFβ signaling also induces SND1 transcriptional activation in a feed forward loop [140]. This feed forward activity can be seen in other SND1-regulated pathways including NF-κB and SREBPs [141]. SND1 further promotes proliferative signals by degradation of miRNA via its nuclease domains. Elbarbary et. al. used
transcriptome profiling to identify miRNAs that increase after knockdown or knockout of SND1, and show that these upregulated miRNAs in turn downregulate a cohort of mRNAs that are needed for G1/S transition [103]. We can speculate that the opposite is also true, when SND1 is upregulated, the G1/S transition may be shortened, and this would help explain one of the characteristics of liver cancer, which is a deregulated cell cycle [142].

NF-κB is a transcription factor that regulates innate immunity, and activation of this pathway promotes an inflammatory response and cellular growth. Chronic inflammation has been linked to many cancers, including HCC [143–145]. Indeed, chronic inflammation and hepatic injury serve as malignant drivers and precede 90% of HCC occurrences [146]. SND1 interacts with AEG-1 (also called metadherin) [119], which regulates multiple signaling pathways including NF-κB, PI3K/Akt and Wnt [147]. The activation of the NF-κB pathway by SND1 overexpression is reported to increase onco-genic miRNAs (oncomiRs) such as miR-221, that target and degrade tumor suppressor RNAs [80,148]. SND1 overexpression functions to increase inflammatory driving cytokines to promote HCC formation, as well as factors such as CXCL16 and angiogenin which promote angiogenesis. The inhibition of NF-κB blocks SND1-induced angiogenesis [80]. The benefits, to liver cancer cells, of having elevated SND1 can thus be explained, in part, by its pro-inflammatory and pro-angiogenic roles.

In order for cancer cells to persist and multiply, they evolve aggressive survival responses to stress signals to evade cell death pathways, which represents one of the major hallmarks of cancer. Stress granules are membraneless organelles that collect in the cytoplasm of cells, and serve as a means of stalling cellular machinery while the cell responds to the strain [149]. This suspended state can buy time sufficient for cells to respond with survival signaling, thereby evading apoptosis. SND1 has been shown to be enriched in stress granules induced from oxidative stress [150–152]. Whether SND1’s role is primarily as a nuclease or as a recruiting/scaffolding protein remains unclear. It has been noted, however, that phosphorylation of SND1 promotes its binding to G3BP [152], which in turn stimulates stress granule formation, suggesting that SND1 works in a recruiting role in stress granule formation. The ability of SND1
to help liver cancer cells evade cell death is not limited to its role in stress granule formation and function. SND1 can also promote the expression of UCA1 expression in HepG2 and SMMC-7721 cells [153]. UCA1 is an oncogenic IncRNA that has anti-apoptotic activity, and is itself a predictor of poor overall survival for patients with HCC [154]. Thus, high levels of SND1 helps tumor cells evade cell death.

A third survival pathway for cancer cells is DNA damage response. Using a laser microirradiation approach, SND1 is clearly localized to the laser-induced DNA dam-aged stripes [113]. Mechanistically, SND1 is recruited by PARP1 to damaged DNA, where it serves as a scaffold for chromatin remodeling proteins that then help facilitate DNA repair, such as SMARCA5 and GCN5 [113]. These two proteins are an ATP-dependent remodeler and a histone acetyltransferase, respectively, and they both act at sites of DNA damage to help open up chromatin so that the repair machinery can access the damaged DNA. SND1 overexpression thereby potentially provides a survival advantage in DNA damaged cells [82]. The combination of the liver as the body’s de-toxification center, along with the ability of elevated SND1 levels to promote survival advantages under DNA damaging conditions, may partially explain why HCC is often chemoresistant and radioresistant. Targeting SND1 may reverse this resistance.

Like PRMT5, SND1 has been noted to have a variety of functions in lipogenesis. SND1 facilitates lipid droplet formation in mammary cells and hepatocytes. This association is lost in milk globules suggesting that SND1 association is specific to formation, but not maintenance of fat droplets [105,155]. SND1 overexpressing cells show a significantly altered lipoprotein secretion content and are saturated with phospholipids over other metabolically common lipids [156]. SREBPs appear to be regulated by SND1, although the difference in activity between normal and diseased states remains unknown [156]. More recently, it was found that hepatoma cells overexpressing SND1 display low triglyceride synthesis and accelerated cholesterol ester synthesis, likely because fat-ty acids are preferentially used for cholesterol esterification [157]. While profiling the target genes of SND1’s transcriptional coactivator activity, using human hepatoma HepG2 cells, it was found that cohort of glycerolipid genes (such as CHPT1, LPGAT1,
PTDSS1 and LPIN1) are regulated by SND1, in response to proinflammatory TNFβ signaling [83]. SND1 is thus key for sustaining glycerophospholipid homeostasis in human HCC cells. The roles of SND1 in lipid metabolism has recently been reviewed in detail [158].

5. Targeting Elevated SND1 Levels with PRMT5 Inhibitors

As highlighted above, PRMT5 is overexpressed in a large number of different tumor types, and the inhibition of PRMT5 has been linked to tumor regression in mouse models [2,16,54]. These findings indicate that PRMT5 might be a promising therapeutic target for both solid and liquid tumors. Indeed, PRMT5 is currently a very popular target for the development of small-molecule inhibitors by both pharma and biomedical startup companies. A search of the published and patent literature reveals the development of at least 13 distinct PRMT5 inhibitors (Table 1). These inhibitors have six different mechanisms of action (MOA) [159,160], namely (1) inhibitors that compete with SAM (but not the peptide substrate); (2) inhibitors that compete with peptide substrate (but not SAM-competitive); (3) inhibitors that block both SAM and the substrate peptide from binding; (4) covalent inhibitors that form a stable bond with Cys449 in the active site and prevent SAM binding; (5) the development of a PROTAC probe that is based on the GSK3326595 compound, and targets PRMT5 for proteasomal degradation; (6) an allosteric inhibitor which causes the formation of an 11 amino acid acidic loop that blocks both SAM binding and peptide substrate binding.

In addition to the panel of 13 different PRMT5 inhibitors that have been developed, it may be possible to target elevated PRMT5 levels using inhibitors for PRMT1 and perhaps even CARM1 (PRMT4). This is because there is clear evidence of redundancy between different PRMT family members. Indeed, we have shown that PRMT1 and PRMT5 share many substrates [7]. Furthermore, GSK and the Guccione lab have shown that PRMT5 and PRMT1 inhibitors function synergistically to target MTAP-null cancer cells [161] and tumors that are driven by splicing mutations [56]. Finally, using a CRISPR-screening approach, we have found that in the presence
Table 1. PRMT5 inhibitor and their different mechanisms of action.

<table>
<thead>
<tr>
<th>Company</th>
<th>Compound</th>
<th>Trials</th>
<th>MOA</th>
<th>Ref. or Patent</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSK/Epizyme</td>
<td>GSK3326595</td>
<td>Ph 1 NCT02783300</td>
<td>b</td>
<td>[164]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ph 2 NCT03614728</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td>PF-06939999</td>
<td>Ph 1 NCT03854227</td>
<td>a</td>
<td>[165]</td>
</tr>
<tr>
<td>Janssen</td>
<td>JNJ64619178</td>
<td>Ph 1 NCT03573310</td>
<td>c</td>
<td>AACR</td>
</tr>
<tr>
<td>Prelude</td>
<td>PRT543</td>
<td>Ph 1 NCT03886831</td>
<td>a</td>
<td>[166]</td>
</tr>
<tr>
<td>Prelude</td>
<td>PRT811</td>
<td>Ph 1 NCT04089449</td>
<td>a</td>
<td>[166]</td>
</tr>
<tr>
<td>Prelude</td>
<td>C449</td>
<td>Pre-clinical</td>
<td>f</td>
<td>[167]</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>LLY-283</td>
<td>Pre-clinical</td>
<td>a</td>
<td>[168]</td>
</tr>
<tr>
<td>Argonaut</td>
<td>T1-44</td>
<td>Pre-clinical</td>
<td>b</td>
<td>[169]</td>
</tr>
<tr>
<td>Jian Jin</td>
<td>MS4322</td>
<td>Pre-clinical</td>
<td>d</td>
<td>[159]</td>
</tr>
<tr>
<td>Merck</td>
<td>Comp 1A</td>
<td>Pre-clinical</td>
<td>e</td>
<td>[160]</td>
</tr>
<tr>
<td>Aurigene</td>
<td>AU-14755</td>
<td>Pre-clinical</td>
<td>b</td>
<td>WO2019-180628</td>
</tr>
<tr>
<td>Angex</td>
<td>Not named</td>
<td>Pre-clinical</td>
<td>a</td>
<td>WO2019-112719</td>
</tr>
<tr>
<td>Jubilant</td>
<td>JPRMT5i</td>
<td>Pre-clinical</td>
<td>b</td>
<td>WO2019-102494</td>
</tr>
</tbody>
</table>

Mechanism of action (MOA): (a) SAM competitive; (b) SAM cooperative and peptide substrate competitive; c) SAM and peptide substrate competitive; (d) PROTAC degrader; (e) allosteric modulator; and (f) covalent inhibitor. The “WO2019” numbers refer to patent submissions.
of PRMT5 inhibitors cells are sensitized to PRMT1 and CARM1 loss [162]. Thus, it may be important to evaluate the effects of a CARM1 inhibitor (GSK3359088) [163] and a Type I PRMT inhibitor (GSK3368715) [161] for their ability to retard the growth of tumors with elevated PRMT5–SND1 signaling.

6. Conclusion and Future Direction

HCC is a major health concern worldwide. It has a 20% five-year survival rate and 1% of the global population are expected to develop HCC in their lifetime. This disease poses a significant health burden which urges additional study. The majority of therapeutic options are hepatic resection and transplant, though transplant needs far out-weigh available organs [13]. Accordingly, a more comprehensive molecular understanding of HCC development is needed to approach the HCC epidemic. The PRMT5–SND1 axis has emerged recently as a key point of inquiry, though we are far from understanding its intricacies in HCC. A lot of the interest in PRMT5 is driven by the fact that there are now very good inhibitors available that target this enzyme, raising therapeutic hope for diseases that are driven by PRMT5 overexpression, or by increased effector molecule activity (such as SND1 overexpression). SND1 has been shown to be a potent hepatic-oncogene, though many important questions still need to be addressed. Clearly, there remains a lot of low-hanging fruit to be picked; for example: (1) In the context of HHC, is SND1 the primary effector molecule for SDMA marks that are deposited by PRMT5? (2) Does SND1 compete with other Tudor domain-containing proteins such as SMN for binding to PRMT5 deposited marks? (3) Will PRMT5 inhibitors block the oncogenic effects of SND1 overexpression in the liver? (4) How important is the Tudor domain of SND1 for its oncogenic function? Many of these questions will require the development of new genetically engineered mouse models that will facilitate pre-clinical studies. A detailed mechanistic elucidation of the PRMT5–SND1 axis in HCC promises to illuminate novel and rational approaches towards treating this terrible disease.
Author Contributions: T.W. wrote the first draft of this review. M.T.B. then revised the review. Y.W. edited the review and contributed to Figure 2. All authors have read and agreed to the published version of the manuscript.

Funding: M.T.B. is supported by an NIH grant—GM126421.

Conflicts of Interest: M.T.B. is a co-founder of EpiCypher.
References


98. Yang, J.; Valineva, T.; Hong, J.; Bu, T.; Yao, Z.; Jensen, O.N.; Frilander, M.J.; Silvennoinen, O. Transcriptional co-activator protein p100 interacts with snRNP proteins


Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.


End of Appendix A
Appendix B - Plasmid maps and sequences

SB Plasmid Sequence:

tgccgcatagttacgcaagtcatgtctccctgctctgtggttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgcttagggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttga
cattgattattgactagttattaatagtaatcaattacggggtcattagttcatag
cccatatatggagttccgcgttacataacttacggta
aatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtacatctacgctattgacgtcaatgacggtaaatggcccgcctggcattatgcccag
tcacttatgaccttatattgggactttcctacttggcagtacatctacgtatta
gtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccacc
ccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtct
atataagcagagctctctggctaactagagaacccactgcttactggcttatcgaaatta
atacgactcactcattagggagaactgcacatggagtctcgagtagctctcttgaaatggtatgttcggcattcctgctaatcagtgctttcgcgatcaccaatttcgcgagccttttccccctccttcccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaattacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaa
ggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacc
cgacaggactataaagatacgcctgcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttat
cgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaac
tacggctacactgagaaagacattttggtatgtcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaagaatttttctctacagtatgatcttttcgaagtatcgggatactcataaataaatcagtcgctggtttgttggtcgcgctttttttaattattagaaaaatcaggggttccgcgcacatttccccgaaaagtgccacctgacgtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctga
Appendix C Figure 1- Sleeping beauty plasmid. Green thing indicates CMV promoter
P53 plasmid sequence:

gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaacacaa
agatattagaccaaaatagtgaacgtggaagagagagaattttttataaaaaattttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt
Appendix C Figure 2- p53 plasmid
Myc Plasmid

ggctccggtgcagtcggcagacgacatgcccacagctcccagagattggcaggggtgggaggggtcggcaattgaaccggtgcctagagaaggtggcgcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggagaaccgtatatagttgcagctttcgccagtctcctctggagcgttcgggaccagttgcgtgagcg

gaaagatggccgcttcccggccctgctgcagggagctcaaaatggaggacgcggcgctcgggagagcgggcgggtgagtcaccacacaaaggaaaagggcctttccgtcctcagccgtcgcttcatgtgactccacggagtaccgggcgccgtccaggcacctcgattaagttctcgagcttttggagtacgtcgtctttaggttggggggaggggttttatgcgatggagtttccccacactgagtgggtggagactgaagttaggcacagctttggcacttgatgtaattctccttggaatttgccctttttgagtttggatcttggttcattctcaagcctcagacagtggttcaaagtttttttcttccatttcaggtgtcgtgaggaattagcttggtaccaatacggatatcaacaagtttgtacaaaaaagcaggctttaggaaccaattcagtcgactggatccaccatgcccctcaacgcgttagcttcaccaacaggaactatgctgttcagctctgacgcgccgccaagctcgtctcagagaagctggcctcctaccaggctgcgcgcaaagacagcggcagcccgaaccccgcccgcggccacagcgtctgctccacctccagcctgtacctgcaggatctgacgccgcctcagagtgcatcgaccccgcggtggtcttcccctaccctctcaacgacagcagctcgcccaagtcctgcgcctcgcaagactccagcgccttctctccgtcctcggaattctctgctctcctcgacggagtcctccccgcagggcagccccgagcccctggtgctccatgaggagacaccgcccaccaccagcagactctgaggaggaacaagaagaagatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttctcgctcactgactcgctgcgcg
cctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagtt
gcctgactccccggtcgtgtagataactacgatagccggaggggctttaccatctggccccccagttgtatattagcatcggcagacccacgc
tcaccgcgtccaggattttatgactggttat ccggagttggagggcgtgtcttcgtgcttactgacgtggtcgtgcttactgcatgcgtggtc
gttgtgttgggtttgttttgggtttgttttgggtttgttttgggtttgttttgggtttgttttgggtttgttttgggtttgttttgggtttg
tttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt
Appendix C Figure 3- c-Myc plasmid
V5-PRMT5 IRES MEPS50 sequence: PRMT5 is highlighted in “RED” and MEPS50 is highlighted in “ORANGE”

ccccgcggccgcctcgagctgtgtgcagccagccccggtgacgcgtgcaagccgttctgtgagacagccgggtacgagtcgtgacgctggaaggggcaagcgggtggtggggcaggaatgcggtccgccctgcagcaaccggagggggagggagaagggagcggaaaagtctccaccggacgcggccatggctcgggggggggggggcagcggaggascgcttccggccgacgtctcgtcgctgattggcttyttttcctcccgccgtgtgtgaacaaatggcgtgttttggttggcgtaaggcgcctgtcagttaacggcagccggagtgcgcagccgccggcagcctcgctctgcccactgggtggggcgggaggtaggtggggtgaggcgagctgnacgtgcgggcgcggtcggcctctggcggggcgggggaggggagggtcagcgaaagtagctcgcgcgcgagcggccgcccaccctccccttcctctgggggagtcgttttacccgccgccggccgggcctcgtcgtctgattggctctcggggcccagaaaactggcccttgccattggctcgtgttcgtgcaagttgagtccatccgcgaggccagcgggggcggcgaggaggcgctcccaggttccggccctcccctcggccccgcgccgcagagtctggccgcgcgccccgtgcgcacgtggcaggaagcgcgcgctgggggcggggacgggcagtagggctgagcggctgcggggcgggtgcaagcacgtttccgacttgagttgcctcaagaggggcgtgctgagccagacctccatcgcgcactccggggagtggagggaaggagcgagggctcagttgggctgttttggaggcaggaagcacttgctctccaaagtcgctctgagttgttatcagtaagggagctgcagtggagtaggcgggagaa
ggcgcacccttctccggaggggggaggggagtgttgcaatacctttctgggagttctctgctgcctcctggcttctgaggaccgccctgggcctgggagaatcccttgccccctcttcccctcgtgatctgcaactccagtctttctagattaattaagggatctgtagggcgcagtagtccagggtttccttgatgatgtcatacttatcctgtcccttttttttccacagctcgcggttgaggacaaactcttgcgcggtctttc
cagtggggatcgacggtatcgtagagtcgaggccgctctagagtttaaacgccaccatgaccgagtacaagcccacggtgcgcctgcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgccacgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatggaaggcctcctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtcggcgtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtgctccccggagtgggcggccgagcgcgccggggtgcccgccttcctggagacctccgcgccccgcaacctccccttctacgagcggctcggcttcaccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgcatgacccgcaagcccggtgcctgacgcccgccccacgcacgcagcgcccgaccgaaaggagcgcacgaccccatgcatcgatgatctagagctcgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggaactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacgtcagttacttcatctttcgggggggtggggtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggaactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacgtcagttacttcatctttcgggggggtggggtgggg
**Plasmid ID** 1712

**Plasmid Name** Rosa26PAS-V5-prmt5-MEP50

**Description**

V5-tagged full length mouse prmt5 adjacent to an IRES and full length mouse MEP50. BGH polyadenylation signal attached to MEP50. Cloned into ROSA targeting vector between homology arms.

Note: Construct is unstable and has a propensity to reduce down from 18kb to 5kb. Amp-25 must be used for all liquid cultures. If using alpha-comp cells, incubate liquid cultures for at least 15 hours. If using a stable cell line, grow at 30°C. Plates must incubate for 24 hours; liquid cultures at least 30 hours.

**Construction Method**

Gel extracted V5-prmt5-MEP50 from p1711 and cloned into gel extracted ROSA targeting vector (p1335, Rosa26Pas) from p1711 using AscI and PacI.

**Construct Map**

![Construct Map](p1712.gbk)

* REQUIRED FIELD

**Save Record**  **Print Current Record**  **New Record**
8 Appendix C- Quantification of myc-Prmt5 OE.

Fig1 - αPRMT5 antibody in Hek293T cells
Fig 2- α- β-actin antibody in Hek293T cells
Fig 3: α-PRMT5 antibody in HepG2 cells
Fig 4- α- β-actin antibody in HepG2 cells.
9 Appendix D- Albumin-Cre documentation

Original documentation for Alb-Cre mice received from the David Johnson lab:

NOTIFICATION OF ORDER RECEIPT

<table>
<thead>
<tr>
<th>Sales order: 3602677</th>
<th>PO: 3000450367</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standing Sales Order:</td>
<td>Ref. No:</td>
</tr>
<tr>
<td>Order date: 01Dec14</td>
<td>Investigator: Dr. David Johnson</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Adj.</th>
<th>Ext. Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>CryoRecov, Stock 016833, Sex F, FVB(Cg)-Tg(Alb1-cre)1Dlr/J, Genotype: , JAXEAST:G200 , Est. Boxes: 1</td>
<td>0.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Notes: 13-16 weeks typical, but could be up to 25 if a second recovery is needed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>RPS0041,Cryo Recovery</td>
<td>2,140.00</td>
<td>2,140.00</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>CryoRecov, Stock 016833, Sex M, FVB(Cg)-Tg(Alb1-cre)1Dlr/J, Genotype: , JAXEAST:G200 , Est. Boxes: 1</td>
<td>0.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Notes: 13-16 weeks typical, but could be up to 25 if a second recovery is needed</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please note: Number of containers and freight charges are estimates based on average packing allowances. The actual number of boxes required to ship your order will vary depending on original cage density and a number of other factors. For an exact quote, please contact our Customer Service Department on the day of shipping.

TOTAL LINE ITEMS 2,140.00
TOTAL MISC CHARGES 0.00
TOTAL TAX 0.00
TOTAL EXCLUDING SHIPPING 2,140.00
Est. box charges (subject to change) 2,140.00
Est. freight (subject to change) 110.00

IMPORTANT NOTES ABOUT YOUR ORDER

1. Please review this notification carefully!! Your order will ship as described above unless you notify us of any changes prior to the scheduled ship dates.

2. The Jackson Laboratory's policies on cancellations, changes to orders, and credits apply to this order (see: http://jaxmice.jax.org/support/orderchanges/index.html).

3. If your organization has animal health restrictions, please review the animal health report of the shipping room (e.g., HB04, AX5, etc.) for your order on-line at: www.jax.org/jaxmice/health.

4. The Jackson Laboratory's current General Terms and Conditions apply to this order (see: http://jaxmice.jax.org/cou/index.html).

JAX is a registered Trademark of The Jackson Laboratory. All rights reserved.
Confirmation of Publication and Licensing Rights

September 3rd, 2023
Science Suite Inc.

Subscription: Institution
Agreement number: NX25T4KDGC
Journal name: Thesis

To whom this may concern,

This document is to confirm that Tanner Wright has been granted a license to use the BioRender content, including icons, templates and other original artwork, appearing in the attached completed graphic pursuant to BioRender’s Academic License Terms. This license permits BioRender content to be sublicensed for use in journal publications.

All rights and ownership of BioRender content are reserved by BioRender. All completed graphics must be accompanied by the following citation: “Created with BioRender.com”.

BioRender content included in the completed graphic is not licensed for any commercial uses beyond publication in a journal. For any commercial use of this figure, users may, if allowed, recreate it in BioRender under an Industry BioRender Plan.

For any questions regarding this document, or other questions about publishing with BioRender refer to our BioRender Publication Guide, or contact BioRender Support at support@biorender.com.
11 Bibliography


a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery. *Genes and Development.* 27, 1903-1916 10.1101/gad.219899.113


Proteostasis of Hematopoietic Stem Cells. Cell Reports. 26, 2316-2328.e2316 10.1016/j.celrep.2019.02.001


activity inhibits the malignancy of hepatocellular carcinoma by promoting the transcription of HNF4α. *Theranostics.* 9, 2606-2617 10.7150/thno.32344


an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. 

**Oncogene.** 36, 1223-1231 10.1038/onc.2016.287


proteins and facilitates the assembly of the spliceosome. *Nucleic Acids Research* 35, 4485-4494 10.1093/nar/gkm470

69. Yang, Y., Hadjikyriacou, A., Xia, Z., Gayatri, S., Kim, D., Zurita-Lopez, C., Kelly, R., Guo, A., Li, W., Clarke, S. G., and Bedford, M. T. (2015) PRMT9 is a Type II methyltransferase that methylates the splicing factor SAP145. *Nature Communications* 6, 10.1038/ncomms7428


139. Mátés, L., L., C. M. K., Belay, E., Jerchow, B., Manoj, N., Acosta-Sanchez, A., Grzela, D. P., Schmitt, A., Becker, K., Matrai, J., Ma, L., Samara-Kuko, E., Gysemans, C.,


Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.

*Gastroenterology.* **157**, 760-776 10.1053/j.gastro.2019.05.001


*Mol Ther.* **15**, 2063-2069 10.1038/sj.mt.6300314

199. Espejo, A. B., Gao, G., Black, K., Gayatri, S., Veland, N., Kim, J., Chen, T., Sudol, M., 


12 Vita

Tanner Janson Wright is the son of VaLee Loertscher Wright and the late Todd Lee Wright. He completed his Bachelor of Science at Utah Valley University with honors and a minor in chemistry in December 2017. While at his alma mater, Tanner helped start the lab of Eric T. Domyan, PhD and worked in the laboratory of Joshua Schiffman, MD and Lisa Abegglen, PhD. Following his undergraduate work, he entered The University of Texas MD Anderson Cancer Center UTH ealth Houston Graduate School of Biomedical Sciences in 2018.

Permanent address:

3517 W 8180 S
West Jordan, UT 84044